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Abstract 
In high-income countries, HIV and tuberculosis are concentrated in hard-to-
reach populations. The epidemiology of HIV and tuberculosis co-infection has not been 
recently described in the UK, and the role of HIV in tuberculosis transmission in low-
burden settings is unclear. 
A systematic review of risk factors for latent tuberculosis infection and active 
tuberculosis disease was undertaken. The national surveillance datasets for HIV and 
tuberculosis were linked, and these datasets were used to investigate risk factors for 
developing tuberculosis for people living with HIV, and to describe trends in HIV co-
infection among tuberculosis patients. Strain typing data on Mycobacterium 
tuberculosis complex isolates from tuberculosis patients were used to examine the role 
of HIV in tuberculosis transmission.  
In England, Wales and Northern Ireland, 6.0% of people diagnosed with HIV 
between 2000 and 2014 had a tuberculosis diagnosis during this time period, and 5.4% 
of tuberculosis patients were co-infected with HIV. The number and proportion of 
tuberculosis patients co-infected with HIV declined from 2005 to 2014. The strongest 
risk factors for tuberculosis among people with HIV were black African ethnicity, birth in 
a country with high tuberculosis incidence, and HIV acquisition through injecting drug 
use. High CD4 count and initiating anti-retroviral therapy were both highly protective 
against tuberculosis. Among tuberculosis patients, drug misuse was the only social risk 
factor associated with HIV co-infection. Tuberculosis patients with HIV had fewer 
subsequent clustered cases than HIV-negative tuberculosis patients, and tuberculosis 
patients with HIV were more often the result of reactivation of latent tuberculosis than 
recent infection. 
Co-infection with tuberculosis and HIV has declined, but further reductions are 
necessary. Increasing screening for HIV and latent tuberculosis in high-risk populations 
such as people of black African ethnicity, people born in high-incidence countries, and 
people who inject drugs, could reduce tuberculosis in people living with HIV.  
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1 General Introduction 
Tuberculosis (TB) and disease caused by the human immunodeficiency virus 
(HIV) are two of the leading infectious causes of death worldwide.[1-3] There is 
considerable geographic and sociodemographic overlap between the two epidemics; 
11% of all new TB cases in 2015 were in people living with HIV (PLHIV). The two 
diseases have a synergistic relationship, resulting in greater morbidity and mortality 
among co-infected patients. This thesis aims to improve our understanding of the 
epidemiology of TB-HIV co-infection in a low-incidence setting, and the role of HIV in 
TB transmission, in England, Wales and Northern Ireland. The introduction outlines the 
burden and epidemiology of HIV, TB and TB-HIV, globally and specifically in low-
incidence settings. I describe the transmission, pathogenesis and treatment of HIV and 
TB, and discuss the tools that have been developed to study and better understand TB 
transmission. The introduction concludes with the objectives for my thesis.  
1.1 HIV infection 
HIV is a retrovirus which targets the human immune system, impairing immune 
function and causing the condition acquired immunodeficiency syndrome (AIDS). 
Infection with HIV is lifelong. 
1.1.1 HIV pathogenesis and disease 
HIV infects cells of the immune system, particularly CD4+ T helper cells.[4, 5] 
This ultimately leads to the depletion of CD4+ cells, predominantly through pyroptosis 
(an inflammatory form of programmed cell death),[6] but also through apoptosis, viral 
killing of infected cells, or the killing of infected cells by cytotoxic CD8+ lymphocytes. 
CD4+ depletion results in the loss of cell-mediated immunity, leading to greater 
susceptibility to opportunistic infections and cancers. 
HIV is a retrovirus, transmitted as two copies of a positive-sense single strand 
of ribonucleic acid (RNA). The virus particle enters the host cell by binding to the CD4 
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receptor on the host membrane and fusing with the cell membrane. After uncoating, the 
viral genome is reverse transcribed into double-stranded deoxyribonucleic acid (DNA) 
and then integrated into the host cell’s genome. Viral replication occurs within the 
nucleus of the host cell; viral RNA is transcribed and exported from the nucleus before 
being translated into new viral proteins. These are then assembled into viral particles 
which bud off from the cell membrane and then mature.[7] 
There are a number of stages to HIV infection. Acute HIV infection occurs within 
2-4 weeks of infection and is frequently asymptomatic, or accompanied by influenza-
like illness such as fever, headache, rash or sore throat.[5] This phase is characterized 
immunologically by a sharp drop in CD4 count and a high viral load (Figure 1.1), 
resulting in widespread dissemination of the virus. Following infection, rapid viral 
replication leads to high viral loads and substantial CD4 depletion. This activates CD8+ 
T cells, which kill HIV-infected cells. The production of antibodies, known as 
seroconversion, occurs 3-12 weeks after infection.[8] 
Figure 1.1: The relationship between CD4 count and viral load during the clinical course 
of HIV infection. 
 
Source: Fanales-Belasio et al. [9] 
Seroconversion is followed by a clinically latent phase of infection, where HIV 
replicates at very low levels.[5] This phase can last for months to years, and can be 
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prolonged by the use of anti-retroviral drugs which limit viral replication and maintain 
CD4 count. Other symptoms follow as the immune system weakens, viral load 
increases and CD4 count falls. These may include swollen lymph nodes, weight loss, 
diarrhea, cough and fever.[3] 
AIDS is the most severe clinical stage of HIV infection; defined by severely 
impaired immunity (CD4 count <200 cells/µl) or AIDS indicator diseases, which are 
usually opportunistic infections, certain cancers, or other severe clinical manifestations. 
These typically include severe infections such as pneumonia, TB, oesophageal 
candidiasis, cryptococcal meningitis, or cancers such as Kaposi’s sarcoma and 
lymphomas.[3, 10] The term AIDS has, however, fallen out of fashion as we have come 
to understand immune impairment and the associated morbidities as a sliding scale 
rather than an all or nothing event. 
1.1.2 HIV diagnosis and treatment 
HIV infection can be diagnosed by detecting HIV-specific antibodies in serum or 
plasma, or by detecting the presence of the HIV p24 antigen or viral nucleic acids. 
Antibody tests can only detect HIV after seroconversion, once an immune response to 
HIV has occurred; usually within 3-12 weeks of infection (this has become quicker over 
time). Antibodies therefore may not be detectable if testing is done before the patient 
has seroconverted.[3] In contrast, antigens are present in high quantities in the early 
weeks following infection, and then stop being detectable.[11] Nucleic acid tests can 
detect virus as soon as 7 days after infection, for as long as the virus is present in the 
blood, however as they are expensive they are generally only used for patients with a 
recent high-risk event.[12] 
Disease stage is also classified based on combinations of laboratory tests and 
clinical signs and symptoms. The USA’s Centers for Disease Control and Prevention 
(CDC) use a three-stage system for HIV-infected persons, based on a combination of 
age, CD4 count, and whether the patient has presented with an AIDS indicator 
disease.[13] The World Health Organization (WHO) classifies HIV/AIDS as primary HIV 
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infection (asymptomatic, or acute retroviral syndrome), or one of four clinical stages 
defined by AIDS indicator diseases of varying severities, ranging from stage 1 
(asymptomatic or persistent generalized lymphadenopathy) to stage 4 (most severe, 
including extra-pulmonary and disseminated TB [discussed in more detail in section 
1.2.1]).[14] 
There is currently no cure or effective vaccine for HIV infection. HIV infection 
can be treated with anti-retroviral drugs, which target various stages of the viral 
replication cycle. The primary function of anti-retroviral therapy (ART) is to reduce the 
viral load, preventing CD4 decline or allowing CD4 recovery to restore immune 
function. ART is highly effective at slowing disease progression and reducing morbidity 
and mortality, particularly when started as soon as possible following HIV diagnosis 
and maintained.[15, 16] 
An additional benefit of ART for PLHIV is that it can reduce the risk of onwards 
transmission of HIV; this is referred to as treatment as prevention. The efficacy of 
treatment as prevention is dependent on treatment adherence and maintaining an 
undetectable viral load.[17, 18] However, there have been no documented cases of 
HIV transmission from people with an undetectable viral load and the preventive action 
of ART against HIV transmission is an important contributor to ending the HIV 
epidemic. 
ART can also be used prophylactically by HIV-negative persons to reduce the 
risk of being infected with HIV. Post-exposure prophylaxis involves administering ART 
to protect against HIV transmission after an event with high risk of transmission 
(described in more detail in section 1.1.3), such as a needle-stick injury with 
contaminated blood, or unprotected sex with someone known to be HIV-positive.[19, 
20] Similarly people who are HIV-negative, but are at very high risk of acquiring HIV 
infection, can take ART regularly to lower their chances of becoming infected. This is 
referred to as pre-exposure prophylaxis. Pre-exposure prophylaxis is between 44-86% 
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effective when compared to placebo or no prophylaxis, and efficacy is strongly 
correlated with adherence.[21] 
1.1.3 Transmission of HIV 
Infection with HIV occurs through the transfer of bodily fluids, including blood, 
semen, vaginal fluids and breastmilk. This means that HIV can be transmitted through 
sexual contact, blood-borne transmission, or vertically from mother to child during 
childbirth.[3] 
The risk of sexual transmission of HIV varies; the risk of infection (per sexual 
act) is higher for sex between men than for heterosexual contact, and transmission 
from men to women is more likely than from women to men. The risk is low for sex 
between women, or for oral sex acts, but anal sex carries a higher risk of HIV 
transmission.[22, 23] Viral load is a measure of the number of copies of the HIV virus in 
the blood. Higher viral loads are associated with increased risk of transmission, 
particularly during the acute phase of infection (see section 1.1.1), due to the 
combination of peaking viral load and the fact that most people are unaware of their 
HIV infection at this stage. The presence of other sexually transmitted infections are 
associated with higher likelihood of HIV transmission due to damaged mucosal 
surfaces, particularly genital ulcers,[23] although STIs such as gonorrhea and 
chlamydia also increase the risk.[24] 
Blood-borne transmission can occur through a number of routes; most 
commonly through needle sharing during injecting drug use, needle stick injury or 
unclean medical injections or transfusion of contaminated blood or blood products. 
Less common routes include through organ or tissue transplantation, or through mucus 
membrane exposure to contaminated blood. Vertical transmission of HIV from mother 
to child may occur during pregnancy, but most commonly occurs during birth, or 
through breastfeeding.[3, 25] 
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It has been demonstrated that HIV-diagnosed persons who are on ART and 
have an undetectable viral load do not transmit HIV.[18] 
1.1.4 HIV epidemiology 
1.1.4.1 The global burden of HIV 
Between 2010 and 2016, the estimated number of PLHIV globally increased by 
around a third, from an estimated 27.7 million in 2000 to 36.7 million in 2016, of which 
34.5 million were adults (17.8 million [52%] women) and 2.1 million children.[26] There 
was an 11% decrease in the estimated number of new HIV infections in adults from 
2010 to 2016 (1.9 million to 1.7 million) and a 47% decrease in new infections among 
children (from 300,000 in 2010 to 160,000 in 2016). 
This growing population of PLHIV and the decrease in the number of new 
infections is partly explained by increased survival and decreases in HIV transmission 
as a result of widespread access to anti-retroviral therapy (ART). ART restores immune 
function,[27] decreases morbidity[16] and mortality,[28] and prevents transmission of 
HIV.[18] The estimated number of people accessing ART globally increased from 
685,000 (3% of all PLHIV) in 2000 to 19.5 million (53%) in 2016.[26] Widespread 
educational campaigns to raise awareness and understanding of HIV infection and 
treatment, and promotion of preventive measures such as condom use and access to 
needle exchange programs, have also contributed to the decrease in new 
infections.[29] 
People living in Africa are disproportionately affected by HIV infection, 
accounting for 70% of all PLHIV and two thirds of all new infections.[26] This is 
primarily due to poverty and a lack of health services supporting HIV prevention and 
treatment, compounded by socioeconomic and sociocultural factors which widen health 
inequalities.[30] However, HIV is also an important public health concern in high-
income countries. In 2016 there were an estimated 2.1 million PLHIV in western and 
central Europe and North America, with 73,000 new infections and 18,000 AIDS-
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related deaths (a decrease of 32% since 2010). An estimated 1.7 million PLHIV (81%) 
were on ART.[26] HIV also causes substantial financial costs; healthcare costs are high 
[31]  and decreasing mortality rates mean that PLHIV are living longer and non-
communicable disease are becoming an increasing problem in PLHIV.[32] 
Important risk factors for HIV globally include men who have sex with men 
(MSM), people who inject drugs (PWID), people in prison or other congregate settings, 
transgender people, and sex workers and their clients.[3] Unprotected sex, other STIs, 
sharing needles or other injecting equipment or drug solutions, unsafe blood 
transfusions or organ transplantations, and accidental needle stick injuries, are also 
risk factors for transmission of HIV.[3] 
1.1.4.2 HIV in the UK 
Reporting of data on HIV infections in the United Kingdom (UK) is described in 
detail in section 3.1.2.2. As of 2015, there were an estimated 101,200 people living with 
HIV in the UK, although an estimated 13,500 were not aware of their HIV infection. This 
gives an overall prevalence of 160 PLHIV per 100,000 population; 210 per 100,000 in 
adults aged 15-74. There were 6,095 new diagnoses of HIV in 2015, a diagnosis rate 
of 11.4/100,000 population.[10] 
The proportions of PLHIV who are diagnosed, linked to care, have initiated 
ART, and are virally suppressed are high in the UK (Figure 1.2). Late diagnosis is 
common; 39% of diagnoses in 2015 were at a late stage of infection (CD4 count less 
than 350 cells/µl), although this had declined from 56% in 2006.[10] Late diagnosis is 
associated with worse outcomes, including a ten-fold increase in the risk of death in the 
first year following HIV diagnosis. 
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Figure 1.2: Continuum of HIV care in the UK, 2015. 
 
Source: Public Health England [10] 
PLHIV in the UK largely acquired their HIV infection through sexual contact; in 
2015 an estimated 47,000 PLHIV were MSM (population HIV prevalence 5,870 per 
100,000), and there were 19,600 heterosexual men and 29,900 heterosexual women 
living with HIV (prevalence 100 per 100,000).[10] 58% of heterosexual PLHIV were 
black African; the HIV prevalence among black African adults was 2%. There is also a 
much smaller population of PLHIV who acquired their HIV infection through injecting 
drug use, approximately 2,500 as of 2015. The estimated HIV prevalence among PWID 
was 380 per 100,000.[10] 
There were 305 diagnoses of AIDS-defining illnesses within 3 months of HIV 
diagnosis in 2015, a decline of over 50% since 2006.[10] The most common AIDS-
defining illnesses were Pneumocystis pneumonia (43%), oesophageal candidiasis 
(11%) and TB (9%). 594 PLHIV died in 2015. Mortality rates were consistent between 
MSM and heterosexuals with diagnosed HIV (480/100,000 and 430/100,000 
respectively), but higher among PWID (2,500/100,000).[10] 
1.2 Tuberculosis 
In humans, TB is a disease predominantly caused by the bacteria 
Mycobacterium tuberculosis (M. tb), but also by other mycobacteria in the 
Mycobacterium tuberculosis complex (MTBC, a genetically related group of 
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Mycobacterium species capable of causing TB) such as M. bovis, M. africanum, and M. 
microti. 
1.2.1 Tuberculosis infection and pathogenesis 
TB is an airborne disease, and infection occurs via the lungs. Following 
infection, a number of scenarios can occur. Infection can be cleared by the immune 
system; this immune response is not well characterized. If infection is established, 
primary disease can occur within the first 1-3 years after infection. Alternatively, latent 
TB infection (LTBI) may be established, where the bacteria lie dormant without 
replicating, and the patient is asymptomatic and non-contagious.[33] LTBI can 
reactivate and cause active TB disease. 
The lifetime risk of progressing from LTBI to active disease is 5-10%; however 
this risk is much higher for certain groups of people such as PLHIV, individuals with 
diabetes, and those who are malnourished or smoke tobacco. The most common 
presentation is pulmonary disease, affecting the lungs, but TB disease can also 
manifest in extra-pulmonary forms such as lymphatic TB, pleural TB, skeletal TB, 
central nervous system TB, meningeal TB, abdominal TB, genitourinary TB, or miliary 
(disseminated) TB.[34] Extra-pulmonary disease is often harder to identify and 
diagnose as clinical signs are less specific. Severe forms of extra-pulmonary TB 
(miliary and meningeal) are associated with worse outcomes.[35, 36] 
1.2.2 Tuberculosis diagnosis 
1.2.2.1 Diagnosis of latent tuberculosis 
As LTBI is asymptomatic and there is no bacterial replication, there are no 
direct diagnostic tests for LTBI. Instead, diagnostics rely on detecting an immune 
response to infection and then ruling out active disease. Widely available diagnostic 
tests for LTBI include the tuberculin skin test (TST) and interferon-gamma release 
assays (IGRAs); whilst a new skin test (C-Tb) has been evaluated but is not yet widely 
used. 
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The TST involves an intradermal injection of tuberculin purified protein 
derivative, which causes a delayed-type hypersensitivity (DTH) reaction if the patient is 
infected with TB.[37] The resulting induration is then measured. Guidelines for 
interpreting the results of the TST vary; the CDC diagnose LTBI based on an induration 
of >10mm (>5mm for immunosuppressed patients),[38] whilst in the UK there is a dual 
threshold of 5mm for people who have not received the Bacillus Calmette-Guérin 
(BCG) vaccine and 15mm for those who have been vaccinated.[39] 
 The TST is generally widely available (although there have been shortages in 
recent years), but has some disadvantages. Administering and interpreting the TST 
requires two visits by the patient 48-72 hours apart,[37] and patients often do not return 
for their second visit.[40] Additionally, TST sensitivity can be reduced by malnutrition, 
severe TB disease or immunosuppression, whilst decreased specificity can occur 
because of infection with non-tuberculous mycobacteria or prior vaccination with the 
BCG vaccination (currently the only licensed vaccine against TB).[40] 
IGRA blood tests are more specific due to a lack of cross-reactivity, detecting 
the interferon-gamma immune response to specific Mycobacterium tuberculosis (M. tb) 
antigens which are not present in BCG or most non-tuberculous mycobacteria,[40] and 
consequently their results are not confounded by prior BCG vaccination. Commercially 
available IGRAs include the QuantiFERON-TB Gold In-Tube (QFT-GIT), the newer 
QuantiFERON-TB Gold-Plus, and the T-SPOT.TB. As well as greater specificity, other 
advantages of IGRA tests include greater sensitivity in PLHIV with low CD4 counts, 
only requiring a single patient visit, the fact that results can be available within 24 
hours, and that results cannot be affect by the perception or bias of healthcare workers 
(although they can return an indeterminate or borderline result).[37, 41] However, 
IGRAs are more expensive, more technically complex to conduct, involve 
venepuncture, and may be less sensitive in high-burden settings.[40, 42] 
The C-Tb skin test is specific to M. tb and is applied in the same way as the 
TST, but which is more specific than the TST and has comparable sensitivity to the 
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QFT-GIT in both HIV-positive and HIV-negative patients.[43, 44] However, like IGRAs it 
lacks sensitivity to M. tb at very low CD4 counts,[44] and it is not yet widely used. 
1.2.2.2 Active tuberculosis diagnosis 
Active TB is usually suspected from clinical signs or symptoms, and confirmed 
by laboratory testing. Symptoms of active TB vary depending on the site of disease, but 
commonly include cough (with sputum and, at times, blood), fatigue, fever, night 
sweats, loss of appetite and weight loss. In cases of pulmonary disease, a chest x-ray 
can show nodules, lesions or cavitation that are symptomatic of TB; although not all 
patients with TB show abnormalities in the lungs, and some lesions are not specific to 
TB. 
The gold-standard for TB diagnosis is culture confirmation of MTBC; a positive 
culture confirms the presence of TB bacteria. Culturing MTBC can take 2-4 weeks, 
therefore if TB is suspected it is usually recommended to begin treatment before the 
results of the culture are available. 
Other methods of diagnosing active TB include sputum smear microscopy, 
histology, or PCR testing. Sputum smear microscopy involves checking for the 
presence of acid-fast bacilli on a sputum smear. Whilst this method lacks sensitivity 
(particularly in immunocompromised individuals) and specificity [45] (as not all acid-fast 
bacilli are MTBC, and it cannot differentiate between live and dead bacteria) it is 
nonetheless a useful diagnostic tool and is often used as a proxy for infectiousness of 
TB. 
The GeneXpert MTB/RIF® test is a nucleic acid amplification test which has 
been recommended by the WHO since 2010.[45] It can detect the presence of live or 
dead M. tb bacteria, and simultaneously assesses whether the bacteria are resistant to 
rifampicin, an important first line anti-TB drug.[46] It is reliable and quick, with results 
available in under two hours, however it is also expensive and reliant on good 
healthcare infrastructure.[47] 
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1.2.3 Treatment of tuberculosis 
Treatment of LTBI can prevent progression to active TB, reducing the risk by at 
least 60%.[48] Testing and treatment for LTBI is recommended by the WHO in specific 
high-risk populations in high- and middle-income countries with TB incidence below 
100/100,000 population.[49] Systematic screening (with IGRA or TST) and treatment is 
recommended for PLHIV, contacts of pulmonary TB cases, and other 
immunocompromised individuals, and should also be considered for prisoners, 
homeless persons, people who use illicit drugs, healthcare workers, immigrants from 
countries with high TB incidence.[49] Standard treatment regimens for LTBI consist of 
6 or 9 months of isoniazid, or other combinations of isoniazid and rifapentine or 
rifampicin, or rifampicin alone. Regimens including rifampicin or rifapentine should be 
prescribed with caution for PLHIV on ART, as there is potential for drug-drug 
interactions.[49]  
Active TB is treatable and can be cured with antibiotics. Standard treatment 
guidelines for drug-sensitive active TB are 2 months of isoniazid, rifampicin, 
pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin.[50, 51] 
Drug resistance is an increasing problem, and this regimen can be adapted and/or 
extended if necessary, guided by the results of drug sensitivity testing and the site of 
disease. TB can be mono-resistant (resistant to a single drug, commonly rifampicin or 
isoniazid), multi-drug resistant (MDR; resistant to multiple drugs), or extensively drug-
resistant (XDR; resistant to isoniazid and rifampicin, a fluoroquinolone, and at least one 
injectable second-line drug). Treatment guidelines for drug resistant TB vary between 
settings and are dependent on affordability, drug availability and drug resistance 
patterns. 
1.2.4 Tuberculosis transmission 
TB is an airborne disease, spread by droplet nuclei when TB patients with 
pulmonary disease cough, sneeze or spit. The risk of transmission is dependent on 
several factors; degree of exposure to an infectious TB case (both duration of exposure 
 1. General Introduction 
 
31 
and proximity of exposure), the infectiousness of the TB case (there is variation in the 
number of infectious quanta produced by patients, e.g. as measured by smear status), 
and the immune status of the individual being exposed.  There are a number of ways 
TB transmission can be studied; these are described in detail below. 
1.2.4.1 Tools for measuring tuberculosis transmission 
TB transmission can be studied at the outbreak level by contact tracing and 
case finding (identifying and screening close contacts of known TB cases for infection 
and/or disease), at the patient level (by longitudinal testing for infection and/or disease 
to establish whether the case patient is infectious), or at the population level. 
Population-level studies can involve longitudinal studies of TST conversion or IGRA 
positivity, to calculate the risk of infection with TB in a given time period, or collecting 
epidemiological and/or genomic data for all TB cases in a given population to try and 
identify chains of transmission. These methods are described in more detail in sections 
1.2.4.1.1 and 1.2.4.1.2. 
Other methods of understanding transmission include using the rate of TB in 
non-foreign-born children as a proxy for the rate of recent, within-country 
transmission,[52] modelling studies,[53, 54] studies of transmission dynamics and 
infectious quanta production using guinea pigs exposed to hospitalized TB patients,[55, 
56] studies of air sharing and the presence of TB in droplet nuclei, and investigating the 
impact of infection control mechanisms such as improved ventilation and decreased 
population density (particularly in confined settings, e.g. prisons),[53, 57] and protective 
mechanisms such as face masks or UV lighting.[58, 59] These fall outside the scope of 
this thesis. 
1.2.4.1.1 Study types 
Contact studies can be carried out prospectively or retrospectively. They 
identify contacts of TB case patients (usually close contacts such as household 
members or colleagues) and measure the incidence and/or prevalence of LTBI and/or 
active TB disease. Data is usually collected on the characteristics of the case patient, 
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and often the characteristics of the contacts, which allows analysis of the incidence or 
prevalence of TB among their contacts. From this, it is possible to infer factors which 
may cause or be associated with infectiousness (of the case patient) and susceptibility 
to infection (of the contact). 
Outbreak studies are usually carried out in response to a particular outbreak of 
TB, usually where it has been identified that a higher number of cases occurred in a 
particular location or time period than would be expected. Contact between case 
patients or locations where transmission may have occurred are retrospectively 
identified, and genotyping of patient samples is often done to establish whether cases 
could be part of the same transmission chain. The results of outbreak investigations 
may prompt ‘active case finding’ of other individuals who may have been infected as 
part of the same outbreak, by screening contacts of the case patients or people with 
whom they may have come into contact in a shared environment, e.g. a workplace, 
hospital or homeless shelter. 
Transmission can also be studied at the population level. Many countries, 
particularly countries with low TB incidence, now routinely genotype samples from 
notified TB cases. This enables the identification of cases that may belong to the same 
outbreak; with some limitations, described in section 1.2.4.1.2. This data can be used 
to initiate outbreak investigations, as described previously, and can also be used to 
group genomically linked cases into clusters. Epidemiological data, where it is 
available, can also be used to define clusters. Data on clusters can be used to estimate 
the proportion of cases that may be due to recent transmission using the ‘n minus one’ 
rule (Figure 1.3), to understand which lineages of TB are driving the epidemic, and can 
also be used to investigate factors associated with transmission. 
Figure 1.3: The ‘n minus one’ rule. 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑒𝑑 𝑐𝑎𝑠𝑒𝑠 − 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑟𝑎𝑖𝑛 𝑡𝑦𝑝𝑒𝑑 𝑐𝑎𝑠𝑒𝑠
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The usefulness of population-level genotyping for estimating clustering is 
dependent on how complete the sampling of the population is. Many studies are only 
representative of a limited population and do not capture all TB cases. Even country-
level studies where notification of TB cases is mandatory are limited; not all TB cases 
are notified, notified cases are not all culture positive (particularly extra-pulmonary TB 
cases), and only culture positive cases can be genotyped. Furthermore, cases may 
belong to clusters with other patients who are outside the region or country of the 
study, or who presented with disease before or after the study time period. 
Incomplete sampling results in underestimation of the clustering of TB cases; 
lower sampling fractions particularly result in greater underestimation of the proportion 
of clustered cases.[60] Incomplete sampling principally affects smaller clusters, which 
are less likely to be identified when the sampling fraction is low; a smaller number of 
larger clusters is less susceptible to bias from incomplete sampling.[60] Smaller 
sampling fractions can cause underestimation of the impact of risk factors associated 
with clustering;[61] although this is ameliorated by the fact that risk factors for 
clustering are often risk factors for increased cluster size, which limits the sampling 
bias.[62] It has also been shown that studies of one year or more, or studies in a limited 
geographical area, could reliably identify risk factors for clustering provided the total 
sample size was more than 1,000 cases, the sampling was random (which is often not 
the case), and the sampling fraction was over 40%.[62] 
The molecular methods by which clusters are defined are described in the 
following section. 
1.2.4.1.2 Genotyping tools 
Genotyping refers to the investigation of the genetic makeup of an organism - in 
this case, MTBC. Genotyping can examine all or parts of the bacterial genome. 
Restriction fragment length polymorphism (RFLP) utilizes the IS6110 DNA 
sequence, which is found in most MTBC genomes (often with multiple copies), to 
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distinguish between strains of MTBC. A restriction enzyme is used to cut the DNA 
strands intro fragments at specific sequences in the DNA. These fragments are then 
sorted by size using gel electrophoresis. A probe which binds to the IS6110 sequence 
visualizes the fragments containing this sequence, and the pattern of bands can be 
compared to a reference standard or patterns from other isolates. TB isolates with the 
same or very closely related genomes share banding patterns. RFLP has high 
discriminatory power, but is intensive in terms of the time and laboratory capabilities 
necessary. Furthermore, some strains of TB contain few copies of IS6110, which 
reduces the discriminatory power of RFLP.[63] 
Mycobacterial interspersed repetitive units – variable number tandem repeats 
(MIRU-VNTR) is a strain typing method which focuses on specific sections of the TB 
genome (loci) which contain specific DNA sequences which repeat a number of times. 
The number of repeats varies between different strains of TB. These sequences can be 
amplified using polymerase chain reaction (PCR), and the number of repeats at each 
locus enables different strains to be classified. The number of loci used can vary, with 
discriminatory power increasing as more loci are used. 24-locus MIRU-VNTR is the 
most discriminatory version used.[64] MIRU-VNTR has comparable resolution to 
RFLP,[64, 65] is considerably less laborious (allowing higher throughput), and results in 
a numerical output that is easily comparable between laboratories. 
Widespread use of whole-genome sequencing (WGS) is a relatively novel 
approach to genotyping MTBC, which replicates and mutates slowly. WGS involves 
sequencing the whole genome of the bacteria in the sample, and has the power to 
detect single nucleotide polymorphisms (SNPs) – single nucleotide changes in the 
genome. This enables the construction of chains and networks of transmission, based 
on small evolutionary changes which occur as the organism replicates. WGS data can 
be used to create phylogenetic trees, showing how samples from an outbreak or 
population are genetically related to each other. These can then be combined with data 
on diagnosis and/or symptom onset date, and duration of infectiousness (where known, 
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estimated by sputum smear testing or dates of TB treatment) to create a model of an 
epidemic, either to aid understanding of an outbreak or estimate the impact of 
interventions which may help prevent similar outbreaks. 
There has been much debate regarding what the SNP threshold should be, as 
a cut-off for determining whether two isolates derive from the same source. It has been 
estimated that the TB genome evolves slowly, at approximately 0.5 SNPs per year.[66-
68] SNP thresholds of between 0-10 SNPs have been used to define transmission,[67] 
supported by an analysis combining WGS and epidemiological data which found that 
there were no epidemiological links between patients whose isolates had >5 SNPs 
difference.[68] 
WGS has also provided a gold-standard against which other genotyping tools 
can be evaluated. WGS has demonstrated the discriminatory power to distinguish two 
separate outbreaks within one MIRU-VNTR cluster,[69] and shown that microevolution 
within a host can change the MIRU-VNTR strain type.[68] However, MIRU-VNTR is still 
considered a highly discriminative technique and has many advantages over WGS in 
terms of cost, throughput and comparability. In particular, strain typing using RFLP or 
MIRU-VNTR has been routine in many countries for several years,[52, 70-72] giving 
datasets of a depth and breadth which is not yet possible or practical with WGS. 
There are some limitations to genotyping. It cannot confirm transmission 
between two individuals as a shared genome between two TB cases does not prove 
that one was infected by the other; it is possible that both patients were infected from a 
common source, or it may be a common genotype. Genotyping also cannot identify the 
direction of transmission between individuals, although this can sometimes be 
estimated from dates of diagnosis or symptom onset. Furthermore, many methods of 
genotyping cannot distinguish between closely related TB isolates. Genotyping can 
therefore only be definitively used to rule out transmission between individuals, not to 
confirm it. 
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1.2.5 Epidemiology of tuberculosis 
1.2.5.1 The global burden of tuberculosis 
It is estimated that between a quarter and a third of the world’s population are 
infected with latent TB.[45, 73] In 2015, an estimated 10.4 million people fell ill with TB 
disease, an incidence of approximately 142/100,000 population.[45] Since 2000, the 
number of incident TB cases has declined from 13.0 million to 10.4 million in 2015 (an 
average of 1.5% per year). This rate of decline will need to be increased if the WHO’s 
sustainable development goals aim of a 35% reduction by 2020 is to be met.[1] Sixty 
percent of the global TB burden is concentrated in six countries - India, Indonesia, 
China, Nigeria, Pakistan, and South Africa - but incidence is high across sub-Saharan 
Africa and much of south-east Asia (Figure 1.4). 
Figure 1.4: Estimated TB incidence rates in 2015. 
 
Source: World Health Organisation [1] 
TB is the leading infectious cause of death globally, responsible for 1.8 million 
deaths in 2015.[1] More than 95% of TB deaths were in low- and middle-income 
countries, with 86% of TB deaths occurring in Africa or south-east Asia. The case 
fatality rate (the proportion of TB patients who die from the disease) was 17% in 2015; 
varying from below 5% in some countries, to over 20% in most of Africa.[1] 
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The majority of TB disease is pulmonary; 6.1 million incident TB cases were 
notified to the WHO in 2015 and 15% of these were extra-pulmonary disease.[1] This 
varies by region, with extra-pulmonary TB representing 8% of TB cases in the western 
Pacific region and 23% in the eastern Mediterranean region. 
Drug resistance is an important problem. In 2015 an estimated 580,000 TB 
cases were rifampicin- or multi-drug resistant, accounting for 4% of new TB cases and 
21% of previously treated cases.[74] Death rates among patients with drug resistance 
are high; an estimated 250,000 people died of rifampicin resistant or multi-drug 
resistant TB in 2015.[74] 
Important risk factors for TB globally include HIV infection (see section 1.3), 
diabetes, malnutrition, drug or alcohol misuse, and smoking of tobacco or other 
substances.[75, 76] Other groups that are particularly vulnerable to TB because of 
difficulties accessing healthcare services include those in poverty, refugees or 
displaced populations, and people who are imprisoned or work in prisons.[77] Globally, 
men have a substantially higher risk of TB than women; there were 5.9 million cases of 
TB in men, 3.5 million in women and 1.0 million in children.[1]  
1.2.5.2 Tuberculosis in the UK 
TB has been a notifiable disease in the UK since 1912.[78] Public Health 
England (PHE) receives statutory notifications of all diagnosed TB cases through a 
national surveillance program (described in detail in section 3.1.2.1). 
In 2015, 5,758 TB cases were notified in England, a rate of 10.5 per 100,000 
population.[52] TB incidence increased from 2000 to 2011, but has since been 
declining (Figure 1.5). Outside England, TB incidence was even lower, with 116 TB 
cases notified in Wales (3.7/100,000), 315 in Scotland (5.9/100,000) and 70 in 
Northern Ireland (3.9/100,000) in 2015.[79-81]   
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Figure 1.5: TB case notifications in England, 2000-2015. 
 
Source: Public Health England [52] 
 
TB cases in England are concentrated in London, which accounted for 39% of 
all cases in 2015. 59% were male and 58% were aged 15-44. Of patients with a 
recorded place of birth, 73% were born outside the UK; the incidence rate of 
73.9/100,000 for foreign-born patients was 15 times higher than that in the UK-born 
population in 2015 (3.4/100,000).[52] The most common countries of birth for patients 
with TB in 2015 were India, Pakistan, Somalia, Bangladesh and Nepal, representing a 
decline in TB patients from sub-Saharan Africa and increases in patients from the 
Indian sub-continent and eastern Europe since the mid-2000s.[82, 83] This changing 
epidemiology is partially due to decreased migration from sub-Saharan Africa since the 
mid-2000s. 
The most common site of disease in 2015 was pulmonary, with 53% of cases 
reporting pulmonary disease (with or without extra-pulmonary disease).[52] 36% 
reported lymph node TB, and severe forms of TB such as miliary and meningeal TB 
were reported for 2.8% and 2.3% of patients, respectively. 61% of cases had a sputum 
smear result reported and 50% of these were sputum smear positive. 95% of sputum 
smear positive cases were also culture confirmed.[52] Overall, 60% of TB cases were 
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culture confirmed; 73% of pulmonary cases and 46% of extra-pulmonary cases. The 
majority of cases were drug-sensitive; of culture confirmed cases 7.4% were resistant 
to at least one first line drug, 6.9% were isoniazid resistant, 1.4% were rifampicin 
resistant, and 1.3% had MDR-TB.[52] Rates of treatment completion (defined as 
completing a full course of treatment within a specified timeframe, usually 12 months) 
without evidence of relapse [84]) were generally high (85% of drug-sensitive cases had 
completed treatment at 12 months), but lower among patients prescribed longer 
treatment regimens, e.g. those with drug-resistant TB (56% completed at 24 months) or 
who had central nervous system, spinal, miliary or cryptic disseminated TB (67% had 
completed treatment at their last recorded outcome).[52] 
Ten percent of notified TB cases in 2015 had at least one social risk factor 
(drug misuse [3.3%], alcohol misuse that would prevent adherence to TB treatment 
[3.3%], imprisonment [3.3%] or homelessness [3.4%]). TB patients with social risk 
factors represented 21.7% of UK-born TB cases.[52] The number of TB cases with 
social risk factors has not declined since 2010; consequently the proportion of TB 
cases with social risk factors has been increasing.  
1.3 HIV and tuberculosis co-infection 
There is a synergistic relationship between HIV infection and TB disease. 
Impaired immune function as a result of untreated HIV infection increases the risk of 
progression from LTBI to active TB.[85, 86] There is also some evidence that TB 
accelerates the progression of HIV-related disease. Higher rates of AIDS-defining 
illnesses other than TB have been observed in co-infected patients than HIV-positive 
patients without TB, even after accounting for CD4 count.[87] Additionally, immune 
system activation in response to TB has been shown to increase HIV replication, 
increasing its severity and infectiousness.[88] 
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1.3.1 The role of HIV in tuberculosis transmission 
It is well established that HIV infection increases susceptibility to active TB 
disease by increasing the rate of progression from LTBI to active disease,[85, 88]  
resulting in substantially higher incidence rates of TB.[89] However, it is unclear 
whether HIV infection increases the risk of infection with MTBC.[90] HIV infection is 
also known to increase the risk of recurrent TB.[91] Recurrent TB can be the result of 
reactivation of LTBI, or re-infection from an exogenous source. A review of TB 
clustering in TB-endemic countries reported that TB cases with HIV were more likely to 
be part of a strain type cluster than HIV-negative TB cases; and based on the 
assumption that PLHIV with TB were less likely to be infectious, concluded that the 
increase in clustering was a result of more recent infection in PLHIV and not increased 
reactivation of LTBI.[92] However, the applicability of this conclusion to low-incidence 
settings, where the majority of TB patients were born abroad and the overall force of 
infection is much lower, has not been investigated.  
Unlike many other risk factors associated disease transmission, HIV may 
increase susceptibility to TB disease whilst also causing TB patients to be less 
infectious. Contact studies have shown lower prevalence of TST-positivity and lower 
rates of TST conversion among contacts of HIV-positive index patients than HIV-
negative index patients,[93-95] particularly where the index patients with HIV were 
immunosuppressed.[96] This may be mediated through a shorter duration of 
infectiousness due to accelerated TB disease progression, earlier diagnosis [88, 89] 
and more rapid commencement of TB treatment,[96] and greater mortality.[97, 98] 
Additionally, lower proportions of cavitary [94, 96] or sputum  smear-positive [94, 95, 
99] TB, greater likelihood of extra-pulmonary disease,[100] lower sputum bacterial 
load,[101, 102] and shorter duration of smear positivity [89] or cough [94] may all make 
HIV co-infected patients less likely to transmit infection than HIV-negative TB patients. 
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1.3.2 Clinical complexity of co-infected patients 
The interaction between TB and HIV is also important clinically, and the two 
diseases need to be managed together for the best outcomes for patients. Co-infection 
with HIV and TB can complicate TB diagnosis and treatment, and is generally 
associated with worse outcomes for patients. Diagnostic tests for LTBI appear less 
sensitive in HIV-infected individuals, although IGRAs are less affected by low CD4 
counts and anergy than TSTs.[103, 104] HIV-positive TB patients often have a lower 
concentration of bacteria in their sputum, making it harder to detect in a sputum 
test.[105] Extra-pulmonary TB is also more common among HIV-positive patients, 
cannot be diagnosed with sputum tests or chest x-rays, and has less specific clinical 
signs, making diagnosis tricky.[105] HIV co-infection is associated with recurrence of 
TB,[91, 106] higher rates of other AIDS-defining conditions or opportunistic 
infections,[87] and higher mortality, particularly at low CD4 counts.[107] 
Co-infection also leads to clinical complexity. Immune reconstitution 
inflammatory syndrome (IRIS) is a condition affecting patients co-infected with TB and 
HIV, which occurs when pathogen-specific immune responses are restored, usually by 
a rapid increase in CD4 count. IRIS typically occurs soon after initiation of ART, and 
can present as the relapse of a previously treated infection, or a new presentation of 
what was previously sub-clinical disease.[108] This has resulted in debate regarding 
the optimal timing of ART initiation for co-infected patients, due to concerns regarding 
drug side effects and adherence; however, general guidance is to start ART as soon as 
possible after TB treatment, particularly for patients at low CD4 counts.[109, 110]  
1.3.3 Epidemiology of HIV-tuberculosis co-infections 
1.3.3.1 Global epidemiology of co-infections 
Globally, PLHIV are 17-22 times more likely to develop TB disease than 
persons not infected with HIV.[111] HIV infection has a significant effect on the 
epidemiology of TB, increasing the risk of progression from LTBI to active TB disease 
from a lifetime risk of approximately 10% to an annual risk of around 10%.[112] The 
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risk of developing TB disease doubles in the year following acquisition of HIV infection, 
and increases further in following years if HIV remains untreated as immunodeficiency 
increases.[85, 113] The one-year mortality rate in HIV-positive people is significantly 
higher in individuals with TB disease, particularly in those with low CD4 counts.[114]  
There is considerable geographic overlap in the burden of HIV infection and TB 
disease globally, particularly in sub-Saharan Africa but also in smaller areas (e.g. 
London in the UK). Shared risk factors for both diseases also contribute to high rates of 
co-infection. Both diseases disproportionately affect disadvantaged populations, such 
as migrants and people who are socioeconomically deprived, homeless, incarcerated 
or have problems with drug misuse. The elevated risk of TB in these populations 
occurs through two mechanisms, increased risk of exposure and infection, and an 
increased risk of progression from LTBI to active TB. Sociodemographic factors such 
as homelessness, imprisonment, and/or crowded and poorly ventilated living or 
working conditions increase the risk of transmission by increasing the likelihood of 
contact with an infectious TB case. Difficulties accessing healthcare can also delay 
diagnosis, allowing disease to progress further and prolonging the infectious period. 
The risk of progression from LTBI to active disease is affected by the host immune 
response; which can also be impaired by other risk factors common to both TB and HIV 
such as undernutrition, diabetes, smoking and alcohol misuse.[87] 
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Figure 1.6: Estimated HIV prevalence among TB cases in 2015. 
 
Source: World Health Organisation [1] 
In 2015, there were an estimated total of 10.4 million TB cases globally, of 
which an estimated 1.2 million (12%) were among PLHIV.[115] Within this total, 6.4 
million people with TB were notified to national TB programs and reported to the WHO. 
3.4 million notified cases (55%) had an HIV test result (this varied by region and was 
over 80% in Africa and the Americas), which represents an 18-fold increase in HIV 
testing among TB patients since 2004.[1] Over 500,000 (15%) notified TB cases with 
known HIV status were HIV-positive. The estimated proportion of TB cases with HIV 
was highest in Africa (31%), exceeding 50% in some parts of southern Africa (Figure 
1.6).[1] The increase in HIV testing of TB patients means that whilst 78% of TB cases 
with HIV notified in 2015 had initiated ART, it is estimated that overall only a third of co-
infected patients globally have started ART; substantially lower than the estimated 53% 
of all PLHIV who are on ART.[26] This is likely a result of simultaneous diagnoses of 
TB and HIV, where patients are unaware of their HIV infection until they are diagnosed 
with TB.[3] The WHO recommends systematic testing for TB among PLHIV, but this is 
an insufficient strategy to prevent TB if HIV has not already been diagnosed. 
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TB is the leading cause of death among PLHIV; around 390,000 co-infected 
patients died in 2015, representing 35% of all HIV-related deaths and 22% of TB-
related deaths.[1, 45] 
1.3.3.2 HIV co-infection in European countries with low tuberculosis incidence 
In countries with low TB incidence, both TB and HIV are at very low levels in the 
general population, with epidemics concentrated in certain populations. There is 
considerable overlap between high-risk populations for TB and HIV. Both diseases 
disproportionately affect migrants (particularly those from countries with high burdens 
of TB and HIV), people who are socially deprived such as homeless people, people 
who inject drugs or misuse other substances and people who are imprisoned. 
A 2009 systematic review of TB-HIV co-infection in Europe reported that the 
proportion of TB cases co-infected with HIV varied between 0-15% across European 
Union (EU) and European Economic Area (EEA) countries, with the highest proportions 
of co-infection in Portugal (14.6% in 2008), Estonia (9.9% in 2008), Malta (9.4% in 
2008) and England and Wales (7.4% in 2005).[116] This was confirmed by an analysis 
of surveillance data collated by the European Centre for Disease Prevention and 
Control (ECDC) in 2014 where the prevalence of co-infection was highest in Latvia 
(19.5%), Malta (17.1%), Portugal (14.7%) and Estonia (10.1%). It is notable that this 
analysis excluded data from the UK, France, Germany and Poland, which do not report 
HIV status for TB cases to ECDC, but together account for 40% of TB cases in Europe. 
This study also excluded data from countries with poor recording of HIV status of TB 
cases (particularly the Czech Republic, Denmark, Hungary and Iceland).[117] 
TB incidence among PLHIV is also substantially higher than in the general 
population. For example, TB incidence among PLHIV was estimated at 370/100,000 in 
Germany between 2001-2011 [118] and 375/100,000 in the UK between 1995-
2005;[119] these incidence rates were 30-45 times higher than the average incidence 
in the general population over these time periods of approximately 8/100,000 and 
13/100,000, respectively.[120] 
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Whilst the absolute numbers of people affected by TB-HIV co-infection are 
relatively few in low-incidence countries, co-infection remains an important clinical 
problem. Treatment outcome success was significantly lower for co-infected patients 
than HIV-negative TB patients across Europe in 2013, with only 58% patients 
successfully completing treatment compared to 84% for HIV-negative patients.[117] 
The proportion of co-infected patients that died whilst on TB treatment was also 
significantly higher; 14% of co-infected patients died compared to 5.6% of HIV-negative 
patients.[117] Rates of death for co-infected patients were substantially higher for 
patients in eastern Europe than western Europe.[121] 
1.3.3.3 Co-infections in the UK 
Using the most recent available data, 197/6,209 (3.2%) of adult TB cases in 
England in 2014 were in people co-infected with HIV.[82] The proportion of new cases 
of TB in England, Wales and Northern Ireland that were in individuals co-infected with 
HIV rose from 3.1% in 1999 to a peak of 9.5% between 2005-2006.[122, 123] Over 
30% of the increase in the number of new TB cases in adults aged 15-64 years 
between 1999 and 2003 was estimated to be as a result of HIV infections.[123] Co-
infection levels have since decreased, to 4.0% in 2011 and 3.2% in 2014.[82, 124] This 
has partly been attributed to changing migration patterns, resulting in less TB in black 
African individuals from countries with a high HIV prevalence and more among 
individuals from Asian countries with low HIV prevalence.[82] 
In the UK, the annual incidence of TB among PLHIV was 1,600/100,000 in 2004 
and 1,750/100,000 in 2008,[125, 126] but incidence declined to 438/100,000 by 
2011.[125] This decline is partly due to an increase in the number of people living with 
HIV who are on effective ART, and also due to a decrease in new HIV diagnoses in 
people originating from sub-Saharan Africa, where the prevalence of both infections is 
high and late presentation to health services is common.[125] Until 2015, TB was the 
second most common AIDS-defining illness among PLHIV in the UK.[10, 125] 
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1.4 Summary and objectives 
Co-infection with HIV and TB is an important clinical and public health problem. 
Despite low levels of both HIV and TB in many high-income countries, both diseases 
are more prevalent in hard-to-reach sub-populations, making it difficult to eradicate 
these diseases. Timely diagnosis of HIV can be challenging, which leaves opportunities 
for diseases such as TB to manifest as immune function declines, causing significant 
morbidity and mortality. In contrast to high-burden settings, where HIV infection 
contributed substantially to the modern TB epidemic, the extent of the role of HIV 
infection in TB transmission in low-incidence settings is less clear. The aims of this 
thesis are therefore as follows: 
1. To review the literature on the risk factors for developing TB for people with HIV 
in settings with low TB incidence (Chapter 2). 
2. To link national TB and HIV surveillance datasets to identify co-infected patients 
in England, Wales and Northern Ireland (Chapter 3). 
3. To describe the epidemiology of TB-HIV co-infections in the UK and examine 
risk factors for developing TB for people living with HIV (Chapter 4). 
4. To describe trends in HIV co-infection among TB cases and investigate risk 
factors for co-infection (Chapter 5). 
5. To examine whether HIV is a risk factor for TB transmission in the UK (Chapter 
6). 
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2 Tuberculosis infection and disease in people living 
with HIV in countries with low tuberculosis 
incidence: A systematic review 
2.1 Introduction 
TB-HIV co-infection remains a persistent public health problem in countries with 
low TB incidence, which is defined by the WHO as less than 10 cases per 100,000 
population.[87] In 2012, an estimated 155,000 people fell ill with TB in low-incidence 
countries and 10,000 people died.[127] TB in low-incidence countries mostly affects 
vulnerable populations, such as recent migrants (particularly those from countries with 
high TB incidence), people who are homeless, incarcerated, or have problems with 
substance abuse, as well as PLHIV.[127] There is considerable overlap between these 
groups, who are often referred to as ‘hard to reach’ by healthcare services as poverty 
and social deprivation make accessing care difficult.[128]  
Accordingly, priority areas of the WHO’s action framework for TB in low-
incidence countries include addressing TB in the most vulnerable and hard-to-reach 
groups, screening for latent and active TB in high-risk groups and ensuring continued 
surveillance, evaluation and case-based data management.[87] Universal screening of 
PLHIV for active TB is recommended, but is not implemented in all low-incidence 
countries.[87] Universal screening for LTBI is also recommended for PLHIV and other 
high-risk groups, but is also not widely implemented. Other interventions - such as the 
offer and recommendation of a HIV test to all people newly diagnosed with TB, contact 
tracing and active case finding - focus more on finding and promptly treating new 
cases, and preventing further transmission, than on preventing TB occurring as a result 
of LTBI reactivation. 
Efforts to control TB in people with HIV are hampered by the significant 
proportion of PLHIV who are undiagnosed, diagnosed late, or not diagnosed until they 
present to healthcare service with other opportunistic infections such as TB.[129] 




Managing TB in PLHIV is also more clinically complex, as a result of side effects of 
treatment, drug-drug interactions, and often a more severe presentation of 
disease.[130] Preventing TB in PLHIV is therefore an important goal. Pressure on 
resources, even in countries with low TB incidence, necessitates the targeting of 
preventative activities such as screening for HIV, LTBI and active TB. It is therefore 
critical to have a clear insight into risk factors for TB disease in PLHIV in countries with 
low TB incidence. This review provides an up-to-date synthesis of such evidence for 
both LTBI and TB among PLHIV. 
2.2 Methods 
A systematic search of PubMed, EMBASE and Web of Science was done on 4th 
May 2017 for articles on risk factors for LTBI or active TB disease among PLHIV in 
countries with low TB incidence. 
Low TB incidence was defined as per the WHO definition, as ≤10 cases per 
100,000 population,[87] in 2015, and included the following countries: American 
Samoa, Andorra, Antigua and Barbuda, Australia, Austria, Barbados, Belgium, 
Bermuda, Bonaire, Saint Eustace and Saba, British Virgin Islands, Canada, Cook 
Islands, Cuba, Curacao, Cyprus, Czechia, Denmark, Finland, France, Germany, 
Greece, Grenada, Hungary, Iceland, Ireland, Israel, Italy, Jamaica, Jordan, 
Luxembourg, Malta, Monaco, Montserrat, the Netherlands, New Zealand, Niue, 
Norway, Oman, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the 
Grenadines, San Marino, the Seychelles, Sint Maarten, Slovakia, Slovenia, Sweden, 
Switzerland, Tokelau, Turks and Caicos Islands, United Arab Emirates, United 
Kingdom of Great Britain and Northern Ireland, United States of America, US Virgin 
Islands, Wallis and Futuna Islands, West Bank and the Gaza Strip. The search terms 
included variations of ‘tuberculosis’, ‘HIV’ and the low-incidence countries; full details of 
the search strategy and results are shown in Appendix 1. Studies presenting data on 
multi-country cohorts were excluded if any country contributing patients to the cohort 




did not have low TB incidence, unless data was presented separately for each country. 
No limits were placed on year or language of publication. 
The search results were de-duplicated and screening was done by title, abstract 
and then full-text by two reviewers (Joanne Winter and Aishatu Adamu), with 10% 
overlap. Review articles, case reports, and original research articles where the 
outcome was not latent or active TB in a population of PLHIV were excluded. Any 
disagreements between the reviewers were resolved by consensus. The reference lists 
of included articles and relevant review articles were screened for additional papers. 
The following data were extracted into a form developed in Excel (Microsoft 
2010): the outcome(s) studied (LTBI and/or active TB), publication details (author, year 
and country), details of the study (the time period covered, location, design, and the 
population of PLHIV that made up the study population), the prevalence of LTBI and 
the test used to detect it (for studies examining LTBI), the incidence of active TB during 
the study (for studies examining active TB), the risk factors the study reported on, and 
the associations between these risk factors and the outcome(s). 
A narrative synthesis of the findings is presented. The review was registered on 
the PROSPERO international prospective register of systematic reviews 
(CRD42017069544). 
2.3 Results 
2.3.1 Search results and included studies 
After de-duplication, the search yielded 5,804 results; full search results are 
shown in Appendix 1. After title, abstract and full-text screening, 45 studies were 
included (Figure 2.1). Initial reviewer agreement was 99.3%, resolved to 100% after 
comparing the discrepant papers against the inclusion criteria. Ten studies which 
reported risk factor data across a mixture of high- and low-burden countries were 
excluded. 




Of the 45 included studies (summarised in Table 2.1), 13 provided data on risk 
factors for LTBI,[104, 131-146] 28 contained data on risk factors for active TB,[118, 
119, 143-172] and 4 studies contained data on both.[143-146] Of the included studies, 
34 were cohort studies (17 prospective,[118, 119, 131, 134, 139, 140, 143, 144, 147, 
148, 150, 152, 153, 156, 163, 169, 172] 12 retrospective,[133, 146, 149, 151, 155, 159, 
164-167, 170, 171] 5 not stated [136, 154, 160-162]), 7 were cross-sectional (5 
collected data prospectively,[104, 132, 137, 138, 142] 2 retrospectively [135, 141]). 
Two studies were case-control studies nested within cohort studies[157, 168] and 3 
were outbreak investigations,[145, 156, 158] one of which included a retrospective 
case-control analysis.[158] 
Figure 2.1: Flow chart of the screening process and included studies. 
 
PLHIV: people living with HIV, TB: tuberculosis. 
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(per 100,000 PY) 











11.8% (TST + QFT-
GIT/T-SPOT.TB), 
14.7% (TST only) 
14.5% over two 
years of follow-up 
Age, sex, country of 
birth/residence, CD4 count, 
viral load, BCG vaccination, 
history of TB, history of 










4.6% (QFT-GIT) N/A age, sex, country of birth, 
year of HIV diagnosis, AIDS-
defining illness, previous TB 
diagnosis and treatment, 
country of birth, exposure to 
smear-positive TB contact, 













18% (QFT-GIT), 11% 
(T-SPOT.TB), 10% 
(TST). 
N/A sex, age, country of birth, 
TB exposure (contact with 
TB, high-incidence country 
of birth, or occupational 
exposure), drug misuse, 
homelessness, 
imprisonment, ART, CD4 












(TST), incidence 5.3% 
(1.77/100PY) (TST 
conversion)  
N/A age, sex, ethnicity, country 
of birth, CD4 count, ever 
homeless, group living, viral 













0.8% conversion PY 
(TST) 
N/A CD4, viral load, time on 
ART. 









Location Study design Study 
population 
LTBI prevalence and 
test used 
TB incidence 
(per 100,000 PY) 















Italy cohort TST-negative 
HIV patients 
on HAART 
5.4% TST conversion 
over 3 years 
N/A age, sex, drug misuse, 
delayed-type 
hypersensitivity result, 
AIDS-defining illness, viral 





London, UK prospective 
cross-sectional 
HIV patients 13.3% (T-SPOT.TB) No active TB 
cases during the 
follow-up period 
age, sex, ethnicity, country 
of birth and TB incidence, 












9.3% (TST) 8.5% 
(QFT-GIT) 
N/A age, sex, ethnicity, 
homelessness, injecting 
drug use, CD4 count, viral 
load, ART, TST placed, TST 
result, prior active TB, BCG, 













6% (standard TST 
definition of 5mm+) or 
9% (using 2mm+ 
definition) 
N/A Age, ethnicity, pregnancy, 
years of education, medicaid 
health insurance, low 











26% (QFT-GIT), 25% 
(TSPOT.TB), 24% 
(TST) 
No active TB 
cases over 24 
months follow-up 
Age, sex, country of birth, 
years resident in Norway, 
previous AIDS-defining 
illness, time since HIV 
diagnosis, CD4 count, ART, 
TB contact, visit to TB-
endemic country, previous 
TB disease. 
         
         
         









Location Study design Study 
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LTBI prevalence and 
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TB incidence 
(per 100,000 PY) 










31.9% (TST) N/A Age, country of birth, 
prenatal care in first 
trimester, unknown HIV at 
first prenatal visit, ADI, drug 












12% (TST), 24% (QFT-
GIT), 24% (TSPOT.TB) 
No active TB 
cases during the 
follow-up period 
age, sex, ethnicity, country 
of birth, route of HIV 
infection, prior AIDS 
diagnosis, CD4 count, viral 
load, ART, time since HIV 
diagnosis, prior TB, 














N/A 400/100,000 age, sex, country of birth, 
duration of follow-up, CD4 
count, viral load, ART, 
region of care, prior AIDS, 
heterosexual route of HIV 











N/A 2250/100,000 Age, sex, HIV transmission 
category, place of 
residence, history of TB, 



















TB exposure, age, sex, 
injecting drug use, prior 
AIDS. 
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TB incidence 
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N/A 790/100,000 age, sex, country of birth, 
place of residence, route of 
HIV infection, history of TB, 
recent TB contact, TST 
result, CD4 count, clinical 
stage, previous isoniazid 















N/A 328/100,000 age, sex, route of HIV 
infection, ethnicity, CD4 
count, time on ART, viral 

















N/A 670/100,000 sex, age, ethnicity, route of 




















age, CD4 count, cumulative 
co-trimoxazole use, region 
















N/A 500/100,000 age, sex, ethnicity, country 
of birth, route of HIV 
transmission, CD4 count, 
ART, isoniazid preventive 












N/A 370/100,000 sex, country of birth, ART, 
viral load, CD4 count, route 















N/A 281/100,000 age, sex, ethnicity, country 
of birth, ART, CD4 count, 
viral load 









Location Study design Study 
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LTBI prevalence and 
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TB incidence 
(per 100,000 PY) 
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N/A 700/100,000 sex, ethnicity, route of HIV 
infection, region, education, 








USA case control 




















N/A 21,100/100,000 CD4 count, close contact 
with TB disease, time in day 
room, TV in cell, prior LTBI 
treatment, prior TB infection 
or disease, anergy, school 
attendance, work, TB inmate 









PLHWA N/A 690/100,000 age, sex, route of HIV 
infection, year of HIV 
diagnosis, time from 


























N/A 65/100,000 ART, age, sex, ethnicity, 
country of birth, injecting 
drug use, CD4 count, viral 













N/A 165/100,000 ART, sex, age, ethnicity, 
country of birth, route of HIV 
infection, CD4 count, viral 
load. 
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TB incidence 
(per 100,000 PY) 












N/A No active TB. age, sex, time since 
migration, years since HIV 
















N/A 1,900/100,000 sex, age, ethnicity, CD4 
count, country of birth, 














































N/A 71/100,000 age, sex, ethnicity, ART, 
CD4 count, viral load, 







Switzerland case control 




N/A 3.4% of cohort 
had TB. Incidence 
not reported. 
age, sex, country of birth, 
route of HIV infection, 
calendar year, CD4 count, 


















N/A 820/100,000 sex, age, year, country of 
birth, CD4 count, viral load, 
route of HIV infection, 
alcohol misuse, ART. 
         
         
         
         









Location Study design Study 
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TB incidence 
(per 100,000 PY) 













N/A 610/100,000 year of birth, sex, ethnicity, 
mother's route of HIV 
infection, level of 
immunosuppression (based 



























N/A 196/100,000 sex, age, country of birth, 
ethnicity, region, clinical 
stage, calendar period, ART, 














5.3% (QFT-GIT) 840/100,000 LTBI: age, sex, ethnicity, 
country of birth, CD4 count, 
ART, viral load, prior TB, 
AIDS-defining illness, route 
of HIV infection. TB disease: 
country of birth, symptoms, 
CD4, viral load, ART, TST 














14.1% (TST) 181/100,000 LTBI: CD4 count, country of 
birth, route of HIV infection, 
ART. TB disease: age, sex, 
country of birth, time from 
HIV diagnosis to first clinic 
visit, HIV infection route, 
ART, CD4 count, LTBI 
treatment. 
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LTBI prevalence and 
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(per 100,000 PY) 













9.4% (TST) 220/100,000 Active TB: route of HIV 
infection, age, region of 
origin, isoniazid preventive 
therapy, ART, viral load, 
sex, CD4 count. LTBI: 
country of origin, sex, route 
of HIV infection, age, CD4 



















55.1% (TST) 30/323 developed 
TB within 1 
month, 32 within 2 
years. 
Days exposed to source 
patients, CD4 count, 
proximity to source patient, 
viral load, ART. 
AIDS: acquired immunodeficiency syndrome, ART: anti-retroviral therapy, BCG: Bacillus Calmette-Guérin, CDC: Centers for Disease Prevention and 
Control, DTH: delayed-type hypersensitivity, LTBI: latent tuberculosis infection, QFT-GIT: quantiFERON-gold in-tube, TB: tuberculosis, TST: tuberculin 
skin test. 





The studies spanned the period 1977-2014. One study examining both latent 
and active TB reported no cases of active TB during the follow-up period and so no 
data on risk factors for active TB were available.[163] 
2.3.2 Risk factors for latent tuberculosis infection 
The documented risk factors for LTBI were divided into two categories: 
sociodemographic and clinical (Table 2.2; shown in more detail in Appendices 2 and 3). 
Sociodemographic factors 
The literature included data on the following socioeconomic risk factors for 
LTBI: age, ethnicity, country of birth or residence, sex, pregnancy, route of HIV 
infection, drug misuse, alcohol misuse, homelessness, imprisonment, level of 
education, income and occupation. 
In terms of ethnicity, LTBI was more common among black, Asian and Hispanic 
study participants than white participants in low TB incidence countries.[133, 135, 137, 
139, 143] These studies were all undertaken in countries where people are 
predominantly white, except one partially conducted in Puerto Rico,[139] which is 
primarily Hispanic. Only two studies reported no difference in LTBI risk by 
ethnicity.[138, 142] Country of birth or residence was a strong predictor of LTBI, which 
was positively correlated with TB incidence in country of birth or long-term residence 
[104, 131, 132, 137, 138, 142, 143, 163] and was higher in participants born 
abroad,[141, 142, 173] particularly those from African countries [173] and medium-risk 
areas.[133, 144, 146] LTBI risk decreased with time since migration for foreign-born 
participants.[163] Visiting a TB-endemic country was not associated with increased risk 
of LTBI.[163] 
  




Table 2.2: Summary of risk factors for LTBI among people living with HIV. 




Age Greater risk with increasing age: 1 study  [139] 
QFT-GIT-positive participants were significantly younger than 
QFT-GIT-negative participants: 1 study [104] 
No association: 11 studies [131-133, 136-138, 141-144, 163] 
Ethnicity Greater risk for black participants than white participants: 4 studies 
[135, 137, 139, 143] 
Greater risk for Asian participants than white participants: 2 studies 
[133, 137] 
Greater risk for Hispanic participants than white participants: 1 
study [135] 
No association: 2 studies [138, 142] 
Country of birth or 
residence 
Greater risk of LTBI in participants who were born abroad: 4 
studies [133, 141, 143, 144] 
Greater risk of LTBI in participants born in Africa: 3 studies [143, 
144, 146] 
Greater risk for participants who were born or long-term residents 
in countries with high TB incidence: 7 studies [104, 131, 132, 137, 
138, 142, 163] 
Risk of TB decreased with time since migration:  1 study [163] 
No association with visiting a TB-endemic country: 1 study  [163] 
Sex Greater risk for women: 2 studies [131, 143] 
Greater risk for men: 1 study [144] 
No association: 9 studies [104, 132, 133, 135-138, 142, 163] 
Single-sex studies: 4 studies [134, 139, 141, 145] 
Pregnancy No association: 1 study [139] 
All participants were pregnant: 1 study [141] 
Route of HIV infection Higher rates of TST positivity among people who inject drugs 
and/or have a partner who injects drugs: 2 studies [135, 144] 
Higher rates of TST positivity among people who acquired HIV 
through heterosexual sex than by sex between men: 1 study [144] 
Significant, but not described, differences in risk by infection route: 
1 study [146] 
No association: 2 studies [142, 143] 
Drug misuse Higher rates of illicit drug use among TST-positive participants 
than TST-negative participants: 1 study [139] 
No association between injecting or recreational drug use and 
LTBI: 8 studies [104, 132, 133, 136, 138, 141-143] 
Alcohol misuse No association: 2 studies [104, 133] 
  




Risk factor for LTBI Summary of results 
Homelessness Greater risk among those who were homeless, or lived in 
group/institutional living or a homeless shelter: 3 studies [131, 133, 
139] 
No association: 3 studies [132, 138, 142] 
Imprisonment No association: 4 studies [132, 133, 139, 142] 
All participants were in prison: 1 study [145] 
Level of education No association: 1 study [139] 
Income No association between income and LTBI: 1 study [139] 
No association between receiving public social aid and LTBI: 1 
study [142] 
Occupation No association: 1 study [132] 
Clinical factors  
CD4 count and DTH result Higher rates of LTBI at higher CD4 counts: 7 studies [133, 136, 
142-144, 146, 163] 
No association between CD4 count and LTBI: 7 studies [104, 131, 
132, 134, 137, 138, 145] 
No association between a positive DTH reaction and LTBI: 1 study 
[136] 
Viral load Greater risk with high viral load: 1 study [143] 
Lower risk with viral load: 1 study [144] 
No association: 9 studies [104, 131-134, 136, 138, 142, 145] 
Anti-retroviral therapy Lower risk of LTBI for participants on ART: 3 studies [134, 143, 
144] 
No association: 8 studies [104, 132, 137, 138, 142, 145, 146, 163] 
All patients were on ART: 1 study [136] 
BCG vaccination No association: 2 studies [131, 138] 
Previous TB disease Greater risk of LTBI for patients with prior active TB disease: 6 
studies [104, 131, 138, 142, 143, 163] 
Latent tuberculosis 
infection 
Greater risk of current LTBI for patients with a history of LTBI: 2 
studies [131, 138] 
Previous treatment for 
LTBI 
Participants with LTBI were more likely to have been previously 
treated for LTBI: 1 study [138] 
Contact with TB, or other 
close exposure to TB 
Greater risk for those living or working in a homeless shelter, 
prison or drug rehabilitation unit: 1 study [138] 
Greater risk for participants with a contact with TB or smear-
positive TB: 5 studies [104, 131, 139, 141, 163] 
Greater risk for prisoners closer to the source patient of an 
outbreak within a prison: 1 study [145] 
No association: 2 studies [132, 138] 
AIDS-defining illness Higher risk of LTBI for patients with prior AIDS: 1 study [142] 
No association: 4 studies[104, 136, 141, 163] 
  




Risk factor for LTBI Summary of results 
Other non-infectious co-
morbidities 
No association between diabetes and LTBI: 1 study [104] 
Time since HIV diagnosis 
or duration of follow-up 
time 
No association: 4 studies [104, 141, 142, 163] 
AIDS: acquired immunodeficiency syndrome, ART: anti-retroviral therapy, BCG: Bacillus 
Calmette-Guérin, DTH: delayed-type hypersensitivity, LTBI: latent tuberculosis infection, 
QFT-GIT: quantiFERON-gold in-tube, TB: tuberculosis, TST: tuberculin skin test. 
 
No studies reported a definitive association between age and LTBI, although 
the majority of studies were restricted to adults, and one was restricted to children.[172] 
Ten studies reported no association between sex and LTBI and four were restricted to 
either men or women; however two studies reported men were more likely to be 
interferon-gamma release assay (IGRA)-positive [131, 143] and one older study found 
that women were less likely to be TST-positive.[144] One study reported no association 
between pregnancy and TST positivity among women.[139] HIV acquisition through 
injecting drug use, heterosexual sex or an unknown route was associated with higher 
prevalence of LTBI than MSM, and having a partner who injected drugs was also 
associated with increased risk.[135, 139, 144] However, two other studies found no 
association between route of HIV infection and LTBI,[142, 143] and eight other studies 
found no association between injecting or recreational drug use and LTBI.[104, 132, 
133, 136, 138, 141-143]. 
Collective living in a group or institution was positively associated with IGRA-
positivity,[131] and TST conversion rates were higher among people who were 
homeless or had ever lived in a shelter.[133, 139] However, three other studies found 
no association between homelessness or living in a shelter and LTBI.[132, 138, 142] 
Living or working in a homeless shelter, prison or drug rehabilitation unit was 
associated with higher rates of TST positivity but not QuantiFERON-TB Gold In-Tube 
(QFT-GIT) positivity.[138] However, in other studies, imprisonment was not associated 
with TST positivity,[139] TST conversion,[133, 142] or QFT-GIT or T-SPOT.TB 
positivity.[132, 142] One study of TST conversion rates during an outbreak of TB in a 




prison found that rates of TST conversion were not significantly different between the 
dormitory of the source patient and other dormitories over the same time period.[145] 
Neither alcohol misuse nor years of education were associated with LTBI. Income was 
not associated with LTBI.[139, 142] One study found no association between 
occupational exposure and LTBI, although ‘occupational exposure’ was not 
defined.[132] 
Clinical factors 
The available literature included data on the following risk factors: CD4 count 
and DTH result, viral load, anti-retroviral therapy, BCG vaccination, previous TB 
disease, LTBI, previous treatment for LTBI, contacts with TB, AIDS-defining illnesses, 
other non-infectious co-morbidities and time since HIV diagnosis. 
Higher CD4 count was associated with higher rates of TST positivity [134, 144, 
146] and TST conversion,[136] whilst an increase in CD4 count from the baseline 
measurement was associated with higher odds of TST conversion compared to 
participants whose CD4 count had decreased.[133] However, three other studies found 
no significant association.[134, 142, 145] Nadir CD4 count >350cells/µl was associated 
with higher rates of TST and QFT-GIT positivity in two studies,[138, 163] and higher 
CD4 counts were associated with QFT-GIT positivity.[132, 142, 143] Other studies 
reported no association between CD4 count and LTBI.[104, 131, 132, 137, 142] Only 
one study reported higher median viral load among participants with a positive QFT-
GIT result,[143] all others reported no significant association between viral load and 
TST positivity,[134, 138, 142, 144, 145] TST conversion,[133, 136] or IGRA-
positivity.[104, 131, 132, 138, 142] The majority of studies found no significant 
association between ART and LTBI diagnosed by TST,[138, 142, 145, 146, 163] QFT-
GIT,[104, 132, 138, 142, 163] or T-SPOT.TB.[132, 137, 142] There was no significant 
association between prior TB disease and TST positivity,[138] but all studies which 
used IGRAs to diagnose LTBI found higher rates of IGRA positivity among patients 
with previous active TB disease than patients who had not previously had TB.[104, 




131, 138, 142, 143, 163] A history of LTBI was associated with IGRA positivity [131] 
and prior TST positivity was associated with current TST positivity and QFT-GIT 
positivity.[138] 
Exposure to TB disease was an important risk factor for having LTBI. Eight 
studies reported data on exposure and only two reported no association with 
LTBI.[132, 138] Having a contact with active TB was associated with higher rates of 
IGRA-positivity[104, 131, 163] and TST positivity,[141] whilst another study found that 
more TST-positive participants had a close contact with TB disease than TST-negative 
participants.[139] The odds of TST conversion during a TB outbreak in a prison were 
increased for patients on the same side of the dormitory as the source patient and 
patients who were exposed for a longer time period.[145] 
BCG vaccination did not appear to be associated with LTBI among PLHIV; both 
studies which examined BCG as a risk factor utilised both IGRAs and the TST and 
found no association using either test.[131, 138] Prior AIDS was not associated with 
LTBI,[104, 136, 141, 163] although one study found that a higher proportion of TST-
positive participants had a prior AIDS diagnosis than TST-negative participants.[142] 
Diabetes was not associated with a positive QFT-GIT result.[104] Time since HIV 
diagnosis was not significantly associated with LTBI risk.[104, 142, 163] 
2.3.3 Risk factors for tuberculosis disease  
The documented risk factors for TB disease were also divided into sociodemographic 
and clinical factors (Table 2.3; shown in more detail in Appendices 4 and 5). 
Sociodemographic factors 
Data were reported on the following sociodemographic risk factors for active 
TB: age, ethnicity, country of birth or residence, region of country of birth, sex, route of 
HIV infection, drug misuse, alcohol misuse, homelessness, imprisonment and level of 
education. 




Black or black African ethnicity was consistently associated with higher risk of 
active TB than for people of white ethnicity.[119, 145, 151, 155, 161, 162, 164, 167, 
170, 171] South Asian [151, 164], Hispanic [167, 170, 171] and ‘other’ [119, 151, 167, 
170] ethnicities were also associated with higher rates of TB, although black Caribbean 
ethnicity was not.[164] Being born in Asia,[152, 169] Africa [146, 152, 169] or sub-
Saharan Africa,[118, 144, 146, 147, 154] or south America [152] was associated with a 
higher risk of TB than being born in the low-incidence countries in which these studies 
were conducted (Canada, Denmark, France, Germany and Switzerland). Five studies 
reporting country of birth as foreign-born or not all found a higher risk of TB for foreign-
born patients.[153, 161, 162, 171, 172] Risk of TB increased with the TB incidence in 
country of birth,[154] and with increasing time interval from entry to the study country to 
HIV diagnosis.[159] 
There was generally no association between age and risk of TB, although the 
only study which included children reported a significantly lower risk for children aged 
0-5 years than the baseline of 5-10 years.[172] Data on the risk of TB associated with 
sex were mixed. Two studies reported a lower risk of TB for men than women,[146, 
170] but several others reported higher rates of TB for men than women.[153, 159, 
162, 164, 165, 169]  




Table 2.3: Summary of risk factors for active TB disease among people living with HIV. 
Risk factor for 
active TB 




Age Risk increases with age: 2 studies [152, 159] 
Risk decreases with age: 1 study [146] 
Risk was highest in the middle age categories: 3 studies [151, 171, 172] 
No association: 17 studies [118, 119, 144, 147-150, 153-155, 160-162, 
164, 167-169] 
Ethnicity Greater risk for black or black African participants than white participants: 
10 studies [119, 145, 151, 155, 161, 162, 164, 167, 170, 171] 
Greater risk for Asian participants than white participants: 3 studies [151, 
164, 171] 
Greater risk for Hispanic participants: 2 studies [167, 171] 
No association: 4 studies [153, 154, 156, 172] 
Country of birth or 
residence 
Greater risk among participants who were born or acquired HIV abroad: 8 
studies [146, 147, 153, 161, 162, 164, 171, 172] 
Greater risk among participants from Africa: 5 studies [118, 144, 147, 
152, 169]  
Greater risk among participants from Asia: 2 studies [152, 169] 
Greater risk among participants from south America: 1 study [152]  
Greater risk for participants from countries with higher TB incidence: 2 
studies [154, 168] 
Risk of TB increased with time since arrival for foreign-born participants: 
1 study [159] 
No association: 2 studies [143, 150] 
Region Risk of TB varied by region of country: 1 study [147] 
No association: 4 studies [148, 150, 156, 172] 
Sex Greater risk for men: 5 studies [153, 159, 162, 164, 165] 
Greater risk for women: 2 studies [146, 170] 
No association: 15 studies [118, 144, 148-151, 155, 156, 160, 161, 167-
169, 171, 172] 
Risk presented grouped with route of HIV infection: 2 studies [119, 147] 












Risk factor for 
active TB 
Summary of results 
Route of HIV 
infection 
Greater risk for people who acquired HIV through heterosexual sex than 
from sex between men: 7 studies [119, 147, 151, 153, 159, 162, 169] 
Greater risk for people who acquired HIV infection through injecting drug 
use than from sex between men: 5 studies [147, 151, 153, 159, 169] 
Greater risk for people who acquired HIV through mother-to-child 
transmission than from sex between men: 1 study [151] 
Greater risk among children with mothers who acquired HIV through 
injecting drug use: 1 study [170] 
No association: 7 studies [118, 144, 146, 148, 150, 156, 168] 
All participants were heterosexual: 1 study [164] 
Drug misuse Greater risk for participants who inject drugs: 3 studies [152, 161, 167] 
Greater risk for participants who used tobacco long-term: 1 study [157] 
No association: 1 study [149] 
All participants had a history of prior or current drug use: 2 studies [157, 
165] 
Alcohol misuse No association: 1 study [169] 
Imprisonment All participants were in prison: 2 studies [145, 158] 
Level of education No association: 1 study [156] 
Clinical factors  
Year of diagnosis Greater risk among those who entered the cohort later: 1 study [147] 
Greater risk of TB if diagnosing with HIV during the ART era than prior to 
ART being introduced: 1 study [159] 
No association: 3 studies [119, 169, 172] 
CD4 count Greater risk at lower CD4 count: 22 studies [118, 119, 143, 144, 147, 
148, 150-156, 158, 160-162, 164, 167-170] 
No association: 3 studies [145, 146, 157] 
Viral load Greater risk with higher viral load: 9 studies [118, 119, 143, 144, 147, 
151, 154, 161, 162] 
No association: 6 studies [145, 153, 155, 167, 169, 172] 
Anti-retroviral 
therapy 
Lower risk for patients on ART: 10 studies [118, 143, 144, 147, 150, 153, 
161, 162, 164, 169] 
Lower risk with increasing time on ART: 4 studies [119, 147, 161, 162] 
No association: 7 studies [145, 146, 148, 154, 155, 167, 172] 
All patients were on ART: 1 study [151] 
Previous TB 
disease 
Greater risk for patients with a history of TB: 1 study [148] 
No association: 1 study [158] 
LTBI infection and 
anergy 
Greater risk for patients with known LTBI: 6 studies [144, 148, 150, 156, 
165, 166] 
Greater risk for anergic patients: 1 study [148] 
No association: 1 study [158] 
  




Risk factor for 
active TB 
Summary of results 
Previous treatment 
for LTBI 
Lower risk for patients who had been treated for LTBI: 4 studies [144, 
146, 165, 166] 
No association: 2 studies [153, 158] 
Contact with TB or 
other close 
exposure to TB 
Greater risk for patients who had been exposed to active TB: 3 studies 
[145, 149, 158] 
AIDS-defining 
illness or other 
opportunistic 
infections 
Greater risk for patients with prior AIDS: 2 studies [147, 153] 
Greater risk for patients with more clinical symptoms of AIDS: 1 study 
[143] 
No association: 4 studies [148-150, 172] 
Lower risk for patients taking prophylactic co-trimoxazole: 1 study [152] 




Decreasing risk over time: 2 studies [118, 147] 
Greater risk for patients with more follow-up time: 1 study [168] 
No association: 1 study [155] 
AIDS: acquired immunodeficiency syndrome, ART: anti-retroviral therapy, BCG: Bacillus 
Calmette-Guérin, LTBI: latent tuberculosis infection, QFT-GIT: QuantiFERON-gold in-
tube, TB: tuberculosis, TST: tuberculin skin test. 
 
Three studies reported no association between route of HIV infection and risk of 
tuberculosis.[148, 150, 168] Other studies reported that MSM had lower risk of TB than 
people who acquired HIV infection through heterosexual sex or other routes of 
infection,[118, 119, 146, 151, 153, 159, 169] injecting drug use [151, 153, 156, 159, 
169] or mother-to-child transmission.[151] One study of children reported HIV infection 
route for the mother, and reported that children with TB were more likely to have 
mothers who acquired HIV through injecting drug use than through heterosexual sex or 
other routes of transmission, compared to HIV-infected children without TB.[170] 
Injecting drug use was associated with increased risk of TB,[152, 161, 167] as was 
long term tobacco use.[157] The risk of TB was not associated with alcohol misuse 
[174] or level of education.[156] 
Clinical factors 
Data were reported on the following clinical risk factors for active TB: year of 
HIV diagnosis, CD4 count, viral load, anti-retroviral therapy, previous TB disease, LTBI, 




previous treatment for LTBI, exposure to TB, AIDS-defining illnesses and time since 
HIV diagnosis. 
Lower CD4 counts were overwhelmingly associated with greater risk of 
developing TB.[118, 119, 144, 147, 148, 150, 152-154, 156, 164, 167-169] Studies 
reported that patients with active TB had significantly lower median CD4 counts [143, 
155, 161, 162] or CD4 percentage[160, 162] during the study period, although lower 
nadir CD4 count was not associated with TB.[143] Four studies reported no association 
between CD4 count and risk of TB.[145, 146, 157, 158] Only one study examined 
differences in risk associated with CD4 counts >500 cells/µl, finding that compared to 
CD4 count >700 cells/µl, the risk of TB was only lower for patients with CD4 counts 
<500, or for patients with unknown CD4 count.[151] 
Fifteen studies reported data on the relationship between viral load and TB 
disease. Viral loads of ≥40,[154] ≥50,[119, 151] and ≥10,000 [118, 147] were 
associated with increased risk of TB in adjusted analyses, whilst other studies 
demonstrated that TB patients had significantly higher HIV-1 RNA levels than PLHIV 
without TB.[143, 144, 161, 162] Six studies reported no association between active TB 
and viral load.[145, 153, 155, 167, 169, 172] The risk of TB was lower for patients who 
were on ART,[118, 144, 147, 150, 153, 164, 169] and further decreased for patients 
who had been on ART for more than 6 months[147, 161, 162] or more than two 
years.[119] Six studies reported no significant association between active TB and ART 
[145, 146, 148, 154, 155, 167] or duration of ART.[167] Two studies reported higher 
risk of TB in the first six months [147] and first year [118] of follow-up. The decrease in 
risk of TB over time was less steep for migrants than for non-migrants.[147]  
The CDC classifies HIV infection into clinical stages according to criteria based 
on CD4 count <200 cells/µl and symptomatic conditions (including tuberculosis). Four 
studies reported that having AIDS (as defined by the CDC, but excluding TB) was not 
significantly associated with risk of TB;[148-150, 172] two of these studies had adjusted 




for ART.[150, 172] One study reported a higher risk of TB among patients with clinical 
AIDS,[153] whilst another found that prior AIDS was associated with an increased risk 
of TB for non-migrant patients, but there was no significant association for 
migrants.[147] 
Three studies reported data on exposure to a TB patient and risk of TB. A study 
in an HIV unit of a hospital reported a greatly increased risk of TB among exposed 
patients than unexposed patients.[149] In two case-control studies in prisons, TB 
patients were more likely to have had contact with a TB case and spent more time in 
the communal day room than control patients,[158] and patients on the same side of 
the dormitory as the source patient were more likely to have TB.[145] 
Anergic patients and patients with a positive TST result had significantly higher 
risk of TB than TST-negative and/or non-anergic patients.[144, 148, 150, 156, 165, 
166] Only one study reported no TB cases among TST-negative participants.[166] Prior 
treatment of LTBI was associated with lower risk of developing active TB in four 
studies,[144, 146, 165, 166] and longer duration of preventive therapy was more 
protective.[166] However, two other studies found no association.[153, 158] Prior active 
TB disease was associated with a higher risk of TB in one study,[148] but a second 
study reported no association.[158] 
2.4 Discussion 
2.4.1 Summary of results 
Sociodemographic risk factors were largely consistent for LTBI and active TB 
disease among PLHIV in countries with low TB incidence. For example, risks were 
greater for people of black ethnicity (particularly black African) but also elevated for 
Asian and Hispanic study participants, compared to white participants. Rates of LTBI 
and TB disease were higher among foreign-born patients, irrespective of their country 
of birth, but were highest among patients from medium and high risk areas (i.e. sub-
Saharan Africa) and correlated with TB incidence in country of birth. The risk of testing 




positive for LTBI decreased with time since migration. The risk of active TB decreased 
over the duration of the studies, although one study demonstrated that the risk 
decreased less for foreign-born patients. 
2.4.2 Strengths and limitations of the study design and findings 
The systematic search strategy enabled a comprehensive review of the 
literature. Due to the high number of records found by the search, 10% of results were 
screened by both reviewers. Between-reviewer agreement was high and the discrepant 
articles were generally excluded after reviewing them against the inclusion criteria. 
Accordingly, the search strategy demonstrated a high sensitivity. 
For the purposes of the inclusion criteria, countries were defined as ‘low 
incidence’ based on the TB incidence of TB in 2015; this was a pragmatic choice as 
many studies spanned several years and TB incidence changed over time. 
Consequently, studies may have been included from periods where the TB incidence 
was above 10/100,000 population, or excluded studies conducted where TB incidence 
was less than 10/100,000 prior to 2015 but not in 2015. This is particularly relevant for 
small countries, where a small change in the number of cases reported could result in a 
substantial fluctuation in incidence. Multi-country studies were excluded if not all the 
countries had low TB incidence and data were not presented stratified by country, 
which led to the exclusion of some large studies of active TB incidence among PLHIV. 
However, the findings of these studies were consistent with those of this review; the 
HIV-CAUSAL study, the EuroSIDA cohort and the ART Cohort Collaboration reported 
that higher TB incidence was associated with low CD4 count, high viral load, HIV 
acquisition by injecting drug use or heterosexual sex (compared to MSM), and being 
born in Africa.[175-178] 
The papers included in this study were of varying quality. The majority were 
large observational cohorts with data collected prospectively or routinely. Several were 
representative of whole countries, particular populations within countries, or specific 




cities. Some studies, particularly older studies, had only small numbers of participants 
or small numbers of participants developing TB, which limited their ability to detect 
associations particularly in multivariable analyses.[139, 156-158] The findings of these 
studies were in line with those of the larger and more rigorous studies; however, there 
were some risk factors which were only examined in these studies. These findings (that 
there was no association between pregnancy and TST positivity;[139] whilst the risk of 
active TB was associated with smoking tobacco,[157] but not with level of education 
[156]) should therefore be interpreted with caution. 
The magnitude of associations between the various risk factors and LTBI or 
active TB varied substantially due to the considerable heterogeneity in the design and 
statistical analyses of the included studies, particularly variation in how variables were 
categorised, which category was used as the baseline, and which other variables (if 
any) were adjusted for. There were no clear differences in the directions of 
associations between risk factors and the outcome in studies which conducted 
multivariable analyses and those which only reported univariable associations; 
accordingly, this does not appear to be a source of bias. 
2.4.3 Sociodemographic risk factors 
Both LTBI and active TB were more likely to occur in study participants who had 
acquired their HIV infection through heterosexual sex, injecting drug use or mother-to-
child transmission than by sex between men. It is likely that routes of HIV infection 
other than sex between men are confounders for exposure to TB, which was an 
important risk factor for both LTBI and active TB, but one which few studies examined 
directly. Similarly, few studies prospectively examined the risk of LTBI and active TB 
disease among PLHIV with socioeconomic risk factors, this would be a useful subject 
for further research so that testing and preventive strategies can be appropriately 
targeted. Mixed results were reported regarding the significance of the association 
between being homeless or living in a shelter and LTBI, but working in a homeless 




shelter was also associated with greater risk of LTBI.[138] Proximity to persons with TB 
was also important; close contact with a TB case increased the risk of LTBI and active 
TB, and a study set in a prison demonstrated that closer proximity was associated with 
increased risk. Known LTBI was also associated with increased risk of TB disease, 
although this was lessened by preventive therapy. 
Globally, men are disproportionately affected by TB and women 
disproportionately affected by HIV,[1, 26] however global estimates of TB-HIV co-
infection have not been stratified by sex.[1] In this review, data on the effect of sex on 
risk of TB among PLHIV was mixed. Of the nine studies which reported no association 
between sex and risk of LTBI, none adjusted for other factors such as route of HIV 
infection, which may have biased associations of risk of TB towards women; people 
who acquire HIV through heterosexual sex usually have higher rates of TB than MSM, 
as black African ethnicity and birth in countries with high TB incidence can be 
confounders for route of HIV infection. Consequently, it is likely that these studies 
underestimated the relative risk of TB among men with HIV, compared to women. Of 
the seven studies which did report differences in risk of TB among PLHIV, five reported 
that the risk was higher among men than women, in line with the higher risk globally of 
TB among men than women. The higher risk among men may be attributable to 
several factors, including greater exposure (from more social mixing) and a higher 
prevalence of smoking, alcohol abuse, imprisonment and silicosis among men.[179, 
180] There may also be immunological or physiological differences which mean men 
are more susceptible than women.[179] There is also a larger gap between TB 
prevalence and reporting of TB cases among men than women,[1] suggesting that men 
face greater difficulties accessing care for TB. If this is also the case for accessing HIV 
care, men with HIV may be at greater risk of developing TB than women with HIV. 
The risk of both LTBI and active TB was greatest among PLHIV from ethnic 
minorities (particularly black African) and those born in countries with high TB 
incidence; both of which are proxy measures for exposure to TB. To decrease TB in 




these populations, prompt identification and treatment of both LTBI and active TB are 
necessary. Clinicians should be particularly aware of the risks of TB in these high-risk 
groups so that any patients from these populations presenting with symptoms 
compatible with TB can be diagnosed promptly. More active screening of high-risk 
populations such as black Africans, those born in high-incidence countries and PWID 
for LTBI, and treating LTBI were appropriate, could significantly reduce the TB burden 
in these populations. Earlier diagnosis of HIV would also enable earlier initiation of 
ART, increase CD4 counts and contribute to TB prevention. As the groups of PLHIV 
who are most at risk for developing TB also have a high risk of HIV, concurrent 
screening for HIV, LTBI and active TB could be an effective measure for preventing TB 
and diagnosing HIV infection sooner. 
One study observed that the risk of TB among migrants decreased with 
increasing time since entry to the country.[159] This may be attributable to a lower risk 
of new infection with MTBC following migration from a high- to low-incidence country, 
and also to the increased risk of TB among people who were infected with HIV 
abroad;[164] as the likelihood of HIV infection remaining undiagnosed decreases with 
time, the risk of TB decreases as patients become aware of their HIV infection and 
initiate ART. Pre-entry screening of migrants from countries with high TB incidence for 
pulmonary TB is now required for migrants moving to the UK, Australia, Canada, New 
Zealand and the USA, and other countries could consider adopting these guidelines to 
reduce the incidence of active TB. However, this cannot prevent reactivation of LTBI 
from causing TB disease after migration, or TB among migrants who arrive via irregular 
routes. Promoting screening for HIV infection and LTBI to migrants from countries with 
high TB incidence, particularly those who have recently entered the country, could be 
an effective measure to diagnose HIV sooner and prevent LTBI from developing into 
active disease. 




2.4.4 Clinical risk factors 
There were differences in the clinical factors that were associated with LTBI and 
active TB disease. There was no consistent association between CD4 count or ART 
and LTBI; however high CD4 count and initiation of ART were both strongly protective 
against active TB disease. High viral load was also associated with increased risk of 
TB. 
Low CD4 count was not associated with an increased risk of LTBI among 
PLHIV, and some studies reported higher rates of LTBI in participants with high CD4 
counts. This suggests that tests for LTBI are not sufficiently sensitive at low CD4 
counts, something which is well documented for TSTs but less so for IGRAs. This lack 
of sensitivity is because a limitation of tests for LTBI is that they measure the immune 
response to tuberculosis infection, rather than directly detecting the presence of MTBC, 
and therefore can be impeded when a person with HIV is immunosuppressed. This 
difficulty diagnosing LTBI at low CD4 count means that it is not established as to 
whether HIV increases the risk of becoming infected with TB (as opposed to 
progression to active disease, the evidence for which is definitive). However, as a 
substantial proportion of HIV infections are diagnosed late, and LTBI tests appear less 
sensitive at low CD4 counts, simultaneous screening for HIV and LTBI would allow a 
negative TST or IGRA to be assessed in the context of CD4 count. Patients newly 
diagnosed with HIV could then be re-tested for LTBI once they have initiated ART and 
their CD4 count has increased. 
A study of PWID with known dates of HIV seroconversion also reported low 
CD4 count as a strong predictor of TB disease. Compared to the first three years of 
HIV infection, in this population the risk of TB was around three times higher 4-6 years 
after HIV infection and five times higher by nine years after HIV infection, although the 
risk was not significantly different in the intermediate period.[181] This contrasts with 
the results presented in this review where the risk of TB was highest immediately 
following HIV diagnosis. This can probably be explained by the fact that many PLHIV 




are not diagnosed with HIV immediately following infection, and half of diagnosed 
PLHIV across Europe are diagnosed late (CD4 count ≤350 cells/µl).[129] 
Prior treatment of LTBI was associated with a significantly reduced risk of 
developing TB in 4 of the 6 studies which examined it as a risk factor; supporting the 
results of a recent meta-analysis which found that treating LTBI reduced the risk of 
active TB disease, and also found no conclusive evidence that treatment efficacy was 
reduced for PLHIV.[182] One study identified in this chapter, which found no 
association, was of an outbreak within a prison.[158] As TB disease in this study was 
predominantly being driven by recently acquired infection, LTBI treatment would not be 
expected to be protective, as LTBI treatment prevents reactivation of LTBI but would 
not prevent a new infection from occurring. The other study which did not report a 
significant association did not report the number of participants who had received prior 
treatment for LTBI, although they stated that only one person who was prescribed 
preventive therapy developed active TB.[153] Consequently, it is possible that the risk 
of TB was decreased for PLHIV who had been treated for LTBI, but that the study 
lacked power to detect the association; or that the relationship was confounded by 
factors which influenced which participants were treated for LTBI, such as LTBI test 
result and CD4 count. 
Two studies examined the relationship between prior active TB disease and the 
risk of active TB; an observational cohort reported that prior TB was associated with a 
higher risk of TB, even after adjusting for LTBI (diagnosed by TST);[148]  however a 
study of an outbreak resulting from a single source patient in a prison found no 
association between prior TB disease and risk of TB.[145] This suggests that prior TB 
increases the risk of active TB either because it is a marker for other risk factors 
relating to risk of exposure to TB or progression from LTBI to active TB. These factors 
could include higher background rates of TB, low CD4 count, unsuccessful treatment of 
prior disease or development of drug resistance during treatment of the previous 
disease.  





To conclude, it is important to note that risk factors for TB in PLHIV in low TB 
incidence countries can be divided into two categories; those which are unalterable 
(but useful for screening purposes) and those which are alterable. Important risk 
factors in the former category include black African ethnicity, birth in a country with high 
TB incidence (particularly sub-Saharan Africa) and HIV acquisition through injecting 
drug use or heterosexual sex; whilst alterable risk factors include CD4 count, viral load 
and initiation of ART. More screening for HIV, TB, and particularly LTBI needs to be 
done in high-risk groups of PLHIV such as PWID and recent migrants from countries 
with high TB incidence. Simultaneously screening for HIV and LTBI among migrants, 
particularly those who have recently migrated, and promoting LTBI treatment to eligible 
PLHIV could be effective mechanisms for reducing TB among people with HIV. 
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3 Record linkage between tuberculosis and HIV 
surveillance data to identify co-infected individuals 
3.1 Introduction 
3.1.1 Surveillance data for use in epidemiological analyses 
Public health surveillance is defined by the WHO as ‘the continuous, systematic 
collection, analysis and interpretation of health-related data needed for the planning, 
implementation and evaluation of public health practice’.[183] Routine collection of 
electronic health records provides an opportunity to undertake epidemiological 
analyses; however, linking records from separate datasets is frequently necessary to 
maximise the usefulness of such studies. For example, laboratory results can be linked 
to clinical data,[184, 185] and databases of different infections can be linked to identify 
patients with co-morbidities or who have died.[123, 164, 186] 
Global TB surveillance is coordinated by the WHO; the 194 member states 
report annually on the number of TB case notifications, demographic factors (age and 
sex) and clinical factors (site of disease, HIV status [when available], drug resistance 
and treatment outcomes).[1]  Countries in the EU report data through The European 
Surveillance System (TESSy) managed by the ECDC. TB incidence is estimated from 
notifications of TB cases; however notification data are of varying quality, there can be 
under-reporting (where TB is undiagnosed or not notified), over-reporting (if there is 
duplication of case notifications) or misclassification (e.g., recurrent TB may be 
misclassified as a new case). Estimates of incidence are calculated at the country level 
and reported with uncertainty bounds, adjusting the case notification rate using data 
from surveys quantifying over- and under-reporting, TB prevalence surveys, mortality 
data, and expert opinion.[187]  
Similarly, global surveillance on HIV is coordinated jointly by the WHO and the 
Joint United Nations Programme on HIV/AIDS (UNAIDS).[188] Since 2000, HIV 
surveillance strategies have been tailored to the needs of each country; with the aims 
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of concentrating resources where they are most useful, collecting data from key 
populations at risk of HIV, and tracking changes in the epidemic over time. In countries 
with generalised HIV epidemics (HIV prevalence >1% in the general population), 
surveillance systems aim to monitor HIV infection and risk behaviours in the general 
population. In concentrated epidemics (HIV prevalence >5% in sub-populations) and 
low-level epidemics (HIV prevalence >1% in sub-populations), surveillance systems 
concentrate on monitoring infections in those populations, and high-risk behaviours in 
the general population.[189] As with TB, data on HIV and AIDS case notifications are 
reported by each country to the WHO/UNAIDS, through TESSy for EU countries.[190] 
TESSy collects data on demographic variables (including age, sex, country of birth and 
nationality) and clinical factors (diagnosis date, CD4 counts, viral load, ART, probable 
route of HIV infection and date and cause of death [if relevant]). Even within the EU the 
quality and coverage of surveillance systems are varied; therefore statistical 
adjustments are made to account for reporting delays which improves the precision of 
estimates of recent trends in HIV epidemiology.[190] 
3.1.2 Tuberculosis and HIV surveillance data collection in the UK 
In the UK, surveillance data on TB and HIV are collected separately, by the 
Respiratory and HIV & Sexually Transmitted Infections departments, respectively, at 
PHE.[191, 192] UK TB surveillance systems do not collect HIV data, because 
personally identifiable information (PII) is recorded and HIV status is considered too 
sensitive to include in such a dataset. The UK’s HIV surveillance systems record data 
on TB as an AIDS-defining illness, but this field only contains a subset of TB diagnoses 
(where a clinical decision has been made that the patient has AIDS) and does not 
record date of TB diagnosis or any clinical data relating to TB disease. Therefore, to 
identify all co-infected individuals and carry out detailed epidemiological analyses, it is 
necessary to link the two surveillance datasets. 
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3.1.2.1 Tuberculosis surveillance 
TB is a notifiable disease in the UK and has been since 1912.[78]  Statutory 
notifications of all new cases of active TB disease are made by staff at TB clinics 
through the Enhanced Tuberculosis Surveillance system (ETS, which includes the 
London TB Register) in England, Wales and Northern Ireland, and through Enhanced 
Surveillance of Mycobacterial Infections (ESMI) in Scotland (Figure 3.1).  Reporting of 
cases is considered to be comprehensive, particularly for patients treated by the 
National Health Service (NHS); there may be underreporting of TB patients who are 
seen in private clinics, but this is estimated to be a negligible number of cases 
(personal communication, Public Health England). 
The information reported includes notification details (patient identifiers and 
notification date), and demographic, clinical and microbiological data. Information on 
treatment outcomes is collected 12 and 24 months from the treatment start date, or the 
notification date if treatment start date is not available. Information on isolates identified 
as part of the M. tuberculosis complex are also collected by ETS, including culture 
confirmation of species, drug sensitivity results, and some clinical and demographic 
information. 
3.1.2.2 HIV surveillance 
Prior to 2015 in England, Wales and Northern Ireland, data on all individuals 
aged 15 or older living with a diagnosed HIV infection who accessed care at NHS 
services was collected through the Survey of Prevalent HIV Infections Diagnosed 
(SOPHID). Information on new diagnoses of HIV infection, AIDS and death, from 
clinicians and microbiologists in England, Wales and Northern Ireland was collected 
through the HIV & AIDS New Diagnoses Database (HANDD). Scottish data is collected 
separately by Public Health Scotland (Figure 3.1). The Recent Infection Testing 
Algorithm (RITA) programme monitors the number of patients who had recently 
acquired HIV infection at the time of diagnosis in England, Wales and Northern Ireland. 
The CD4 Surveillance Scheme monitors immunosuppression in adults living with HIV in 
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England, Wales and Northern Ireland by collecting longitudinal data on the CD4 count 
of HIV patients. 
Whilst HIV infection is not a notifiable disease in the UK, the funding that NHS 
healthcare facilities receive is dependent on the reporting of new diagnoses of HIV and 
patients seen for HIV care to PHE; correspondingly the datasets are considered to be 
indicative of all patients diagnosed with HIV, or seen for HIV care. However, the 
national surveillance datasets cannot include the estimated 13% of HIV infections in 
the UK that were undiagnosed in 2016.[10] 
From 2015, HIV surveillance data in England has been collected through the 
HIV and AIDS Reporting System (HARS), which collects detailed patient demographic 
details, clinical and risk factor data, including data about clinic attendance, and HIV 
diagnosis and treatment. HARS collects data on all patients who have been confirmed 
as HIV antibody positive (Figure 3.1). 
3.1.2.3 Data protection and patient consent 
All databases contain minimal patient identifiers, are under strict data protection 
and are held securely at PHE.[191] Patient consent for data linkage and the 
subsequent epidemiological analyses was not required, as PHE has authority under 
the Health and Social Care Act 2012 to hold and analyse national surveillance data for 
public health and research purposes. 
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Figure 3.1: The flow of data in TB and HIV surveillance systems in the UK, until 2014. 
 
(1) and (2): The variables 
used to link ETS to 
MycobNet, and SOPHID 
to HANDD and CD4 
surveillance, are shown in 
Figure 3.2. 
(3) Matching between ETS 
and the HIV dataset has 
previously been done 
using EMS and the 
following variables: 
Soundex of surname, date 
of birth, sex, initial of first 
name, postcode, country 
of birth, most recent 
postcode, hospital and 
date of death. 
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3.1.3 Methods for record linkage 
There are three commonly used methods of matching records between 
datasets; exact matching, deterministic matching and probabilistic linkage. Exact 
matching requires all records in both datasets to have a unique identifying variable, 
such as NHS number. Probabilistic and deterministic methods of record linkage are 
both dependent on the quality and completeness of the original data. They are 
described in more detail below. 
3.1.3.1 Probabilistic matching 
Probabilistic record linkage utilises the probabilities of agreement and 
disagreement between variables to determine whether or not two or more records are a 
match; i.e. whether they belong to the same person.[184] Probabilistic linkage can 
account for errors and omissions of data in variables used in the matching process and 
records can be linked without the need for a unique identifier such as NHS number. 
However, its main disadvantage is the need to define a threshold score below which 
records are deemed to not be matches, or undertake a significant amount of manual 
review above and below the threshold value. Manual review introduces subjectivity 
which limits the repeatability of the process, particularly as those doing the manual 
review are normally removed from the clinical situation and therefore do not have any 
personal insight into whether or not two records are a match. This may bias the results 
of the matching process by introducing non-random error. In addition, manual review is 
very time-consuming, and therefore costly. 
3.1.3.2 Deterministic Matching 
Deterministic record linkage is the process of linking records based on rules of 
agreement. Deterministic matching algorithms are often structured hierarchically. For 
example, records may initially be matched based on the agreement of several key 
fields such as NHS number, first name and surname, address, and date of birth/death. 
If unsuccessful, this can be followed by less restrictive criteria, such as a combination 
of parts of the above data in combination with demographic information such as 
ethnicity or country of birth. 
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Deterministic matching has many advantages; it is straightforward to 
understand and easily repeatable, with no time-consuming manual review. However, it 
is limited in that there is no way to weight matches, and the rigid ‘rules’ which define 
whether records match or not mean that any small discrepancies or errors in the data 
will result in matches being missed. 
3.1.3.3 Considerations when choosing a method of record linkage 
It is important to consider the purpose of linking records when deciding which 
method of record linkage to use. If any clinical decisions are to be made on the basis of 
the linked data, then the specificity of the methods used is the most important 
consideration. For surveillance purposes, precise estimates of the burden of number of 
patients and the use of a consistent methodology are both crucial. For epidemiological 
analyses, it is more important that the dataset is representative of the underlying 
population. Purely deterministic methods of record linkage can be inappropriate for 
epidemiological analyses, as patients missing data may be systematically different from 
patients with complete data and this could bias the dataset. As an example, hard-to-
reach patients may be more likely to have missing data, and therefore may be less 
likely to be linked if a purely deterministic algorithm was used for record linkage. This 
could lead to underestimation of the prevalence of co-infection among these patients. 
3.1.4 Record linkage at Public Health England 
At PHE, both the TB and HIV sections use record linkage to match records from 
different data sources to produce their final datasets. The methods are described in 
more detail below, and summarised in Figure 3.2. 
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Figure 3.2: The steps involved in probabilistic matching (using EMS) to link TB datasets and deterministic matching to link HIV datasets, at Public Health 
England 
 
AKA: also known as, EMS: enhanced matching ETS: enhanced tuberculosis surveillance, HANDD: HIV and AIDS new diagnoses database, NHS: National 
Health Service, SOPHID: survey of prevalent HIV infections diagnosed.  
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3.1.4.1 Tuberculosis record linkage 
The Enhanced Matching System (EMS) is a probabilistic matching algorithm 
developed by the Tuberculosis section at PHE.[184] EMS was developed primarily to 
link notifications of TB cases to reports of culture-positive isolates from TB reference 
laboratories, due to low recording rates of unique identifiers (specifically, National 
Health Service [NHS] number, a unique 10-digit patient identifier assigned to each 
patient registered with the NHS). 
EMS generates weights for matches that reflect the probability of agreement 
and disagreement between variables.  The variables utilised can vary depending on 
which are available, but routine linkage between ETS and laboratory data utilises 
patient identifiers such as names, date of birth/death, sex, address variables, ethnicity, 
country of birth, hospital/clinic identifiers, and diagnosis dates. Where a unique 
identifier such as NHS number is available, this is also included. Agreement weights 
(the probability that two matching records are in fact a match) depend on the 
commonality of specific variable values (for example, rare surnames will be weighted 
more strongly than very common ones) and data quality, whilst disagreement weights 
reflect the probability of random agreement of two variables. The weights for each 
variable are summed to give an overall ‘match score’ for each possible pairing of 
records. A threshold score, at which there is a 99% probability that two records belong 
to the same person, is calculated. Pairs of records with a score greater than this 
threshold are accepted as matches and assumed to belong to the same patient, whilst 
pairings below the threshold are rejected. Manual review of a limited number of records 
above and below the threshold value can be done to refine the process. 
EMS has been validated against a gold-standard identifier (NHS number) using 
the subset of ETS data for which NHS number was available, demonstrating a 
sensitivity of up to 99.5% and specificity of up to 100.0% when probabilistic matching 
was combined with manual review.[184] 
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3.1.4.2 HIV record linkage 
Internal matching within the HIV surveillance system between SOPHID and 
HANDD was done using a hierarchical deterministic matching system which first 
attempts to link records using combinations of Soundex code (a four-digit 
characterisation of a surname which cannot be back-translated),[193] date of birth, sex, 
clinical ID number and clinic name. Records not successfully linked using these criteria 
were then matched, where possible, using combinations of Soundex (or part of), date 
of birth (or part of), sex, initials, region and ‘Also Known As’ (‘AKA’) Soundex (where 
people have changed their name or use more than one name) or ‘AKA’ date of birth 
(where it has been verified that the date of birth on previous records was incorrect). 
3.1.4.3 Previous record linkage between the tuberculosis and HIV datasets 
Until 2011, matching the TB and HIV datasets was done using the probabilistic 
system EMS,[98, 164] using the following fields: Soundex of surname, date of birth, 
sex, initial of first name, postcode, country of birth, most recent postcode, hospital, date 
of death. However, a number of issues make linking the TB and HIV datasets more 
difficult than the internal matching of different datasets within the TB or HIV 
surveillance systems. 
The lack of a unique identifier, such as NHS number, for even a subset of the 
HIV surveillance data has prevented validation of the methods used to match records 
between the HIV and TB datasets against a gold-standard. 
Even without manual review, EMS has very high sensitivity (99.3%) and 
specificity (99.9%) when matching ETS data to other TB surveillance data. However, a 
sensitivity analysis demonstrated that omission of address variables from the matching 
process resulted in a decreased sensitivity of 97.1%,[184] although specificity 
remained high at 100.0%. For TB-HIV matching the sensitivity of EMS is likely to be 
even lower as there are fewer variables which can be used. HIV surveillance data 
includes little PII (no NHS numbers, names or addresses) due to the confidentiality 
requirements of HIV surveillance and clinical data recording. Individuals are identified 
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by a Soundex code, the initial of their forename and their postcode. This limits the 
ability of EMS to successfully link the two datasets. 
The HIV surveillance system collects other fields that are useful in matching, 
e.g. AKA Soundex, AKA date of birth and postcode over time (longitudinal data is 
collected on people living with HIV), which cannot be used in probabilistic matching 
algorithms for logistical reasons relating to the amount of computational power 
necessary. 
When linking records within the HIV or TB surveillance systems, the majority of 
individuals would be expected to appear in both datasets. This simplifies the matching 
process as it is more likely that two records belong to the same person if they are 
reasonably similar across key fields. However, when matching between the TB and 
HIV datasets expect a much lower proportion of overlap would be expected, reflecting 
the proportion of co-infected individuals (previously around 5-10%).[123] Identifying 
individuals expected to be in both the HIV and TB datasets is difficult; ETS does not 
collect data on HIV status (the only HIV variable collected being the offer of a HIV test), 
and data on TB as an AIDS-defining illness in the HIV data is not always well 
completed. 
Some fields that are useful in internal matching, such as clinic ID, cannot be 
used for TB-HIV matching as many patients receive HIV and TB treatment at different 
locations. Diagnostic dates are also of limited use because TB and HIV diagnoses are 
not always made concurrently. Other problems arise due to the demographics of the 
populations with TB and HIV. Patients in both populations can be very transient, so 
postcodes are not necessarily consistent even over short periods of time, and some 
individuals have no fixed abode and therefore no postcode. Postcodes are therefore a 
useful field for confirming records belong to the same person, but disagreeing 
postcodes should not be used to discount a match. 
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3.1.5 Summary and objectives 
TB and HIV surveillance data are collected separately in the UK, and the two 
datasets therefore need to be linked in order to identify co-infected patients and 
conduct epidemiological analyses. The lack of a unique identifier between the TB and 
HIV surveillance datasets means that exact matching is not possible for UK 
surveillance data. There were three options for linking the two datasets; probabilistic 
matching, deterministic matching, or a combination of the two. Given the lack of an 
effective, accurate and repeatable method, a primary aim of this PhD was to 




For the period 2001-2011, the TB and HIV datasets collated by PHE had 
previously been linked using EMS.[184] To determine the most efficient, accurate and 
repeatable methodology for future matching between the TB-HIV datasets, the two raw 
datasets used for matching 2001-2011 data were retrieved. These datasets were used 
to make comparisons between the results of the previous probabilistic linkage using 
EMS (i.e. the list of HIV and TB records matched by the algorithm) and the results of 
the alternative methods that were investigated; a deterministic matching algorithm and 
subsequently a hybrid method which utilised both probabilistic and deterministic 
techniques. 
3.2.2 Investigation of deterministic matching 
The first objective was to determine if deterministic matching was a reasonable 
alternative to EMS for linking records between the TB and HIV datasets. A 
deterministic algorithm was developed using expertise from both database managers 
and epidemiologists within the HIV and TB sections at PHE to identify potential criteria 
for defining a match. The criteria used various combinations of the following fields: 
Soundex of surname, date of birth, sex, initial of first name, ethnicity, country of birth, 
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postcode and date of death. Partial fields (initial of Soundex, day/month/year of birth 
and postal district) and alternative fields (AKA Soundex and AKA date of birth) were 
also used. These criteria are shown in Table 3.1. 
 3. Record linkage between tuberculosis and HIV surveillance data to identify co-infected individuals 
 
91 
Table 3.1: Hierarchy of the matching criteria developed for the deterministic algorithm. 
AKA: also known as. Brackets indicate that the criteria was an alternative criteria (AKA Soundex or AKA sex), or that it was considered a match if the 
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As HIV surveillance data does not include NHS number, there was no unique 
identifier available for even a subset of records, meaning that the matching criteria 
could not be validated against a gold-standard identifier. Comparisons were made 
between the number of matches found and the number of matches missed 
(approximations of sensitivity and specificity) between the different techniques. Where 
matches were found using both methods, the average (mean) and distribution of the 
probabilistic score was calculated for each of the matching criteria. This gave an insight 
of the approximate range of scores found by each deterministic criterion. This was 
used to refine the matching criteria. 
3.2.3 Development of hybrid method 
A ‘hybrid’ matching method was developed, using a combination of probabilistic 
and deterministic methods. Two thresholds of match score were defined for the 
purposes of accepting/rejecting probabilistic matches. The upper threshold was the 
probabilistic score at which there was a 99% probability that two matched records 
belonged to the same person;[184] the lower threshold was the score at which the 
probability was 50%. Matches with a probabilistic score above the upper threshold 
were accepted and matches below the lower threshold were rejected. Deterministic 
criteria were used in place of manual review to decide whether matches with scores 
between the upper and lower thresholds should be accepted or not. 
Where matches were found by both probabilistic and deterministic matching 
methods, the average probabilistic score for matches found by each deterministic 
criterion was calculated. Deterministic criteria with an average score below the upper 
threshold were excluded, except for criteria which included an AKA Soundex or AKA 
date of birth, which would be expected to have significantly lower scores. This is 
because AKA Soundex and AKA date of birth are not included in the probabilistic 
matching algorithm, and so agreement on these fields cannot increase the probabilistic 
score of a match. Additionally, Soundex and date of birth are two of the most heavily 
weighted fields in the probabilistic algorithm, meaning that disagreement on these 
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fields (because they agree on AKA Soundex/date of birth) are strongly weighted 
negatively. 
The average scores of each criterion were used in combination with expertise 
from PHE epidemiologists to determine the order in which the criteria should be used, 
in order to create a hierarchical algorithm. If a record was not matched using the first 
criterion, matches were attempted using subsequent criteria in the order shown in 
Table 3.1. 
Additional criteria were added to refine the final list of matches and exclude 
matches which could not belong to the same person, based on diagnosis dates of TB, 
HIV infection and AIDS and dates of death from both datasets. HIV records with TB as 
an AIDS-defining illness were given a ‘TB flag’, which was used to identify HIV records 
that were expected to match to the TB data. 
As part of the algorithm development process, a limited amount of manual 
review was done to evaluate the final combination of probabilistic cut-off scores and 
deterministic criteria, particularly to investigate matches that were ranked highly by 
probabilistic or deterministic methods but missed by the other. 
3.3 Results 
3.3.1 Deterministic matching algorithm 
The final deterministic matching criteria were based on combinations of all 
variables that were common to both the TB and HIV datasets: Soundex of surname, 
sex, date of birth, initial of first name, country of birth, ethnicity, postcode and date of 
death (Table 3.1). 
Deterministic matching alone was not considered to be accurate enough for TB-
HIV matching, as many more matches (n=1,084, Figure 3.3) were found using the 
deterministic algorithm than were found using EMS, which were not considered close 
enough matches upon manual inspection. However, investigating the criteria that these 
additional matches were selected on (Table 3.2) demonstrated that many were very 
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strong matches; particularly the 185 pairs of records which had matched on Soundex, 
date of birth, sex, initial and postcode (criterion 1). It was evident that a number of 
records which clearly matched strongly were not being detected by EMS. As a result, 
the use of a hybrid method incorporating both probabilistic and deterministic techniques 
was investigated. 
Figure 3.3: Comparison of matching results from EMS (with manual review of borderline 
matches) and the deterministic matching algorithm. 
 
 
Table 3.2: The deterministic matching criteria of the 1084 additional matches found by 
the deterministic matching algorithm. 
Criterion n % Cumulative % 
1 185 17.1 17.1 
1a 25 2.3 19.4 
2 124 11.4 30.8 
3 122 11.3 42.1 
3a 18 1.7 43.7 
4 28 2.6 46.3 
4a 1 0.1 46.4 
6 430 39.7 86.1 
6a 48 4.4 90.5 
7 41 3.8 94.3 
7a 5 0.5 94.7 
8 57 5.3 100.0 
Total 1,084 100.0 
 
n: number. Full explanations of each criterion are shown in Table 3.1 




Of the 2,248 HIV patients with a report of TB as an AIDS-defining illness 
between 2001 and 2011, 1,534 (68.2%) were linked to a TB case in ETS using the 
deterministic matching algorithm. This was slightly higher than the 1,471 (65.4%) which 
were linked to a TB case using EMS with manual review. 
3.3.2 Description of a hybrid matching method 
The number and percentage of matches which were found using each criterion, 
and the mean probabilistic score of the matches, are shown in Table 3.3. All criteria 
had a mean probabilistic score of greater than the upper threshold of 27.88, except for 
those using AKA Soundex or AKA date of birth. 
Table 3.3: The number and percentage of matches found by each of the deterministic 
matching criteria used in the hybrid matching algorithm, and the average probabilistic 
score for each criterion, using data for the period 2001-2011. 
Criteria Number of matches Mean probabilistic score 
n % 
1 2336 51.8 47.7 
1a 179 4.0 33.6 
1b 0 0.0 -* 
1c 0 0.0 -* 
2 1006 22.3 34.6 
3 433 9.6 43.8 
3a 31 0.7 27.7 
4 50 1.1 35.5 
4a 4 0.1 17.9 
5 4 0.1 41.3 
5a 0 0.0 -* 
5b 0 0.0 -* 
5c 0 0.0 -* 
6 286 6.3 32.4 
6a 70 1.6 20.1 
6b 0 0.0 -* 
6c 0 0.0 -* 
7 41 0.9 32.5 
7a 6 0.1 11.0 
8 63 1.4 38.7 
8b 0 0.0 -* 
Total 4509 92.9  
* could not be calculated. n: number. 382/4,891 (7.1%) of all matches were found by 
probabilistic matching only and therefore no match type was available 
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The criteria for accepting pairs of records into the final dataset as matches were 
based on a combination of probabilistic score and deterministic criteria (Figure 3.4). 
Pairs of records with a probabilistic score above the 99% probability threshold (27.88) 
were accepted as matches. Pairs of records with a match score between 21.25 (the 
lower threshold, at which the probability of two records being a match is 50%) and 
27.88 were accepted as matches if they were also matched deterministically, or if the 
HIV record was flagged as having TB as an AIDS-defining illness. Pairs with a score 
below 21.25 were accepted only if they matched on a criteria utilising AKA Soundex or 
AKA date of birth (criteria 1a/1b/1c/3a/4a/5a/5b/5c/6a/6b/6c/7a/8b). Records matched 
on criteria 1/1a/1b/1c were considered ‘perfect’ matches and accepted regardless of 
whether they had been matched probabilistically or not. 
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Figure 3.4: Flow chart of the hybrid matching process. 
 
27.88 was the score at which there was a 99% probability that two matched records 
belonged to the same person. 
21.25 was the score at which there was a 50% probability that two matched records 
belonged to the same person. 
Deterministic matching criteria are detailed in Table 3.3. 
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Where records matched to more than one record in the other dataset, the 
highest scoring or highest ranked match was accepted. If an HIV record matched to 
multiple TB records believed to belong to the same person then the earliest TB case 
was used as the match; recurrent cases of TB were not matched. Matches were 
discounted if the TB diagnosis was more than 8 years before the HIV diagnosis, if HIV 
or AIDS diagnosis date was >30 days after the date of death reported in the TB data, 
or if the TB notification was more than one year after the date of death reported in the 
HIV data (Figure 3.4). 
As part of the algorithm development process, hybrid records were manually 
reviewed if they met any of the following criteria: probabilistic score >50 and not 
deterministically matched, probabilistic score <21.25 and matched using criteria 1 or 
1a, probabilistic score <15 and had a TB flag in the HIV record. All of these records 
were considered acceptable matches and no adaptations were made to the algorithm 
as a result. 
3.3.3 Comparison of the hybrid method to EMS, using data for the period 
2001-2011 
Using data from the period 2001-2011, the hybrid matching method found 4,891 
matches, compared to 4,574 using EMS with manual review of borderline cases 
(Figure 3.5). 4,308 matches were found by both the hybrid method and EMS, 
representing 94.2% of the matches found probabilistically and 88.1% of the matches 
found using the hybrid method. Of the additional 583 matches found using the hybrid 
method, 29% matched on the highest criteria (1/1a: Soundex/AKA Soundex, date of 
birth, sex, initial of first name and postcode) whilst 60% matched on the top three 
criteria and a further 28% matched on criteria 6 (Soundex, date of birth and sex) (Table 
3.4). Criteria 6 is considered a ‘perfect match’ in internal HIV matching, but is not 
specific enough alone for TB-HIV matching as many of the matches found using this 
criteria had low probabilistic scores due to disagreement on other fields such as 
ethnicity and country of birth. Of the 266 ‘not matched’ records from the probabilistic 
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matching results, 142 were where multiple TB records had been matched to a single 
HIV record, and therefore were not considered as having been missed by the new 
method. 
Of the 2,248 HIV patients who had TB reported as an AIDS-defining illness, 
1,580 (70.2%) were linked to a TB case in ETS using the hybrid method. This was 
higher than the 1,534 (68.2%) and 1,471 (65.4%) found by the deterministic and 
probabilistic methods individually. Of the 668 patients with TB as an AIDS-defining 
illness who were not linked to ETS, 20 had probabilistic scores below the lower 
threshold and the remaining 648 (97.0%) were not linked at all using the probabilistic 
algorithm. 
Figure 3.5: Comparison of matching results from the hybrid method, and probabilistic 
matching (EMS, with manual review of borderline matches). 
 
  




Table 3.4: Distribution of the deterministic match types of 471/583 additional matches 
found using the hybrid method. 
Match type n % Cumulative % 
1 122 25.9 25.9 
1a 15 3.2 29.1 
2 82 17.4 46.5 
3 51 10.8 57.3 
3a 14 3.0 60.3 
4 19 4.0 64.3 
4a 1 0.2 64.5 
6 85 18.1 82.6 
6a 48 10.2 92.8 
7 22 4.7 97.5 
7a 5 1.1 98.5 
8 7 1.5 100.0 
Total 471 100.0 
 
n: number. Only 471/583 additional matches found using the hybrid method had a match 
type available, others were accepted at lower probabilistic scores because they had a TB 
flag. 
 
3.3.4 Matching results for the period 2000-2014 
Following the development of the hybrid method of record linkage, individuals 
co-infected with TB and HIV were identified from all TB cases notified to ETS from 
2000 to 2014 and all patients reported to HARS as having been seen for HIV care 
between 2000 and 2014. Both datasets of patients included adults (≤15 years) in 
England, Wales and Northern Ireland only. 
For this period, there were 112,660 TB cases and 124,588 HIV patients. The 
hybrid matching method resulted in 5,810 matches. Of these, 5,737 (98.7%) matched 
probabilistically, with a mean match weight of 43.8 (standard deviation 12.8). 5,386 
(92.7%) were matched using deterministic criteria. The distribution of the hierarchical 
deterministic criteria used for the deterministic matches is shown in Table 3.5. 
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Table 3.5 Distribution of the match types of the 5,386 deterministic matches identified for 
the period 2000-2014. 
Match type n % Cumulative % 
1 3,304 61.3 61.3 
1a 113 2.1 63.4 
1b 60 1.1 64.6 
1c 6 0.1 64.7 
2 1,173 21.8 86.5 
3 311 5.8 92.2 
3a 25 0.5 92.7 
4 33 0.6 93.3 
4a 13 0.2 93.5 
6 93 1.7 95.3 
6a 60 1.1 96.4 
6b 54 1.0 97.4 
6c 1 0.0 97.4 
7 26 0.5 97.9 
7a 3 0.1 97.9 
8 108 2.0 99.9 
8b 3 0.1 100.0 




Additionally, of the 3,079 HIV patients reported to HARS with TB as an AIDS-
defining illness, 695 (22.6%) were not linked to a record in ETS. These were included 
in the analysis presented in Chapter 4, but excluded from the analyses in Chapters 5 
and 6 as there was no data on the characteristics of their TB disease (Figure 3.6). 
The data used in each chapter of this thesis are shown in Figure 3.6. 
 
 3. Record linkage between tuberculosis and HIV surveillance data to identify co-infected individuals 
 
102 
Figure 3.6: Flow chart of the datasets linked in this chapter, and the records used in each 
thesis chapter. 
 
The numbers of cases in this diagram only includes adults. 
 





The aim of this chapter was to investigate and develop an efficient and 
repeatable alternative to using the probabilistic algorithm of EMS for linking the TB and 
HIV surveillance datasets collated by PHE. A deterministic algorithm was developed 
and compared to existing probabilistic methods. The large number of additional 
matches found using the deterministic algorithm, some of which had low probabilistic 
scores and disagreed on other fields not included in the criteria used, indicated that 
deterministic matching alone was not discriminative enough to be used in place of 
EMS. A hybrid method of record linkage was the optimal solution, maintaining the 
ability to weight matches (using probabilistic methods) whilst using a set of consistent 
rules (the hierarchy of deterministic criteria) to accept or reject intermediate matches. 
3.4.2 Strengths, limitations and implications of the work 
The hybrid method provides a number of advantages over probabilistic or 
deterministic methods alone. The main advantage is the elimination of the manual 
review which is a necessary part of probabilistic matching using EMS; resulting in a 
much quicker, more consistent and repeatable method, with less potential to introduce 
systematic bias. Whilst the development of the algorithm involved manual review to 
confirm that the final selection of matching criteria were appropriate, this manual review 
will not be necessary as part of the routine use of the hybrid method. This is 
advantageous because where co-infection with TB and HIV is used as the outcome of 
epidemiological analyses, systematic misclassification of the outcome has the potential 
to significantly bias the results of any analyses due to over- or under-estimation of the 
number of co-infected cases. 
One limitation of this work was that there was no gold-standard identifier to 
validate the method against. EMS was previously validated using a subset of the ETS 
data for which NHS number was available,[184] however the HIV dataset does not 
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contain any unique identifiers for patients. However, this limitation would exist 
regardless of the method used for linking TB and HIV records, and the deterministic 
algorithm used for internal matching within the HIV surveillance system has not been 
validated against a gold-standard for the same reason. The probabilistic algorithm EMS 
was validated using two TB surveillance datasets and several variables of PII which are 
not available when matching between the TB and HIV datasets. The sensitivity of EMS 
decreased from 99.5% to 97.1% when address variables were omitted, and it is 
reasonable to assume that the sensitivity would decrease further when other variables 
such as first name, surname and hospital names also cannot be used, as is the case 
for TB-HIV matching. 
Another limitation was that there were 695 individuals with HIV reported to have 
TB as an AIDS-defining illness, who were not linked to a record in the TB surveillance 
dataset. This may be because of combinations of missing data, names having been 
changed but this not being reported, names which do not convert well to Soundex 
codes (particularly very short or very long names), or common combinations of name, 
ethnicity and date of birth; all of which could result in a low probabilistic matching score 
and therefore the match being missed. It is also possible that some of these were 
misdiagnosed cases of TB, which were reported to ETS but then later de-notified, or 
that this is an indication that there is under-reporting of TB cases. The hybrid matching 
method resulted in a higher proportion of the HIV patients with TB as an AIDS-defining 
illness being linked to a TB case in ETS (70.2%) than either the probabilistic or 
deterministic approaches alone (65.4% and 68.2% respectively), and this proportion 
was even higher (77.4%) when the datasets were matched for the period 2000-2014. 
However, it was not clear whether the remaining 22.6% remained unmatched as a 
result of the limitations of the matching algorithms or the limitations of the surveillance 
data collection. Future work to improve surveillance data collection or linkage could 
include an audit of these patients’ clinical records to determine whether their TB was 
notified to ETS, and if so, why their records were not linked. 
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When developing the deterministic criteria and the hybrid method, the results 
were evaluated by making comparisons with the results from matching done using 
EMS. However, it is important to consider that the previous results are not a gold-
standard; some matches may have been incorrectly matched and others missed. For 
this reason, the sensitivity and specificity of individual deterministic criteria could not be 
calculated. Future work could include recruiting a subset of patients, gaining patient 
consent to collect PII (including NHS number) and then using this data to validate the 
algorithm. Alternatively, the use of latent class models (which are often developed for 
evaluating new diagnostic tests) could be investigated.[194] 
The hierarchical nature of the hybrid matching method means that sensitivity 
analyses can be done during epidemiological analyses to evaluate the impact of 
including ‘less certain’ matches in the analysis. This will not only inform on the reliability 
of the epidemiological results, but could also be used to further develop and refine the 
matching method by identifying specific groups which may be more or less likely to be 
matched on a low probabilistic score or a less stringent deterministic criterion. The 
results of the sensitivity analyses are described in sections 4.3.5 and 5.3.2.2. 
3.4.3 Conclusions 
Data linkage is an important epidemiological tool, and needs to be accurate so 
that the resulting datasets are free from bias. The hybrid matching method developed 
in this chapter is a considerable improvement on the use of EMS in the case of TB-HIV 
data linkage. The elimination of the time-consuming manual review means that the 
overall process is considerably quicker, more repeatable and less subject to bias, 
whilst the use of deterministic criteria in addition to probabilistic matching facilitated the 
finding of a number of very strong matches which EMS had failed to identify. 
106 
4 Sociodemographic and clinical risk factors for 
developing tuberculosis disease among people 
living with diagnosed HIV 
 
4.1 Introduction 
4.1.1 HIV and tuberculosis co-infection in the UK 
In 2015, an estimated 101,200 people were living with HIV in the UK,[10] a 
prevalence of 0.16%.[195] 6,095 PLHIV were newly diagnosed in 2015 and 39% of 
these were diagnosed late, with a CD4 count of less than 350 cells/µl. PLHIV are 
known to be at a higher risk of developing TB than people without HIV. 
In 2015, there were just over 6,000 TB cases notified in the UK.[52, 79-81] As 
HIV infection is a chronic, lifelong condition, which is known to increase the risk of 
developing TB; a substantial proportion of these would be expected to occur in PLHIV. 
The epidemiology of both TB and HIV in the UK was described previously in Chapter 1. 
Previous estimates of the incidence of TB among PLHIV in the UK have varied 
as a result of differing methodologies. Studies using national surveillance data reported 
a TB incidence of 1,900 per 100,000 person-years (PY) among people who acquired 
their HIV infection through heterosexual sex from 2002-2010,[164] and 669/100,000 PY 
for all PLHIV from 2007-2011.[151] However, neither of these studies specified a 
minimum follow-up period, and began the follow-up period on the date of HIV 
diagnosis. They therefore included patients who were diagnosed simultaneously with 
their TB and HIV infections, leading to inflated estimates of incidence as a result of 
including a substantial number of TB cases without accounting for the time they spent 
at risk of disease. A study of TB incidence among PLHIV in an observational cohort 
reported a much lower incidence of 328/100,000 PY from 1996-2005,[119] having 
excluded TB cases where patients were diagnosed with TB and HIV within 91 days of 
each other. The difference between these estimates highlights the importance of 




separating prevalent TB cases (present at the time of HIV diagnosis) from incident TB 
cases (where the disease actually occurs during the follow-up period) when calculating 
incidence rates. Additionally, evaluating risk factors separately for prevalent and 
incident cases is important, because different interventions are required to prevent 
them.  
4.1.2 Known risk factors for co-infection 
A series of risk factors for active TB disease for PLHIV in countries with low TB 
incidence have been documented and were described in detail in Chapter 2. A 
summary of the evidence is presented below. 
Two large, high-quality prospective cohort studies in France and Germany 
reported that TB incidence decreased with time since HIV diagnosis.[118, 147] 
Similarly, a UK study of people who acquired HIV heterosexually demonstrated a high 
proportion (54%) of TB diagnoses were made simultaneously with HIV diagnosis;[164] 
and most TB diagnosis among people with diagnosed HIV were in the first two years 
after diagnosis, although this study did not adjust for the duration of follow-up. 
Injecting drug use was associated with TB disease for PLHIV in large 
observational cohort studies in Switzerland, Canada and the USA.[152, 161, 167] 
Several other large cohort studies in the UK, USA, Canada, Denmark and Israel 
reported that PLHIV who acquired their HIV infection through heterosexual sex and/or 
people who inject drugs had substantially higher incidence rates of TB than MSM.[119, 
146, 151, 153, 156, 159, 169] However, of the two studies in the UK, one was 
restricted to PLHIV on ART [151] and the other did not examine injecting drug use as a 
risk factor for TB.[119] 
Some studies suggested a lower risk of TB for men than women in the USA and 
Canada,[146, 153, 170] but studies in the UK and Israel which adjusted for route of HIV 
infection (and the substantial number of MSM in most populations of PLHIV who are at 
low risk of TB) reported a higher risk of TB for men than women.[119, 159, 164] Being 




of black African or south Asian ethnicity was also associated with higher TB incidence 
than white ethnicity in three UK studies,[119, 151, 164] although none adjusted for TB 
incidence in country of birth, which is related to black African ethnicity. Studies 
conducted in other low-incidence countries found that TB incidence was consistently 
higher among foreign-born patients than those born in the countries in which the study 
was conducted,[153, 161, 162] particularly among patients born in sub-Saharan Africa 
or other countries with a high incidence of TB.[118, 144, 147, 169] 
In the UK, the proportion of PLHIV that are diagnosed late varies for different 
sub-populations (Figure 4.1). Multiple cohort studies reported that late diagnosis of HIV 
infection and low CD4 count were important risk factors for TB disease; particularly for 
CD4 counts below 500 cells/µl,[118, 119, 144, 147, 148, 150, 152-154, 156, 164, 167-
169] though risks have not been shown to be substantially different between the strata 
of 500-699 cells/µl and >700 cells/µl.[151] 
Figure 4.1: Proportion of adults diagnosed late (with a CD4 cell count of less than 350 
cells/µl) by demographic in the UK in 2015. 
 
Source: Public Health England [10] 
 




The evidence for viral load as an independent risk factor for TB is unclear. 
Several studies in the UK, France and Germany have reported associations between 
higher viral loads and TB.[118, 119, 147, 151, 154] Other studies in the USA, Canada 
and Denmark reported no association between viral load and risk of TB after adjusting 
for CD4 count and anti-retroviral therapy;[145, 153, 167, 169] however, adjusting for all 
three of these variables (which are causally related and highly collinear) can make it 
difficult to determine which variable is causing the effect. 
Similarly, initiating ART [118, 144, 153, 164, 169] and increased duration of 
time on ART [119, 161, 162] were generally associated with lower rates of TB, although 
some studies found no significant association after adjusting for CD4 count and/or viral 
load.[145, 148, 154, 155, 167]  
The risk of TB was significantly higher for patients with known LTBI,[144, 148, 
150, 156, 165, 166] although this was decreased for patients who had taken preventive 
therapy.[144, 146, 165, 166] Age was not generally associated with risk of TB for 
PLHIV. 
4.1.3 Summary and objectives 
To conclude, there is a substantial body of literature on risk factors for 
developing TB for PLHIV in countries with low-incidence settings. However, previous 
studies in the UK have left a number of gaps in the literature through not considering 
HIV acquisition through injecting drug use as a risk factor for TB,[119] or restricting the 
studies to heterosexuals or those who have initiated ART.[164, 196] Additionally, none 
of these studies adjusted for the incidence of TB in the country of birth of patients born 
abroad, which may confound the association between ethnicity and risk of TB for 
PLHIV. 
The aims of this chapter were to use HIV and TB national surveillance datasets 
to describe the incidence and epidemiology of TB-HIV co-infections in England, Wales 
and Northern Ireland over a 15-year period (2000 to 2014), to examine the relationship 




between the timing of TB and HIV diagnoses for different sub-populations, and quantify 
clinical and demographic risk factors for TB across the whole population of PLHIV. 
4.2 Methods 
4.2.1 Study population 
The study population was adults aged 15 years or older notified to PHE’s HARS 
(described in section 3.1.2.2), who first presented with HIV to health services in 
England, Wales or Northern Ireland from 1st January 2000 to 31st December 2014.  
4.2.2 Outcome: tuberculosis disease diagnosed from 2000-2014 
HIV surveillance data collected in HARS were linked to TB surveillance data 
collected in ETS, as described in Chapter 3. HIV patients were considered to have TB 
disease if they were linked to a culture-confirmed or presumptive (clinical and 
radiological signs, including a response to specific therapy) diagnosis of TB reported to 
ETS, or if they had TB reported to HARS as an AIDS-defining illness. 
Incident TB was defined as TB disease notified to ETS, or reported to HARS as 
a new AIDS-defining illness, that was diagnosed >91 days after HIV diagnosis. To 
differentiate patients who were not aware of their HIV infection prior to their TB 
diagnosis, TB cases diagnosed within 91 days of HIV diagnosis were considered 
simultaneous diagnoses. TB cases diagnosed >91 days before HIV were considered 
existing disease. A 91 day threshold for defining simultaneous diagnoses was a 
pragmatic choice to account for delays in diagnosis and reporting, and to exclude ART-
induced unmasking immune reconstitution inflammatory syndrome. 
4.2.3 Exposure variables 
A series of demographic and clinical exposure variables, which were routinely 
collected in HARS or derived from other variables, were deemed of interest. 
Demographic factors included age at HIV diagnosis, sex, ethnicity, country of birth, TB 
incidence in country of birth, route of HIV infection, year of HIV diagnosis, and index of 




multiple deprivation [IMD] decile. IMD scores represent relative levels of deprivation of 
income, employment, health, education, housing and services, crime and living 
environment for small areas in England and Wales, and are ranked into deciles where 
one is the most deprived and ten is the least deprived.[197, 198] The most recent IMD 
data for each country between 2000 and 2014 were used; 2010 for England and 2014 
for Wales. 
Composite variables were created combining ethnicity and country of birth or 
sex and infection route due to mutually exclusive combinations (e.g. being a woman 
and a MSM is impossible) and known associations. As a proxy for TB exposure, 
countries of birth outside the UK were grouped by TB incidence; ‘high incidence’ was 
defined as >40 cases/100,000 adult population in 2013.  
Clinical risk factors included viral load, CD4 count and whether the patient was 
receiving ART. Longitudinal data was available for all three of these risk factors. Data 
were available for every CD4 count taken for each patient. Data on ART included the 
date the patient first initiated ART, and annual data on whether they were on ART at 
their last clinic visit. Data on viral load were available at diagnosis, and for the last clinic 
visit each year.  
4.2.4 Statistical Analysis 
4.2.4.1 Descriptive analysis 
Data were analysed in Stata version 13.1. The proportion of the population of 
PLHIV diagnosed with TB and the relationship between the timing of HIV and TB 
diagnoses (simultaneous, TB first, or HIV first), were described both for the whole 
population and stratified by each exposure variable. Nelson-Aalen cumulative hazard 
plots were used to assess the cumulative risk of TB disease over time, whilst 
accounting for censoring of data due to shorter durations of follow-up. 




4.2.4.2 Poisson regression modelling of risk factors for developing tuberculosis 
after HIV diagnosis 
To investigate risk factors for developing TB following HIV diagnosis, incidence 
rates of TB per 100,000 PY follow-up were calculated. Individuals diagnosed with TB 
≤91 days after HIV diagnosis were excluded. Cox regression was precluded as the 
data did not satisfy the proportional hazards assumption for key variables such as route 
of HIV infection, and therefore incidence rate ratios were estimated using univariable 
and multivariable Poisson regression models, offset by follow-up time. Follow-up began 
92 days from date of HIV diagnosis or date of first presentation to UK health services, 
and ended on the date of TB diagnosis, death, or 31/12/2014, whichever was earliest. 
 CD4 count and ART initiation were included in the Poisson regression model 
as time-updated covariates. Incidence rates for different CD4 strata were calculated 
using the number of days from each CD4 count to the date of the next CD4 count for 
each patient. As data on ART is only reported annually from the most recent clinic visit 
for each patient, it was not possible to accurately determine when patients discontinued 
or reinitiated ART. Therefore, TB incidence was compared between ART-naïve 
patients and patients who had initiated ART, rather than patients who were on ART and 
patients who were not on ART. Patients were considered ART-naïve from the date of 
their HIV diagnosis until the date they first initiated ART, and to have initiated ART from 
that date until the end of their follow-up period. In a post-hoc analysis of patients who 
had initiated ART, the proportion of patients who were not on ART at their last clinic 
visit during the study period was examined for patients who developed TB and patients 
who remained TB-free. The proportion of patients who initiated ART and the time from 
the most recent clinic visit to the end of the study period were compared for different 
stratum of risk factors. 
Potential confounders and effect modifiers were prospectively identified [199] 
and a causal framework was built (Figure 4.2). As there was not a single ‘main’ 
exposure variable, there were no confounders in the traditional sense, and therefore 




the multivariable model was informed by the causal inference framework defined a 
priori. From this framework, it was determined that viral load should be excluded from 
the multivariable model because of the potential for causal loops between viral load 
and CD4 count, which could not be adequately accounted for in the data available as 
there were data on all performed CD4 counts but only one viral load measurement per 
year for each patient. Linearity (of age, CD4 count and year of HIV diagnosis) and 
statistical interactions (between ART status and CD4 count) were assessed using 
likelihood-ratio tests. Statistical interactions were considered significant at P<0.05; this 
was considered appropriate due to the large size of the dataset. All stated confidence 
intervals were two-sided 95% confidence intervals. Patients missing data on one or 
more variables were excluded. To assess the likely impact of missing data, the 
distributions of age, sex, route of HIV infection, CD4 count and ethnicity/country of birth 
were compared for cases with missing vs. complete data on infection route, CD4 count, 
IMD score and country of birth.  
Figure 4.2: Causal diagram of potential risk factors for developing TB disease among 
people diagnosed with HIV. 
 
ART: anti-retroviral therapy, IMD: index of multiple deprivation, TB: tuberculosis. 
Arrows show the direction of effect 




4.2.4.3 Sensitivity analyses 
Sensitivity analyses were planned as follows. (1) Investigating the impact of 
using a 6-month threshold (182 days) for simultaneous diagnosis, rather than a 91-day 
threshold. (2) Examining the impact of excluding weaker matches between HARS and 
ETS, excluding co-infected patients in the lowest quartile of probabilistic matching 
score, and excluding patients who were matched using the three weakest deterministic 
matching criteria. (3) Excluding patients who acquired HIV infection through mother-to-
child transmission, as the dataset only contained adults and so individuals infected 
through this route could be missing 15 years of follow-up.  
4.3 Results 
4.3.1 Description of co-infected patients 
Between 2000 and 2014, 102,202 adults were newly diagnosed with HIV, 
among whom 5,649 (6%) had TB. 3,103 (55%) were simultaneously diagnosed with TB 
and HIV, 2,187 (39%) developed TB after more than 91 days and 359 (6%) were 
diagnosed with TB first (Table 4.1).  
Of people with TB who acquired HIV infection through heterosexual sex, over 
half were diagnosed simultaneously with TB and HIV; 60% for men and 54% for 
women. In contrast, more TB cases in MSM and PWID were diagnosed more than 91 
days after diagnosis of HIV infection (51% and 54%, respectively). The proportion of 
TB cases occurring after HIV diagnosis was highest in white, UK-born individuals 
(179/359, 48%) and those born in low TB incidence countries (116/245, 47%); these 
two groups comprise 38% of the cohort. 
There was no substantial difference in the age, sex, ethnicity/country of birth, 
route of HIV infection or CD4 count of patients with missing data on any of the following 
variables: route of HIV infection, CD4 count, IMD decile and country of birth. Patients 
with missing route of infection were less likely to be diagnosed with TB; however, there 
were no substantial differences for patients missing data on any other variable.  




Table 4.1: TB diagnoses in people notified with HIV from 2000 to 2014 in England, Wales and Northern Ireland, and the incidence rates of TB in people 































Incidence rate after 
365 days from HIV 
diagnosis* 
(95% CI) 
Total 102,202 5,649 (5.5) 359 (6) 3,103 (55) 2,187 (39) 635,591 344 (330 - 359) 247 (234 - 260) 
Route of HIV infection 
       
 
MSM 35,879 (35.1) 462 (1.3) 31 (7) 195 (42) 236 (51) 212,844 111 (98 - 126) 86 (74 - 100) 
Heterosexual men 18,738 (18.3) 2,013 (10.7) 127 (6) 1,205 (60) 681 (34) 113,802 598 (555 - 645) 402 (365 - 443) 
Heterosexual women 30,489 (29.8) 2,815 (9.2) 167 (6) 1,520 (54) 1,128 (40) 201,644 559 (528 - 593) 404 (376 - 434) 
Men who inject drugs 1,453 (1.4) 132 (9.1) 5 (4) 55 (42) 72 (55) 8,216 876 (696 - 1,104) 660 (499 - 873) 
Women who inject drugs 532 (0.5) 35 (6.6) 1 (3) 15 (43) 19 (54) 3,138 605 (365 - 945) 526 (295 - 868) 
Blood/Tissue transfer 505 (0.5) 58 (11.5) 6 (10) 31 (53) 21 (36) 2,928 717 (468 - 1,100) 527 (288 - 883) 
Mother-to-child 253 (0.2) 15 (5.9) 1 (7) 4 (27) 10 (67) 863 1,159 (556 - 2,131) 836 (307 - 1,819) 
Unknown≠ 14,353 (14.0) 119 (0.8) 21 (18) 78 (66) 20 (17) 92,155 22 (14 - 34) 13 (7 - 24) 
Ethnicity/Country of 
birth        
 
White, UK-born 27,320 (26.7) 359 (1.3) 24 (7) 161 (45) 174 (48) 160,488 108 (93 - 126) 84 (70 - 100) 
Black African, UK-born 947 (0.9) 51 (5.4) 6 (12) 25 (49) 20 (39) 5,556 360 (232 - 558) 260 (151 - 448) 
Other ethnicity, UK-born 2,687 (2.6) 72 (2.7) 6 (8) 26 (36) 40 (56) 14,948 268 (196 - 365) 217 (151 - 313) 
Ethnicity unknown, UK-
born 
403 (0.4) 3 (0.7) 0 (0) 3 (100) 0 (0) 544 0 (0 - 678)‡ 0 (0 - 876)‡ 
Born in low-TB incidence 
country 
11,551 (11.3) 245 (2.1) 11 (4) 118 (48) 116 (47) 65,376 177 (148 - 213) 125 (99 - 157) 

































Incidence rate after 
365 days from HIV 
diagnosis* 
(95% CI) 
White, born in high-TB 
incidence country 
7,461 (7.3) 126 (1.7) 4 (3) 71 (56) 51 (40) 47,593 107 (81 - 141) 84 (61 - 116) 
Black African, born in 
high-TB incidence 
country 
35,035 (34.3) 3,877 (11.1) 223 (6) 2,142 (55) 1,512 (39) 234,853 644 (612 - 677) 454 (426 - 483) 
Other ethnicity, born in 
high-TB incidence 
country 
6,756 (6.6) 518 (7.7) 52 (10) 311 (60) 155 (30) 35,614 435 (372 - 509) 290 (236 - 356) 
Ethnicity unknown, born 
in high-TB incidence 
country 
1,140 (1.1) 13 (1.1) 2 (15) 10 (77) 1 (8) 7,556 13 (0 - 74)‡ 15 (0 - 81) 
White, country of birth 
unknown 
3,065 (3.0) 52 (1.7) 4 (8) 31 (60) 17 (33) 23,968 71 (41 - 114) 54 (28 - 95) 
Other ethnicity, country of 
birth unknown 
4,226 (4.1) 300 (7.1) 23 (8) 181 (60) 96 (32) 33,093 290 (237 - 354) 210 (164 - 268) 
Both Unknown≠ 1,611 (1.6) 33 (2.0) 4 (12) 24 (73) 5 (15) 6,002 83 (27 - 194) 39 (5 - 141) 
Age at HIV diagnosis (years) 
      
 
15-24 11,513 (11.3) 437 (3.8) 25 (6) 173 (40) 239 (55) 73,647 325 (286 - 368) 260 (224 - 302) 
25-34 38,910 (38.1) 2,227 (5.7) 129 (6) 1,121 (50) 977 (44) 261,955 373 (350 - 397) 280 (260 - 302) 
35-44 31,894 (31.2) 1,944 (6.1) 133 (7) 1,147 (59) 664 (34) 199,946 332 (308 - 358) 232 (211 - 255) 
45-64 18,357 (18.0) 973 (5.3) 64 (7) 619 (64) 290 (30) 93,708 309 (276 - 347) 183 (156 - 214) 
65+ 1,479 (1.4) 68 (4.6) 8 (12) 43 (63) 17 (25) 5,764 295 (172 - 472) 99 (172 - 472) 
CD4 count at HIV diagnosis† (incidence rates are calculated for time-updated CD4) 
   
 
≥500 20,153 (19.7) 381 (1.9) 30 (8) 88 (23) 263 (69) 187,994 139 (123 - 157) 122 (106 - 139) 
350-499 14,801 (14.5) 455 (3.1) 34 (7) 133 (29) 288 (63) 114,505 259 (231 - 290) 270 (241 - 304) 
200-349 16,282 (15.9) 861 (5.3) 61 (7) 388 (45) 412 (48) 81,579 527 (480 - 579) 454 (407 - 506) 

































Incidence rate after 
365 days from HIV 
diagnosis* 
(95% CI) 
100-199 9,514 (9.3) 1,039 (10.9) 79 (8) 613 (59) 347 (33) 24,933 1,356 (1,219 - 1,508) 785 (673 - 916) 
50-99 5,039 (4.9) 718 (14.2) 35 (5) 525 (73) 158 (22) 6,247 2,209 (1,870 - 2,610) 1,072 (817 - 1,407) 
0-49 8,731 (8.5) 1,241 (14.2) 63 (5) 956 (77) 222 (18) 5,166 2,788 (2,368 - 3,282) 891 (648 - 1,224) 
Unknown≠ 27,682 (27.1) 954 (3.4) 57 (6) 400 (42) 497 (52) - - - 
Viral load at diagnosis (copies/ml) 
      
 
≤200 13,951 (13.7) 580 (4.2) 51 (9) 311 (54) 218 (38) 63,098 345 (303 - 395) 227 (190 - 270) 
>200 58,824 (57.6) 3,735 (6.3) 229 (6) 2,050 (55) 1,456 (39) 339,621 428 (407 - 451) 305 (286 - 325) 
Unknown≠ 29,427 (28.8) 1,334 (4.5) 79 (6) 742 (56) 513 (38) 232,872 221 (202 - 241) 170 (153 - 188) 
Ever started ART (incidence rates calculated for time-updated ART)§ 
    
 
No 32,207 (31.5) 809 (2.5) - - 1336§ 261,662 511 (484 - 539) 337 (314 - 362) 
Yes 69,995 (68.5) 4,840 (6.9) - - 851§ 373,929 228 (213 - 243) 188 (174 - 203) 
         
         
         
         
         
         
         
         
         
         
         

































Incidence rate after 




       
 
1 13,498 (13.2) 900 (6.7) 64 (7) 470 (52) 366 (41) 75,516 485 (437 - 537) 343 (301 - 390) 
2 15,075 (14.8) 920 (6.1) 66 (7) 510 (55) 344 (37) 86,339 398 (358 - 443) 286 (251 - 327) 
3 12,746 (12.5) 688 (5.4) 53 (8) 385 (56) 250 (36) 72,760 344 (304 - 389) 247 (212 - 288) 
4 9,150 (9.0) 474 (5.2) 29 (6) 273 (58) 172 (36) 52,758 326 (281 - 379) 222 (183 - 268) 
5 6,732 (6.6) 336 (5.0) 22 (7) 191 (57) 123 (37) 37,961 324 (272 - 387) 235 (189 - 293) 
6 5,233 (5.1) 253 (4.8) 18 (7) 134 (53) 101 (40) 29,630 341 (280 - 414) 238 (186 - 304) 
7 3,870 (3.8) 164 (4.2) 10 (6) 89 (54) 65 (40) 21,596 301 (236 - 384) 233 (174 - 312) 
8 3,304 (3.2) 140 (4.2) 6 (4) 83 (59) 51 (36) 17,934 290 (221 - 381) 207 (147 - 291) 
9 2,809 (2.7) 110 (3.9) 7 (6) 64 (58) 39 (35) 15,846 246 (180 - 337) 163 (108 - 245) 
10 2,217 (2.2) 97 (4.4) 3 (3) 52 (54) 42 (43) 11,925 352 (260 - 477) 274 (190 - 394) 
Unknown≠ 27,568 (27.0) 1,567 (5.7) 81 (5) 852 (54) 634 (40) 213,326 297 (274 - 321) 217 (197 - 238) 
* Incidence is given per 100,000 population aged ≥15 years, per year. † Incidence rates are calculated for time-updated CD4 count. ≠ Unknown strata 
includes both unknown and missing data. ‡One-sided, 97.5% CI. §Of the 5,649 PLHIV who got TB, 809 never initiated ART. However, of the 2,187 who got 
TB >91 days after their HIV infection, 1,336 had not initiated ART at the time of their TB diagnosis. ART: anti-retroviral therapy, CI: confidence interval, 
IMD: index of multiple deprivation (only available for patients in England and Wales), MSM: men who have sex with men, n: number, PWID: people who 
inject drugs, PY: person-years, TB: tuberculosis.  





4.3.2 Incidence of tuberculosis following HIV diagnosis 
95,003 adults were TB-free 92 days after presenting for HIV care, with a total of 
635,591 PY follow-up. Median age at HIV diagnosis was 34 years (inter-quartile range 
[IQR] 28-42) and median CD4 count was 340 cells/µl (IQR 170-527). 95% of patients 
who were linked to CD4 surveillance data had more than one CD4 count; the median 
number of counts was 14. 
Overall TB incidence following HIV diagnosis was 344/100,000 PY (95% 
confidence interval [CI]: 330-359, Table 4.1). The risk of developing TB was highest in 
the year following HIV diagnosis and then decreased (Figure 4.3); after the first year 
the incidence of TB was 247/100,000 PY [234-260/100,000] (Table 4.1). 
Figure 4.3: Cumulative hazard plot of the probability of developing TB from 91 days after 
HIV diagnosis for all people diagnosed with HIV in England, Wales and Northern Ireland 
from 2000 to 2014. 
 
Incidence was high in PWID (men 876/100,000 [696-1,104/100,000]; women 
605/100,000 [386-949/100,000]) and heterosexuals (men 598/100,000 [555-
645/100,000], women 559 [528-593/100,000]), particularly compared with MSM 





(111/100,000 [98-126/100,000]). Incidence among PLHIV who acquired their HIV 
infection through blood or tissue transfer or mother-to-child transmission was also high, 
although the number of person-years of follow-up for both of these groups was low 
(2,928 and 863 PY respectively, Table 4.1).  
PLHIV born in countries with high TB incidence had substantially higher 
incidence rates of TB compared to people born in the UK or other low-incidence 
countries. TB incidence in people born in the UK was 108/100,000 [93-126/100,000] for 
white people, 360/100,000 [232-558/100,000] for people of black African ethnicity and 
268/100,000 [196-365/100,000] for people of other ethnicities. In comparison, TB 
incidence in people born in countries with high TB incidence was 644/100,000 [612-
677/100,000] for black Africans, 435/100,000 [372-509/100,000] for other ethnicities 
and 107/100,000 [81-141/100,000] for white people. 
Stratifying by both route of HIV infection (Figure 4.4) and ethnicity (Figure 4.5), 
the largest differences in cumulative probability of TB diagnosis occurred in the first two 
years following HIV diagnosis; the rate of diagnosis remained relatively constant across 
all groups thereafter. The risk of TB was greatest for men who injected drugs and 
people who acquired HIV heterosexually, but also high among people who were 
infected with HIV through blood/tissue transfer or through mother-to-child transmission, 
although the numbers of patients in the latter categories were much lower. Men who 
injected drugs also had highest cumulative risk of TB over the study period (Figure 
4.4). 
  





Figure 4.4: Cumulative hazard plot of the probability of developing TB from 91 days after 
HIV diagnosis for people diagnosed with HIV in England, Wales and Northern Ireland 
from 2000 to 2014, stratified by route of HIV infection. 
 
Figure 4.5: Cumulative hazard plot of the probability of developing TB from 91 days after 
HIV diagnosis for people diagnosed with HIV in England, Wales and Northern Ireland 
from 2000 to 2014, stratified by ethnicity. 
 





TB incidence was highest among PLHIV who were aged 25-34 years at the 
time of their HIV diagnosis (373/100,000 [350-397/100,000], and decreased with age at 
HIV diagnosis to 295/100,000 [172-472/100,000] for people aged over 65 years when 
diagnosed with HIV. 
TB incidence increased with decreasing time-updated CD4 count, from 
139/100,000 (123-157/100,000) for those with CD4 count ≥500 cells/µl to 
2,788/100,000 (2,368-3,282/100,000) for those with CD4 count <50 cells/µl. 
Irrespective of CD4 count at diagnosis, the risk of TB was greatest in the first year 
following diagnosis, but the cumulative risk of TB was inversely associated with CD4 
count at diagnosis (Figure 4.6). The only exception to this was for patients who had a 
CD4 count of <50 cells/µl at HIV diagnosis, who had a lower cumulative risk of TB than 
those with CD4 counts between 50 and 199 cells/µl. 
Figure 4.6: Cumulative hazard plot of the probability of developing TB from 91 days after 
HIV diagnosis for people diagnosed with HIV in England, Wales and Northern Ireland 
from 2000 to 2014, stratified by CD4 count at HIV diagnosis. 
 
  





TB incidence was 511/100,000 (484-539/100,000) in people who had never 
received ART (26% of all PY) compared to 228/100,000 (213-243/100,000) in people 
who had (74% of PY). TB incidence was higher for PWID who had never initiated ART 
(1,478/100,000 [95% CI 1,157-1,888/100,000] than for black Africans from high-TB 
incidence countries who had never initiated ART (991/100,000 [929-1,058/100,000]) 
although incidence rates following ART initiation were similar in both groups 
(384/100,000 [264-560/100,000] for PWID versus 421 [389-456/100,000] for black 
Africans). 
TB incidence was highest in those living in areas of England and Wales with the 
lowest decile of IMD score (485/100,000 [437-537/100,000]) and decreased with 
increasing IMD decile. 
4.3.3 Factors associated with developing tuberculosis disease 
62,684 individuals with complete case data and a TB-free follow-up period of 
>91 days following HIV diagnosis were included in the time-to-event analysis. There 
were a total of 414,714 PY of follow-up (median follow-up 7.1 years, IQR 3.6-10.4), 
during which there were 1,591 TB diagnoses (Table 4.2). The median duration of 
follow-up was 7.3 years (IQR 3.9-10.4) for patients who did not develop TB, whilst 
patients who did develop TB did so in a median of 0.2 years (IQR 0.1-0.5). Black 
African patients born in high-TB countries had a slightly longer median follow-up period 
of 8.2 (4.7-11.0) years, compared to 6.3 (3.1-9.8) for MSM and 6.5 (3.4-9.8) for PWID, 
as black Africans were more likely to be diagnosed earlier in the study period than 
PWID or MSM. 
  





Table 4.2: Univariable and multivariable incidence rate ratios from Poisson regression of 
factors associated with incident TB disease (more than 91 days after HIV diagnosis) 







PY IRR (95% CI) IRR (95% CI) 
Route of HIV infection 
    
MSM 184 172,708 1.00 (P<0.001) 1.00 (P<0.001) 
Male heterosexual 474 82,460 5.40 (4.55 - 6.40) 1.70 (1.38 - 2.10) 
Female heterosexual 837 148,391 5.29 (4.51 - 6.21) 1.86 (1.51 - 2.29) 
Male PWID 61 5,895 9.71 (7.27 - 12.97) 5.47 (4.07 - 7.35) 
Female PWID 16 2,514 5.97 (3.58 - 9.95) 4.59 (2.75 - 7.67) 
Blood/Tissue transfer 14 2,251 5.84 (3.39 - 10.05) 2.70 (1.55 - 4.71) 
Mother-to-child 5 494 9.51 (3.91 - 23.11) 2.80 (1.13 - 6.97) 
Ethnicity/Country of birth 
    
White, UK-born 134 127,453 1.00 (P<0.001) 1.00 (P<0.001) 
Black African, UK-born 13 4,317 2.86 (1.62 - 5.06) 1.97 (1.10 - 3.51) 
Other ethnicity, UK-born 31 12,040 2.45 (1.66 - 3.62) 1.92 (1.29 - 2.84) 
Ethnicity unknown, UK-born 0 252 † † 
Born in low-TB incidence 
country 
98 53,647 1.74 (1.34 - 2.25) 1.33 (1.02 - 1.73) 
White, born in high-TB 
incidence country 
38 12,606 2.87 (2.00 - 4.11) 2.19 (1.53 - 3.15) 
Black African, born in high-
TB incidence country 
1,093 148,017 7.02 (5.87 - 8.40) 4.27 (3.42 - 5.33) 
Other ethnicity, born in high-
TB incidence country 
105 22,219 4.50 (3.48 - 5.80) 3.36 (2.57 - 4.39) 
Ethnicity unknown, born in 
high-TB incidence country 
1 323 2.95 (0.41 - 21.07) 1.35 (0.19 - 9.71) 
White, country of birth 
unknown 
12 15,491 0.74 (0.41 - 1.33) 0.52 (0.29 - 0.94) 
Other ethnicity, country of 
birth unknown 
66 18,348 3.42 (2.55 - 4.59) 1.60 (1.17 - 2.20) 
CD4 count (time-updated, 
cells/µl)     
≥500 259 185,719 1.00 (P<0.001) * 
350-499 293 113,185 1.86 (1.57 - 2.19) 
 
200-349 427 80,443 3.81 (3.26 - 4.44) 
 
100-199 332 24,367 9.77 (8.30 - 11.49) 
 
50-99 137 6,093 
16.12 (13.11 - 
19.83)  
0-49 143 4,905 
20.90 (17.04 - 
25.64)  
Ever initiated ART (time-
updated)     
No 928 107,477 1.00 (P<0.001) * 
Yes 663 307,237 0.25 (0.23 - 0.28) 
 
Viral load at HIV diagnosis 
(copies/ml)     
≤200 154 43,347 1.00 (P=0.006) - 
>200 1,063 261,249 1.15 (0.97 - 1.36) 
 
     
     











PY IRR (95% CI) IRR (95% CI) 
Age at HIV diagnosis 
    
15-24 169 48,805 0.95 (0.79 - 1.13) 0.92 (0.77 - 1.10) 
25-34 714 170,957 1.14 (1.02 - 1.28) 1.06 (0.94 - 1.19) 
35-44 477 130,441 1.00 (P<0.001) 1.00 (P=0.332) 
45-64 220 61,028 0.99 (0.84 - 1.16) 1.11 (0.95 - 1.31) 
≥65 11 3,484 0.86 (0.47 - 1.57) 0.92 (0.51 - 1.68) 
Year of HIV diagnosis 
    
(for each year increase from 
2000) 
1,591 414,714 0.98 (0.97 - 1.00) 1.02 (1.00 - 1.04) 
   
P=0.036 P=0.014 
IMD decile (England and 
Wales only)     
1 264 51,685 1.00 (P<0.001) - 
2 269 63,391 0.83 (0.70 - 0.98) 
 
3 193 54,955 0.69 (0.57 - 0.83) 
 
4 127 38,159 0.65 (0.53 - 0.81) 
 
5 83 26,725 0.61 (0.48 - 0.78) 
 
6 78 20,986 0.73 (0.57 - 0.94) 
 
7 47 15,254 0.60 (0.44 - 0.82) 
 
8 38 12,644 0.59 (0.42 - 0.83) 
 
9 24 10,743 0.44 (0.29 - 0.66) 
 
10 32 8,326 0.75 (0.52 - 1.09)   
62,684 PLHIV were included in this analysis; 32,319 were excluded from the model due to 
missing data on ethnicity and country of birth, route of HIV infection, CD4 count or age at 
HIV diagnosis. Viral load was not included in the multivariable model due to collinearity 
with CD4 count and ART status. *Interaction present between time-updated CD4 count 
and time-updated ART status, see Table 4.4 and Table 4.3. †Not calculated as numerator 
was zero. ART: anti-retroviral therapy, CI: confidence interval, IMD: index of multiple 
deprivation, MSM: men who have sex with men, PWID: people who inject drugs, PY: 
person years, IRR: incidence rate ratio, TB: tuberculosis. 
  





4.3.3.1 Univariable results 
In univariable analyses, the incidence rate ratio (IRR) for TB in PLHIV was 
significantly higher for all other routes of HIV infection than for MSM. The IRR was 9.71 
[7.27-12.97] for men who inject drugs, 5.97 [3.58-9.95] for women who inject drugs, 
5.40 [4.55-6.40] for heterosexual men, 5.29 [4.51-6.21] for heterosexual women and 
9.51 [3.91-23.11] for people infected with HIV by mother-to-child transmission (Table 
4.2). 
Compared to white, UK-born people, TB incidence was higher for black Africans 
(IRR 2.86 [1.62-5.06]) and people of other ethnicities (2.45 [1.66-3.62]) born in the UK, 
and slightly higher for people of all ethnicities born in other low-incidence countries 
(1.74 [1.34-2.25]). However, the IRR was significantly higher for people born in 
countries with high TB incidence, with an IRR of 2.87 [2.00-4.11] for white people, 7.02 
[5.87-8.40] for black Africans and 4.50 [3.48-5.80] for other ethnicities. 
Age at HIV diagnosis was associated with incidence of TB; compared to people 
aged 35-44 years the IRR was elevated for people aged 25-34 (1.14 [1.02-1.128]) but 
not significantly different for other age groups. 
TB incidence generally decreased as IMD decile increased; compared to the 
baseline of the lowest decile the IRR was 0.61 [0.48-0.78] for the 5th decile and 0.44 
[0.29-0.66] for the 9th decile, although CIs overlapped.  
Decreasing time-updated CD4 count was strongly and significantly associated 
with higher IRRs. Compared to a CD4 count >500 cells/µl, the IRR was 1.86 [1.57-
2.19] for 350-499 cells/µl and this increased to 20.90 [17.04-25.64] for <50 cells/µl. 
Having ever initiated ART was significantly associated with substantially lower IRR of 
TB [0.25 [0.23-0.28]. 





Viral load at HIV diagnosis was also positively associated with risk of 
developing TB; compared to the baseline of ≤200 copies/ml the IRR for >200 copies/ml 
was 1.15 [0.97-1.36]. 
4.3.3.2 Multivariable results 
All exposures were included in the multivariable Poisson regression model 
(Table 4.2), except viral load and IMD decile. IMD decile was excluded as there was a 
high degree of missing data and no association with the outcome in a multivariable 
model; it was included in a sensitivity analysis. CD4 count and age at HIV diagnosis 
were treated as categorical variables (tests for linearity P<0.001 and P=0.005, 
respectively); year of HIV diagnosis was included as linear variable (P=0.412). There 
was a statistically significant interaction between time-updated CD4 count and time-
updated ART status (P<0.001). 
Compared to MSM, PWID had increased rates of TB (incidence rate ratio [IRR] 
for men 5.47 [95% CI 4.07-7.35]; women 4.59 [2.75-7.67]). Rates were also higher in 
those infected through heterosexual sex (men 1.70 [1.38-2.10]; women 1.86 [1.51-
2.29]). UK-born black Africans (1.97 [1.10-3.51]) and people of other ethnicities (1.92 
[1.29-2.84]) were associated with increased incidence rates versus white UK-born 
individuals, as were those born in high TB incidence countries (black African 4.27 
[3.42-5.33], white 2.19 [1.53-3.15], other ethnicities 3.36 [2.57-4.39]) and people born 
in low-incidence countries other than the UK (1.33 [1.02-1.73]). 
Overall, and within each stratum of CD4 count, TB rates were greatly reduced 
in individuals who had received ART compared to those who had not (Table 4.3). 
Compared to never having initiated ART, the IRR for TB in people who had initiated 
ART was 0.07 [0.05-0.10] for people with a CD4 count ≥500 cells/µl, and 0.49 [0.35-
0.69] for people with a CD4 count of <50 cells/µl. 
  





Table 4.3: Multivariable Poisson regression of the association between time-updated ART status and TB disease, stratified by CD4 count, among PLHIV 
in England, Wales and Northern Ireland from 2000 to 2014. 
  CD4 count (cells/µl)           
 
≥500 350-499 200-349 100-199 50-99 0-49 
Ever on ART IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
No 1.00 1.00 1.00 1.00 1.00 1.00 
Yes 0.07 (0.05 - 0.10) 0.14 (0.11 - 0.18) 0.21 (0.17 - 0.25) 0.32 (0.26 - 0.40) 0.35 (0.25 - 0.49) 0.49 (0.35 - 0.69) 
Incidence rate ratios derived from multivariable Poisson regression of the association between time-updated ART status and TB disease, stratified by 
CD4 count. Model adjusted for the variables in the multivariable model in Table 4.2. 62,684 PLHIV were included in this analysis; 32,319 were excluded 
from the model due to missing data on ethnicity and country of birth, route of HIV infection, CD4 count or age at HIV diagnosis. ART: anti-retroviral 
therapy, CI: confidence interval, IRR: incidence rate ratio, TB: tuberculosis. 
 
Table 4.4: Multivariable Poisson regression of the association between time-updated CD4 count and TB disease, stratified by ART status, among PLHIV 
in England, Wales and Northern Ireland from 2000 to 2014. 
  Ever on ART 
CD4 count No Yes 
(cells/µl) IRR (95% CI) IRR (95% CI) 
≥500 1.00 1.00 
350-499 1.28 (1.06 - 1.55) 2.51 (1.77 - 3.56) 
200-349 2.22 (1.84 - 2.66) 6.37 (4.66 - 8.72) 
100-199 4.74 (3.79 - 5.93) 21.21 (15.59 - 28.85) 
50-99 7.07 (5.26 - 9.51) 34.29 (24.10 - 48.77) 
0-49 6.42 (4.87 - 8.46) 44.21 (30.90 - 63.24) 
Incidence rate ratios derived from multivariable Poisson regression of the association between time-updated CD4 count and TB disease, stratified by 
ART status. 62,684 PLHIV were included in this analysis; 32,319 were excluded from the model due to missing data on ethnicity and country of birth, 
route of HIV infection, CD4 count or age at HIV diagnosis. Model adjusted for the variables in the multivariable model in Table 4.2. ART: anti-retroviral 
therapy, CI: confidence interval, IRR: incidence rate ratio, TB: tuberculosis.  





When stratifying by ART initiation status, lower time-updated CD4 count was 
strongly associated with increased TB rates (Table 4.4). For individuals who had never 
initiated ART, the IRR for TB increased with decreasing CD4 count to 6.42 [4.87-8.46] 
for 0-49 cells/µl compared to ≥500 cells/µl. The increased risk at low CD4 count was 
higher in individuals who had initiated ART, with an IRR of 44.21 [30.90-63.24] for 0-49 
cells/µl, compared to ≥500 cells/µl. 
4.3.4 Anti-retroviral therapy initiation and discontinuation 
In a post-hoc analysis of patients who had initiated ART, PLHIV who developed 
TB were more likely to have discontinued ART at their last clinic visit (27%, versus 6% 
of those without TB, P<0.001, Table 4.5). Rates of ART initiation, and the time period 
from the most recent clinic visit to the end of the study were similar for MSM, 
heterosexuals and PWID (Table 4.5). 
4.3.5 Sensitivity analysis 
Sensitivity analyses were conducted as follows: (1) excluding 241 individuals 
who acquired HIV infection through mother-to-child transmission, (2) excluding 595 
individuals with TB whose probabilistic matching scores (linking to their HIV record) 
were in the lowest quartile, (3) excluding 137 individuals with TB who were matched to 
their HIV record using the three lowest-ranked deterministic criteria, (4) excluding 424 
individuals diagnosed with TB 92-182 days after HIV diagnosis, (5) including IMD score 
and excluding data on 12,432 individuals missing IMD score. All analyses provided 
consistent results with the main model (Table 4.6, Table 4.7, Table 4.8). 
 
  




Table 4.5: ART initiation rates, median time from date of last ART status to study end, and rates of ART discontinuation at the last clinic visit prior to the 
end of the study. 
      
Initiated ART by 
end of study 
Median months from last 
ART status to study end 
Patients who had initiated ART but 
were not on ART at their last clinic visit 
prior to study end* 
Probable route of HIV infection Outcome n n (%) n (95% CI) n (%) 
All groups No TB 61,093 52,207 (86%) 6.9 (2.8-16.3) 2,965 (6%) 
 
TB 1,591 1,095 (69%) 9.4 (3.6-20.3) 294 (27%) 
Men who have sex with men No TB 27,566 23,268 (84%) 6.3 (2.5-12.9) 1,058 (5%) 
 
TB 184 118 (64%) 8.0 (2.9-16.1) 35 (30%) 
Heterosexual sex No TB 31,773 27,476 (87%) 7.6 (3.1-26.8) 1,815 (7%) 
 
TB 1,311 913 (70%) 9.6 (3.6-21.5) 250 (27%) 
People who inject drugs No TB 1,297 1,058 (82%) 7.9 (2.8-34.9) 72 (7%) 
  TB 77 47 (61%) 9.6 (3.8-21.5) 6 (13%) 
* Study end was TB diagnosis, death, or 31/12/2014, whichever was soonest. Patients with unknown ART status were classed as not being on ART. ART: 
anti-retroviral therapy, CI: confidence interval, TB: tuberculosis. 
 




Table 4.6: Sensitivity analyses of multivariable Poisson regression models of factors associated with incident TB disease among PLHIV in England, 








25%) excluded 2 
Weakest deterministic 
matches excluded 3 
182 day cut-off for 
‘simultaneous’ 
diagnosis 4 
IMD decile included 
5 
  IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
Route of HIV infection 
     
MSM 1·00 1·00 1·00 1·00 1·00 
Heterosexual men 1·79 (1·45 - 2·21) 1·63 (1·28 - 2·09) 1·84 (1·48 - 2·30) 1·83 (1·45 - 2·31) 1·83 (1·44 - 2·31) 
Heterosexual women 1·95 (1·59 - 2·41) 1·94 (1·53 - 2·46) 2·04 (1·64 - 2·53) 1·96 (1·56 - 2·46) 1·97 (1·56 - 2·48) 
Men who inject drugs 5·42 (4·03 - 7·29) 4·67 (3·26 - 6·68) 5·73 (4·22 - 7·79) 5·44 (3·91 - 7·56) 4·79 (3·35 - 6·85) 
Women who inject drugs 4·89 (2·93 - 8·16) 4·01 (2·11 - 7·62) 5·35 (3·20 - 8·95) 5·76 (3·44 - 9·64) 6·18 (3·49 - 10·93) 
Blood/Tissue transfer 3·08 (1·77 - 5·38) 2·82 (1·47 - 5·44) 2·92 (1·61 - 5·32) 3·28 (1·80 - 5·98) 2·79 (1·45 - 5·37) 
Mother-to-child - 2·74 (0·85 - 8·78) 4·03 (1·61 - 10·04) 3·78 (1·37 - 10·44) 5·58 (2·22 - 14·02) 
Ethnicity/Country of birth 
     
White, UK-born 1·00 1·00 1·00 1·00 1·00 
Black African, UK-born 1·94 (1·09 - 3·47) 1·66 (0·80 - 3·45) 2·00 (1·12 - 3·58) 1·54 (0·77 - 3·07) 1·67 (0·83 - 3·33) 
Other ethnicity, UK-born 1·82 (1·23 - 2·70) 2·02 (1·29 - 3·15) 1·76 (1·17 - 2·65) 1·78 (1·16 - 2·71) 1·97 (1·28 - 3·05) 
Ethnicity unknown, UK-born -† -† -† -† -† 
Born in low-TB incidence country 1·25 (0·96 - 1·63) 1·28 (0·94 - 1·75) 1·15 (0·87 - 1·52) 1·16 (0·87 - 1·55) 1·22 (0·91 - 1·64) 
White, born in high-TB incidence 
country 
2·02 (1·40 - 2·92) 2·37 (1·57 - 3·56) 1·93 (1·32 - 2·82) 1·90 (1·27 - 2·85) 1·85 (1·23 - 2·79) 
Black African, born in high-TB 
incidence country 
4·01 (3·21 - 5·02) 4·17 (3·21 - 5·42) 3·92 (3·12 - 4·93) 3·84 (3·02 - 4·89) 3·55 (2·75 - 4·57) 
Other ethnicity, born in high-TB 
incidence country 
3·27 (2·50 - 4·28) 3·29 (2·40 - 4·51) 3·01 (2·27 - 3·99) 3·13 (2·33 - 4·20) 3·12 (2·31 - 4·22) 
Ethnicity unknown, born in high-TB 
incidence country 
1·03 (0·14 - 7·42) -† 1·07 (0·15 - 7·70) 1·35 (0·19 - 9·71) 2·30 (0·32 - 16·53) 










25%) excluded 2 
Weakest deterministic 
matches excluded 3 
182 day cut-off for 
‘simultaneous’ 
diagnosis 4 
IMD decile included 
5 
  IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
White, country of birth unknown 0·44 (0·25 - 0·80) 0·36 (0·17 - 0·78) 0·46 (0·26 - 0·84) 0·48 (0·26 - 0·89) 0·60 (0·33 - 1·09) 
Other ethnicity, country of birth 
unknown 
1·36 (0·99 - 1·86) 1·28 (0·88 - 1·87) 1·36 (0·99 - 1·88) 1·32 (0·94 - 1·87) 0·97 (0·65 - 1·43) 
CD4 count 
     
≥500 * * * * * 
350-499      
200-349      
100-199      
50-99      
0-49      
Ever on ART 
     
No * * * * * 
Yes      
Age at HIV diagnosis 
     
15-24 0·88 (0·73 - 1·05) 0·87 (0·71 - 1·07) 0·86 (0·71 - 1·04) 0·89 (0·73 - 1·08) 0·88 (0·70 - 1·09) 
25-34 1·02 (0·91 - 1·15) 0·98 (0·86 - 1·12) 1·04 (0·92 - 1·17) 1·01 (0·89 - 1·15) 1·12 (0·97 - 1·29) 
35-44 1·00 1·00 1 1·00 1·00 
45-64 1·11 (0·95 - 1·31) 1·13 (0·94 - 1·36) 1·09 (0·92 - 1·29) 1·03 (0·86 - 1·24) 1·30 (1·09 - 1·56) 
≥65 0·92 (0·50 - 1·67) 0·78 (0·37 - 1·66) 0·90 (0·48 - 1·68) 0·85 (0·42 - 1·71) 1·95 (1·03 - 3·67) 
Year of HIV diagnosis 
     
(for each year increase from 2000) 1·02 (1·01 - 1·04) 1·02 (1·01 - 1·04) 1·03 (1·01 - 1·04) 1·00 (0·98 - 1·02) 1·01 (0·99 - 1·03) 
      
      
IMD decile 
     










25%) excluded 2 
Weakest deterministic 
matches excluded 3 
182 day cut-off for 
‘simultaneous’ 
diagnosis 4 
IMD decile included 
5 
  IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
1 - - - - 0.92 (0.77 - 1.09) 
2 - - - - 0.89 (0.74 - 1.07) 
3 - - - - 0.85 (0.68 - 1.05) 
4 - - - - 0.81 (0.63 - 1.04) 
5 - - - - 0.94 (0.73 - 1.21) 
6 - - - - 0.92 (0.67 - 1.26) 
7 - - - - 0.84 (0.59 - 1.18) 
8 - - - - 0.65 (0.43 - 1.00) 
9 - - - - 1.03 (0.71 - 1.49) 
10 - - - - 0.92 (0.77 - 1.09) 
1 241 individuals who acquired HIV infection through mother-to-child transmission were excluded. 2 2,057 of 2,187 individuals with TB and HIV were 
linked via probabilistic matching. The lowest quartile of probabilistic match scores (595 individuals) were excluded. 3 1951 of 2,187 individuals with TB 
and HIV were linked using 8 hierarchical deterministic matching criteria. 137 individuals matched using the three lowest-ranked criteria were excluded. 4 
424 individuals diagnosed with TB 92-182 days after HIV diagnosis were excluded. 5 IMD score was included in the analysis, 12,432 individuals with no 
data on their IMD score were excluded. *An interaction was present between time-updated CD4 count and time-updated ART status, see Table 4.7 and 
Table 4.8. †Not calculated as numerator was zero. ART: anti-retroviral therapy, CI: confidence interval, IMD: index of multiple deprivation (only available 
for patients in England and Wales), IRR: incidence rate ratio, MSM: men who have sex with men, PWID: people who inject drugs, PY: person-years, TB: 
tuberculosis. 
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Table 4.7: Sensitivity analyses of multivariable Poisson regression models of the association between time-updated CD4 count and TB disease, stratified 





matches (lowest 25%) 
excluded 2 
Weakest deterministic 
matches excluded 3 
182 day cut-off for 
‘simultaneous’ diagnosis 4 
IMD decile included 5 
 
Ever on ART 
 
Ever on ART 
 
Ever on ART 
 
Ever on ART 
 
Ever on ART 
 
 
No Yes No Yes No Yes No Yes No Yes 
CD4 
count 
IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 




(1·31 - 3·76) 
2·98 
(1·82 - 4·88) 
2·05 
(1·13 - 3·73) 
2·88 
(1·65 - 5·03) 
2·09 
(1·22 - 3·59) 
2·91 
(1·75 - 4·82) 
2·27 
(1·32 - 3·89) 
2·99 
(1·80 - 4·94) 
2·29 
(1·27 - 4·14) 
2·71 




(1·35 - 3·60) 
5·83 
(3·68 - 9·25) 
2·01 
(1·15 - 3·51) 
5·62 
(3·34 - 9·45) 
2·23 
(1·35 - 3·69) 
5·91 
(3·69 - 9·45) 
2·21 
(1·33 - 3·68) 
5·29 
(3·29 - 8·53) 
1·91 
(1·11 - 3·31) 
5·31 




(1·44 - 3·84) 
18·46 
(11·74 - 29·04) 
2·25 
(1·29 - 3·92) 
17·89 
(10·73 - 29·83) 
2·5 
(1·52 - 4·13) 
18·99 
(11·98 - 30·12) 
2·66 
(1·60 - 4·42) 
16·98 
(10·64 - 27·09) 
1·85 
(1·07 - 3·19) 
16·95 
(10·27 - 27·98) 
50-99 
2·35 
(1·33 - 4·15) 
29·15 
(17·27 - 49·20) 
2·05 
(1·05 - 3·97) 
25·23 
(13·73 - 46·37) 
2·35 
(1·32 - 4·21) 
29·42 
(17·26 - 50·14) 
2·6 
(1·39 - 4·86) 
22·58 
(12·81 - 39·81) 
1·92 
(1·01 - 3·65) 
27·35 
(15·25 - 49·04) 
0-49 
3·84 
(2·23 - 6·63) 
46·89 
(28·31 - 77·68) 
3·47 
(1·87 - 6·45) 
45·33 
(25·58 - 80·34) 
3·77 
(2·16 - 6·60) 
45·99 
(27·44 - 77·08) 
4·38 
(2·42 - 7·92) 
36·91 
(21·50 - 63·37) 
2·56 
(1·38 - 4·78) 
39·07 
(21·98 - 69·44) 
Incidence rate ratios derived from multivariable Poisson regression models of the association between time-updated CD4 count and TB disease, 
stratified by ART status. Models adjusted for the variables in the multivariable model in Table 4.6. 1 241 individuals who acquired HIV infection through 
mother-to-child transmission were excluded. 2 2,057 of 2,187 individuals with TB and HIV were linked via probabilistic matching. The lowest quartile of 
probabilistic match scores (595 individuals) were excluded. 3 1951 of 2,187 individuals with TB and HIV were linked using 8 hierarchical deterministic 
matching criteria. 137 individuals matched using the three lowest-ranked criteria were excluded. 4 424 individuals diagnosed with TB 92-182 days after 
HIV diagnosis were excluded. 5 IMD score was included in the analysis, 12,432 individuals with no data on their IMD score were excluded. *An interaction 
was present between time-updated CD4 count and time-updated ART status, see Table 4.7 and Table 4.8. †Not calculated as numerator was zero. ART: 
anti-retroviral therapy, CI: confidence interval, IMD: index of multiple deprivation, IRR: incidence rate ratio, MSM: men who have sex with men, PWID: 
people who inject drugs, PY: person-years, TB: tuberculosis. 
  




Table 4.8: Sensitivity analyses of multivariable Poisson regression models of the association between time-updated ART status and TB 
disease, stratified by CD4 count, among PLHIV in England, Wales and Northern Ireland from 2000 to 2014. 
    CD4 count           
  
≥500 350-499 200-349 100-199 50-99 0-49 




No 1·00 1·00 1·00 1·00 1·00 1·00 




25%) excluded 2 
No 1·00 1·00 1·00 1·00 1·00 1·00 
Yes 0·04 (0·02 - 0·06) 0·07 (0·05 - 0·11) 0·07 (0·05 - 0·10) 0·08 (0·06 - 0·11) 0·07 (0·05 - 0·12) 0·12 (0·08 - 0·19) 
Weakest 
deterministic 
matches excluded 3 
No 1·00 1·00 1·00 1·00 1·00 1·00 
Yes 0·03 (0·02 - 0·05) 0·07 (0·05 - 0·10) 0·08 (0·06 - 0·10) 0·09 (0·07 - 0·11) 0·08 (0·05 - 0·12) 0·13 (0·09 - 0·18) 
182 day cut-off for 
‘simultaneous’ 
diagnosis 4 
No 1·00 1·00 1·00 1·00 1·00 1·00 
Yes 0·03 (0·02 - 0·05) 0·08 (0·06 - 0·11) 0·08 (0·06 - 0·10) 0·09 (0·07 - 0·12) 0·09 (0·06 - 0·14) 0·15 (0·10 - 0·22) 
IMD decile included 
5 
No 1·00 1·00 1·00 1·00 1·00 1·00 
Yes 0·03 (0·02 - 0·05) 0·07 (0·05 - 0·11) 0·06 (0·05 - 0·08) 0·06 (0·04 - 0·08) 0·06 (0·04 - 0·10) 0·08 (0·05 - 0·12) 
Incidence rate ratios derived from multivariable Poisson regression models of the association between time-updated CD4 count and TB 
disease, stratified by ART status. Models adjusted for the variables in the multivariable model in Table 4.6. 1 241 individuals who acquired 
HIV infection through mother-to-child transmission were excluded. 2 2,057 of 2,187 individuals with TB and HIV were linked via probabilistic 
matching. The lowest quartile of probabilistic match scores (595 individuals) were excluded. 3 1951 of 2,187 individuals with TB and HIV were 
linked using 8 hierarchical deterministic matching criteria. 137 individuals matched using the three lowest-ranked criteria were excluded. 4 
424 individuals diagnosed with TB 92-182 days after HIV diagnosis were excluded. 5 IMD score was included in the analysis, 12,432 
individuals with no data on their IMD score were excluded. *An interaction was present between time-updated CD4 count and time-updated 
ART status, see Table 4.7 and Table 4.8. †Not calculated as numerator was zero. ART: anti-retroviral therapy, CI: confidence interval, IMD: 
index of multiple deprivation, IRR: incidence rate ratio, MSM: men who have sex with men, PWID: people who inject drugs, PY: person-years, 
TB: tuberculosis.  




4.4.1 Summary of findings 
Within our cohort of over 100,000 adults diagnosed with HIV from 2000 to 2014, 
six percent had a diagnosis of TB. Over half of these were simultaneously diagnosed 
with TB and HIV. Simultaneous diagnoses were most common among people who 
acquired their HIV infection via heterosexual sex, and/or who were born in countries 
with high TB incidence, and least common among MSM and PWID. 
The incidence of TB in PLHIV after HIV diagnosis in this study was 344/100,000 
PY, thirty times higher than the national TB incidence in the general adult (≥15 years) 
population of 11.5 per 100,000 population per year.[52] For patients not simultaneously 
diagnosed with HIV and TB, the risk of developing TB was highest in the first two years 
after HIV diagnosis. The differences in incidence between MSM, PWID, and people 
who acquired HIV infection through heterosexual sex, and between patients of different 
ethnicity, were also greatest in the first two years after HIV diagnosis. After two years 
TB incidence was relatively consistent across different risk groups. 
The risk of developing TB following HIV diagnosis was highest for people who 
acquired HIV through injecting drug use (largely UK-born patients), and incidence rates 
in this population were comparable to those in black Africans born in high TB incidence 
countries; almost five-fold more than MSM after accounting for other factors including 
starting ART. TB incidence among MSM was ten times higher than in the general 
population (111/100,000 compared to 11.5/100,000)[52], whilst TB incidence in black 
African PLHIV was more than six times that in the general population (644/100,000 
compared to 102/100,000 in black African people born outside the UK [irrespective of 
HIV status], [52] although these estimates are not directly comparable as the national 
figures for the general population were not stratified by TB incidence in country of 
birth). 




Consistent with previous research, higher CD4 count [119, 164] and initiation of 
ART [200] were associated with lower incidence of TB. 
4.4.2 Strengths and limitations of the study 
This study benefitted from the very large national HIV-positive cohort, providing 
comprehensive results for England, Wales and Northern Ireland. The large sample size 
resulted in strong statistical evidence that the associations between the risk of TB and 
route of HIV infection, ethnicity, country of birth, CD4 count, and ART initiation (all 
P<0.001) did not occur by chance. The large sample also enabled composite variables 
to be created for sex and route of HIV infection, and for ethnicity and TB incidence in 
country of birth, to avoid these known interactions within the model, and to test for the 
interaction between CD4 count, ART and risk of TB. The algorithm linking patients with 
TB and HIV utilised ethnicity, year and country of birth; all variables with very high 
completeness: 97.3%, 99.9% and 90.5% respectively. 
There were no substantial differences in the demographics or proportion of TB 
in patients missing data on each of these variables; however patients missing data on 
one variable were more likely to have other missing data. Patients missing data for 
multiple variables were less likely to be linked to a TB notification meaning that TB 
incidence may have been underestimated. It is likely that the low incidence of TB in 
patients with unknown ethnicity or route of HIV infection was a symptom of this, despite 
the fact that patients with extensive missing data may be more likely to be from 
populations at high risk for TB. Additionally, the record linkage algorithm is less 
sensitive to non-English names,[184] and therefore TB incidence in foreign populations 
may have been underestimated. 
One limitation was missing CD4 count data for approximately a third of patients, 
who were therefore excluded from the risk factor analysis. This was partly due to 
difficulties linking data because of missing or incomplete PII in the CD4 database, and 
partly because some large hospitals do not supply CD4 count data to HARS. However, 




there was no evidence that patients with missing CD4 count data were systematically 
different to the analysis cohort. As the sample size remained very large, it was decided 
to conduct a complete-case analysis rather than using multiple imputation. The 
decision was also influenced by the complexity of the dataset as a result of using time-
updated data with intervals of varying lengths for CD4 count and ART initiation, and the 
fact that patients with missing data for one variable were also more likely to be missing 
data on other variables (leaving few complete variables from which to impute). There 
was also no evidence that patients missing data were systematically different to those 
with complete case data; although patients with missing data were less likely to be 
linked to a TB case, this was probably because they were also missing PII (used in the 
record linkage process) rather than because they were less likely to develop TB 
disease. As a result, it is likely that excluding records with incomplete data biased the 
results towards the null, and that the true effect sizes are larger than estimated. As this 
analysis used routinely collected surveillance data, all diagnoses were made according 
to standard definitions, which should have reduced measurement error and 
misclassification. TB diagnoses later found not to be MTBC were de-notified and not 
included in the analysis. 
Composite variables were created for sex/route of HIV infection, and for 
ethnicity/country of birth, to avoid confounding as there are known associations 
between these variables; e.g. MSM cannot be women and white PLHIV are less likely 
to be born abroad.  However, the results presented may have been confounded by 
other factors. The increased risk of TB among people who acquired HIV through 
injecting drug use may have been confounded by other social risk factors which 
increase susceptibility or exposure to TB, such as homelessness and imprisonment. 
Unfortunately no data were available on these risk factors, or on other sources of 
exposure to TB such as household contacts with TB, occupational exposure, or travel 
to areas where TB is endemic.  




There are causal relationships between being on ART, CD4 count, and viral 
load (Figure 4.2). Whilst there was data on all CD4 counts for the majority of patients, 
data on viral load and whether or not a patient is on ART were only reported annually, 
from their most recent clinic visit; which is not necessarily representative of the whole 
year. As there was higher frequency data for CD4 count, viral load was excluded from 
the model, and a binary variable for whether individuals had ever started ART was 
used in order to utilise the time-updated CD4 count data without creating causal loops 
which could not be adequately reflected in the data. This enabled a more accurate 
assessment of the risk of TB at different CD4 counts; however it also meant that the 
effect of viral load on the risk of developing TB could not be assessed in the 
multivariable model. Data were available on ART discontinuation, but were of poor 
quality and could not be included in the model. Consequently, the association between 
starting ART and lower TB incidence may have been underestimated because it was 
assumed that all individuals remained on treatment for the duration of the study. 
Whether the patient was on ART at their last clinic visit during the study period was 
examined, however these figures are also likely to underestimate ART discontinuation 
as they cannot account for patients who have stopped and then restarted ART, or 
PLHIV who have dropped out of care completely. 
Individuals entered the study cohort 92 days after HIV diagnosis or first 
presentation to UK health services; therefore TB incidence in people diagnosed abroad 
who were at risk prior to entering the UK may have been underestimated, as TB cases 
diagnosed during the initial period following HIV diagnosis when TB incidence is 
highest would have been missed. A recent study of PLHIV had 18% loss to follow-up 
over 4 years, and 14% of TB cases diagnosed more than 91 days after HIV diagnosis 
were in these patients.[196] As TB and HIV are sometimes treated (and usually 
reported) separately in the UK, and notification of TB cases is mandatory, dropping out 
of HIV care does not prevent notification of a TB diagnosis. This study therefore used 
passive censoring, continuing follow-up until 31/12/2014 rather than the date last seen 




for HIV care. Consequently, migration out of the UK may have caused an 
underestimation of TB incidence. 
A possible limitation of the Poisson regression model was censoring due to 
competing risks, specifically deaths from non-TB causes. However, very few patients 
died (3%) and the median time to death was 3.4 years, substantially longer than the 
median time to TB diagnosis (1.8 years). Therefore, any impact of such censoring is 
likely to be minimal. 
There may have been some misclassification of the ‘route of HIV diagnosis’ 
variable. As this variable was assigned at HIV diagnosis; the PWID category does not 
necessarily reflect current injecting drug use at the time of TB diagnosis. Phylogenetic 
analyses have estimated 1-11% of male heterosexual PLHIV may be misclassified 
MSM, and this may be as high as 21% for black African men.[201] Consequently, the 
TB risk in black African MSM may have been underestimated due to some MSM not 
disclosing their behaviour. However, this misclassification is unlikely to affect which 
interventions are most effective; MSM who have been misclassified as heterosexual 
are likely to be also missed by HIV interventions which target MSM, and the low overall 
risk of TB for MSM means that targeting TB interventions to this population is unlikely 
to be cost-effective. Increased screening for both HIV and TB among black African 
communities may be more likely to be effective. 
4.4.3 Implications of the research 
PWID represented less than 2% of PLHIV in this cohort, but accounted for 3% 
of TB cases and more than 4% of cases diagnosed more than 91 days after HIV 
diagnosis. TB incidence in PWID in this study (876/100,000 PY in men and 
605/100,000 in women) was higher than the 420/100,000 reported in a cohort of 
German PLHIV,[118] possibly because that cohort utilised active rather than passive 
follow-up and excluded patients who did not present to care for 6 months or more, who 




may be more likely to develop TB disease than patients who remain engaged with 
care. 
PWID are typically diagnosed with HIV late,[202] have slower rates of linkage to 
care and lower rates of viral suppression,[10] all of which may contribute to increased 
risk of TB. Rates of ART initiation and the time from the last clinic visit to the end of the 
study were comparable for MSM, heterosexuals and PWID; and PWID did not have 
higher rates of ART discontinuation at their last clinic visit prior to study end (Table 
4.5). Consequently, it seems high rates of TB among PWID were caused by difficulties 
in linking to care and not lack of engagement with health services once linked. 
Increasing HIV testing for PWID and supporting them to link to HIV care could help to 
diagnose HIV infection sooner and reduce the loss of immune function, and thereby 
reduce the incidence of TB.  
Many PWID have other co-morbidities which may cause immunosuppression, 
make HIV care more challenging, or be associated with increased risk of TB.[203] 
Additionally there are high rates of alcoholism and homelessness, and living in hostels 
is common.[204] These factors, in addition to injecting drugs in shared social settings, 
may drive close mixing of people with similar risk factors for TB disease resulting in TB 
transmission. High rates of smoking may also have impacts on both local lung 
immunity and TB transmission. Further studies are needed to explore the impact of 
these factors and to design effective interventions.  
The majority of PWID were white (51%) and born in the UK or low TB incidence 
countries (72%). It is therefore likely that most TB in this group was acquired in the UK, 
meaning these cases may be preventable by diagnosing HIV sooner and ensuring 
prompt ART initiation. More could also be done to diagnose TB cases sooner; the 
impact of active case finding in PLHIV should be evaluated. In contrast, people who 
acquired HIV through heterosexual sex were typically of black African ethnicity (61%) 
and born in high TB incidence countries (69%), both populations which also have high 




rates of TB among HIV-negative people. It is likely that their TB infections were 
acquired abroad, limiting the ability to prevent TB infection if they present with clinical 
TB at the time of HIV diagnosis.[205] As more than 60% of people who acquired HIV 
heterosexually were diagnosed with TB simultaneously or prior to HIV diagnosis, 
greater efforts to diagnose these HIV infections and initiate ART would reduce TB in 
this population. A greater focus on screening and treating latent TB infection (LTBI) 
could also prevent these cases.[206] There is little data available on the prevalence of 
LTBI and the use of preventive therapy among PLHIV in the UK. Rates of LTBI 
screening and uptake of preventive therapy vary substantially between HIV clinics, 
[137, 207] and a survey of UK HIV healthcare providers providing care to 90% of 
PLHIV in the UK found that only 54% offered LTBI screening and preventive 
therapy.[208] Health economics evaluations would be useful to determine the most 
effective screening measures for these populations. 
Over half of all TB cases (55%) were diagnosed simultaneously with HIV 
infection, and of the 39% diagnosed later, the probability of a TB diagnosis was highest 
in the first year following HIV diagnosis (Figure 4.3). This suggests that TB disease is 
largely the result of TB infection acquired prior to HIV diagnosis. This could result from 
late diagnosis of existing active TB, particularly in migrants who have recently moved to 
the UK from high-burden countries and whose TB is largely attributable to reactivation 
of remotely acquired infection.[209] Additionally, the incidence of TB among migrants 
decreases with time since entry to the UK, as new TB infection is less likely in the UK 
than their country of origin. Other factors which could explain this trend are increased 
surveillance for opportunistic infections following HIV diagnosis, or ‘unmasking-type’ 
immune reconstitution inflammatory syndrome (IRIS) as a consequence of ART.[108] 
The risk of TB in the first year after HIV diagnosis was particularly high for 
PLHIV of black African or Indian, Pakistani or Bangladeshi ethnicity, although these 
groups also saw the largest increases in cumulative risk over the remainder of the 
study period (Figure 4.5). Similarly, people who acquired HIV through heterosexual sex 




or injecting drug use both had the greatest risk of developing TB in the first year 
following HIV diagnosis, and remained more likely to develop TB throughout the study 
period (Figure 4.4). This suggests that LTBI screening of these high-risk groups 
immediately following HIV diagnosis (and preventive therapy where appropriate) could 
have a substantial impact in reducing TB incidence after HIV diagnosis. Whilst TB 
incidence was lower after the first year following HIV diagnosis (Table 4.1), 25% of all 
TB cases occurred more than one year after HIV diagnosis. There is an even greater 
opportunity to prevent these cases with LTBI treatment, regardless of whether they 
were the result of reactivation of LTBI or more recent TB infection. 
The British HIV Association (BHIVA) currently recommends IGRA testing and 
treatment of LTBI among PLHIV using criteria based on CD4 count, time on ART and 
TB incidence in country of birth.[110] In this study, the incidence of TB among PWID 
was comparable to that of black African patients born in countries with high TB 
incidence. Extending the BHIVA guidelines to include PWID, and providing additional 
screening and preventive therapy for PWID with LTBI should be considered to reduce 
TB incidence in this population. 
Recent clinical trials [16, 17] indicated a protective effect against TB when HIV-
positive individuals started ART as soon as possible rather than deferring until a lower 
CD4 threshold is reached. Our findings were consistent with this; patients who had 
initiated ART had greatly reduced rates of TB compared to those who had not (Table 
4.3). BHIVA guidelines have recently been updated and now recommend all PLHIV 
initiate ART, regardless of CD4 count.[210] If implemented, these guidelines could lead 
to a significant reduction in TB cases in PLHIV, as many of the TB cases in ART-naïve 
patients may have been preventable with earlier initiation of ART. Whilst the majority of 
TB cases had not initiated ART at the time of their TB diagnosis (Table 4.1), some TB 
cases did still occur in patients on ART. These may have been existing disease that 
was previously undiagnosed, due to the limited sensitivity of some diagnostic tests for 




LTBI in immunocompromised individuals. Other patients may have had subclinical 
disease when initiating ART, resulting in unmasking IRIS. 
The risk of developing TB was greatest in the first year after HIV diagnosis for 
patients in all CD4 strata, but there was a substantial increase in the risk of TB among 
PLHIV who were diagnosed with HIV late (defined as a CD4 count below 350 cells/µl at 
diagnosis). This risk remained elevated throughout the study period (Figure 4.6) and 
was also associated with lower CD4 count; the cumulative risk was substantially higher 
for patients with CD4 count below 200 cells/µl at diagnosis than for patients with a CD4 
count of 200-349. The cumulative risk appeared higher for patients with a CD4 count of 
100-199 at diagnosis than for PLHIV diagnosed with a CD4 count below 100 cells/µl, 
but this is likely because there were a greater proportion of simultaneous HIV and TB 
diagnoses among PLHIV diagnosed with CD4 <100 cells/µl than for patients with CD4 
of 100-199 at diagnosis (Table 4.1). Patients with very low CD4 counts at HIV 
diagnosis (<100 cells/µl) may also have initiated ART more rapidly, thereby reducing 
their ongoing risk of TB.  
Time-updated CD4 count and ART initiation status interacted within the 
multivariable model. This could be a result of differing CD4 trajectories for patients who 
have or have not initiated ART; CD4 counts of patients who are on ART should be on 
an upwards trajectory, whereas CD4 count is likely to be declining for patients who are 
not on ART. Higher rate ratios for TB at low CD4 count in people on ART could also be 
attributable to late ART start (i.e. long periods of low CD4 count prior to initiating ART 
and then little time on ART prior to TB diagnosis), or due to ART discontinuation. The 
SMART trial demonstrated an association between stopping ART and increased risk of 
opportunistic disease and death.[211] The post-hoc analysis of patients who had 
started ART demonstrated that patients who went on to develop TB were more likely to 
have discontinued ART at their last study visit than individuals who remained TB-free 
(Table 4.5). This suggests ART discontinuation leaves patients at risk of new TB 
disease. Improving understanding of why PLHIV stop taking ART, and developing 




interventions to support PLHIV to remain on ART long-term could also help reduce TB 
incidence among PLHIV.  
4.4.4 Conclusions 
In England, Wales and Northern Ireland, PLHIV who acquired HIV by injecting 
drugs had higher rates of TB after their HIV diagnosis than MSM, comparable to black 
Africans born in countries with high TB incidence. High rates of TB in PWID are likely to 
result from transmission within the UK. ART is highly protective against TB, but the 
majority of TB diagnoses were in people who have never started ART. ART 
discontinuation rates were much higher in people who subsequently developed TB 
than those who did not. Earlier diagnosis of HIV, quicker initiation of ART (as per the 
recently updated BHIVA guidelines), and improving retention in care and ART 
continuation should decrease incident TB in PLHIV. 
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5 Trends in factors associated with HIV co-infection 
among tuberculosis patients 
5.1 Introduction 
5.1.1 HIV co-infection of tuberculosis patients in the UK 
The number of TB cases reported in England and Wales increased from 2000, 
peaking at 8,280 cases in 2011 (15.6/100,000 population), but then declined by a third 
to 5,758 in 2015.[52] HIV co-infection contributed substantially to the rise in TB from 
1999 to 2003; 31% of the increase in TB was in people with HIV co-infection and by 
2003 the prevalence of HIV co-infection was 8.3%.[123] Whilst the number of PLHIV in 
the UK increased by 10% to over 100,000 in 2015,[10] HIV co-infection among TB 
cases decreased to 3.2% (197/6,209) by 2014.[52] However, both the proportion and 
number of co-infected individuals remain among the highest in western Europe,[52, 
116] and trends in TB-HIV epidemiology and risk factors for co-infection have not been 
recently described. 
5.1.2 Known risk factors for HIV co-infection 
A previous study of HIV among TB cases in England and Wales reported higher 
prevalence of HIV co-infection among women than men (6.1% vs. 5.2%), those aged 
30-39 years at TB diagnosis (12.9%, vs. 5.6% for those aged 20-29, 8.1% for those 
aged 40-49, and an even lower prevalence outside of these age brackets).[123] 
Patients of black African ethnicity or who were born in Africa also had high rates of co-
infection (20.5% and 19.8% respectively); overall the prevalence of HIV among TB 
patients born outside of the UK was 7.3%, compared to 1.5% in UK-born patients. The 
HIV prevalence was lower in TB patients who had been in the UK for more than five 
years (2.9%) than those who had arrived within the last five years (10.7%).[123] 
However, this study did not present any adjusted estimates of the risk or consider 
confounding or overlap in risk factors. Another study reported that HIV prevalence was 
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higher among healthcare workers with TB than other TB patients, particularly for 
nurses, women, and patients born in sub-Saharan Africa.[212] 
A comparable study using surveillance data from the Netherlands reported that 
HIV co-infection was lower among women than men (2.6% vs. 5.1%, multivariable OR 
0.62 [0.50-0.77]).[213] In this study HIV prevalence among TB patients from Africa  
(4.9%) was not significantly higher in a multivariable analysis than in patients born in 
the Netherlands (3.8%), possibly because African TB patients in the Netherlands tend 
to be from north Africa,[214] where TB is less prevalent than sub-Saharan Africa. 
However, HIV prevalence was higher among patients born outside the Netherlands in 
western Europe, north America, Israel or Australia (23.1% co-infected, multivariable 
OR 3.05 [2.06-4.50]) but lower among patients from Asia (1.2%, multivariable OR 0.22 
[0.15-0.34]) or eastern Europe (1.7%, multivariable OR 0.43 [0.20-0.94]).[213] There 
was no significant association between HIV and site of TB disease. 
A Europe-wide study of data reported to ECDC up until the end of 2014 
reported a higher risk of HIV co-infection for men than women (4.2% vs. 4.3%, 
multivariable OR 1.25 [1.07-1.46]).[117] Compared to TB patients from within the 
EU/EEA (4.2% co-infected), the risk of HIV was higher for patients from other 
European countries (8.5%, multivariable OR 1.91 [1.15-3.17]) and Africa (17.7%, OR 
3.28 [2.35-4.57]), but lower for patients from other regions (not including the Americas, 
3.7%, multivariable OR 0.64 [0.42-0.98]). Patients with only extra-pulmonary disease 
were more likely to have HIV than patients with pulmonary disease (7.3% vs. 4.5%, 
multivariable OR 1.81 [1.50-2.19]), although extra-pulmonary disease varies in severity 
by site, and this study did not stratify by site.[117] In contrast, a prior UK study reported 
no association between extra-pulmonary TB and HIV co-infection compared with 
pulmonary TB alone, but found that HIV co-infection was a risk factor for miliary TB 
(OR 4.5 [3.4-5.8]),[215] and a 2013 meta-analysis reported a pooled OR of 1.3 (95% CI 
1.05-1.6) associated with extra-pulmonary TB for PLHIV compared to HIV-negative 
people.[216] 
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Social risk factors such as drug misuse, homelessness and imprisonment may 
contribute to TB-HIV co-infection. HIV acquisition by injecting drug use is a known risk 
factor for developing TB;[151] however the interactions between different social risk 
factors and HIV co-infection have not been investigated in the UK. A study from the 
Netherlands also found substantially higher HIV prevalence among TB patients who 
were illegal residents (9.1%, multivariable OR 1.67 [1.08-2.40]), misused drugs (29.2%, 
OR 5.13 [3.81-6.89]) or were homeless (20.1%, OR 1.55 [1.01-2.40).[213] The 
proportion of TB patients in England with social risk factors rose from 9.8% in 2010 to 
12% in 2015, although the numbers remained relatively constant.[52] Tackling TB in 
under-served populations is one of the key areas for action in the 2015-2020 
Collaborative tuberculosis strategy for England.[217]  
5.1.3 Summary and objectives 
Understanding the factors associated with TB-HIV co-infection allows us to 
target screening for both HIV and LTBI to patients most at risk of developing TB 
disease. Testing for and treating LTBI has been recommended by both BHIVA and the 
National Institute for Health and Care Excellence (NICE) since 2011 for high-risk 
PLHIV, with criteria based on TB incidence in country of birth, time on ART and/or CD4 
count.[110, 218] Although screening and treating LTBI is cost-effective,[219] a recent 
audit found that very few eligible patients were being screened.[207] The aims of this 
chapter were to describe temporal trends in HIV co-infection of TB patients, examine 
changes in the demographics of co-infected patients and the timing of TB and HIV 
diagnoses relative to each other, and to identify factors associated with co-infection, 
focussing on social risk factors (drug and alcohol misuse, homelessness and 
imprisonment). A secondary aim was to assess whether the current (2011) BHIVA 
guidelines on testing for HIV and LTBI remain appropriate. 




5.2.1 Study population 
This was a retrospective study of all adult (≥15 years) TB patients in England, 
Wales and Northern Ireland, notified to PHE’s Enhanced TB Surveillance system (ETS) 
from 1st January 2000 until 31st December 2014. 
5.2.2 Outcome: HIV status 
Data from ETS was linked to HARS as described in Chapter 3, using a 
probabilistic matching algorithm (adapted from [184]) with supplementary deterministic 
matching to accept/reject borderline matches. Patients were considered to be co-
infected with HIV if they were diagnosed with HIV or seen for HIV care between 1st 
January 2000 and 31st December 2014. TB cases notified to HARS as an AIDS-
defining illness, which were not linked to a case notification in ETS, could not be 
included in this analysis. As in section 4.2.2, diagnoses were classed as ‘simultaneous’ 
if TB and HIV were diagnosed within 91 days of each other. 
5.2.3 Exposure variables 
Sociodemographic (sex, ethnicity, HIV prevalence in country of birth, IMD 
decile, and history of drug misuse, alcohol misuse, homelessness or imprisonment) 
and clinical (site[s] of disease, year of TB notification, age at TB notification) exposure 
variables were included. Data on social risk factors (IMD decile, current alcohol misuse, 
current or previous drug misuse, imprisonment or homelessness) were only available 
from 2010 onwards. As the prevalence of social risk factors was low, cases reported in 
2010 or later with missing data for these variables were considered to not have these 
risk factors. Drug misuse was defined as problem drug use of illicit injecting drug use or 
long duration/regular use of illicit opiates, cocaine, and/or amphetamines, and/or 
daily/almost daily use of cannabis (or synthetic cannabinoids). 
Composite variables were created, combining ethnicity and country of birth due 
to known interactions.[52] As a proxy for HIV exposure, countries of birth outside the 
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UK were grouped by HIV prevalence; ‘high prevalence’ was defined as >1% in the 
adult population living with HIV, as per WHO estimates.[74] Site of TB disease was 
categorised into three discrete groups; miliary or meningeal TB (with or without 
pulmonary disease), pulmonary disease with or without other extra-pulmonary disease 
(excluding miliary or meningeal TB), and other extra-pulmonary disease only. Miliary 
and meningeal TB were categorised separately as severe forms of disseminated TB 
may be more likely to develop for patients with HIV co-infection.[215] 
5.2.4 Statistical Analysis 
5.2.4.1 Descriptive analysis 
Data were analysed in Stata version 13.1. Descriptive analyses of the cohort 
were undertaken, examining the proportion of TB cases co-infected with HIV for the 
whole population and stratified by each exposure variable. Trends in the proportion of 
TB cases co-infected with HIV over the study period were examined for key variables 
(age, sex and ethnicity). The proportion of TB cases with different combinations of 
social risk factors, and the proportion of each of these combinations that were co-
infected with HIV, were calculated. Among co-infected patients, trends in the order of 
TB and HIV diagnoses were examined. 
5.2.4.2 Factors associated with HIV co-infection 
To investigate factors associated with HIV co-infection, the proportion of cases 
co-infected with HIV stratified by exposure variable was calculated, and odds ratios 
were estimated using univariable logistic regression models. Potential confounders 
were prospectively identified,[199] and a causal framework was built (Figure 5.1). As 
there was no single ‘main’ exposure being investigated, there were no confounders in 
the traditional sense, and therefore the variables included in the multivariable models 
were informed by the causal framework defined a priori. Two multivariable models were 
built, a ‘whole-cohort’ model including all cases, and a model including only cases from 
2010-2014 so that data on social risk factors could be included. Year of TB notification, 
age at TB notification, sex, ethnicity and country of birth and site of TB disease were 
5. Trends in factors associated with HIV co-infection among tuberculosis patients 
 
151 
included in both models; social risk factors were only included in the ‘2010-2014’ 
model. Linearity (of age group, year and IMD decile) and statistical interactions 
between social risk factors (drug misuse, alcohol misuse, homelessness and 
imprisonment) were assessed using likelihood-ratio tests. Variables were treated as 
categorical if P<0.05, and statistical interactions were considered significant at P<0.05. 
Patients missing data on one or more variables were excluded. To assess the impact 
of missing data, the distributions of all demographic factors for cases with missing vs. 
complete data were compared. 
Figure 5.1: Conceptual framework of potential factors associated with HIV co-infection 
among TB cases. 
 
IMD: index of multiple deprivation, TB: tuberculosis 
 
5.2.4.3 Sensitivity analyses  
To examine the impact of a different threshold for ‘simultaneous’ diagnoses, a 
sensitivity analysis was conducted using a 30 day threshold rather than 91 days for 
examining trends in timing of diagnoses. To evaluate the impact of the matching 
algorithm used on the results of this study, planned sensitivity analyses investigated 
the impact of excluding weaker matches between ETS and HARS from the two logistic 
regression models. 




5.3.1 Descriptive epidemiology and trends in HIV co-infection 
106,829 cases of TB in adults (≥15 years) were reported to ETS in England, 
Wales and Northern Ireland for the period 2000-2014. Overall, 5,792 people (5.4%) 
were identified as being co-infected with HIV through record linkage. The proportion of 
TB patients co-infected with HIV peaked in 2004 (543/6,782, 8.0%, Table 5.1), 
although the absolute number was higher in 2005 (555/7,489). This decreased to 
205/6,461 (3.2%) in 2014 (Figure 5.2). 
Figure 5.2: The number and proportion of notified TB cases with and without HIV in 
England, Wales and Northern Ireland by year of TB diagnosis. 
 
  




Table 5.1: The number and percentage of notified TB cases with and without HIV co-
infection in England, Wales and Northern Ireland, 2000-2014. 
  Number of TB cases (whole cohort) 
  HIV-negative HIV-positive (%) Total 
Total 101,037 5,792 (5.4%) 106,829 
Year    
2000 5,701 224 (3.8%) 5,925 
2001 5,697 279 (4.7%) 5,976 
2002 6,057 440 (6.8%) 6,497 
2003 6,003 511 (7.8%) 6,514 
2004 6,239 543 (8.0%) 6,782 
2005 6,934 555 (7.4%) 7,489 
2006 7,027 527 (7.0%) 7,554 
2007 6,926 454 (6.2%) 7,380 
2008 7,102 473 (6.2%) 7,575 
2009 7,582 393 (4.9%) 7,975 
2010 7,168 364 (4.8%) 7,532 
2011 7,769 316 (3.9%) 8,085 
2012 7,631 277 (3.5%) 7,908 
2013 6,945 231 (3.2%) 7,176 
2014 6,256 205 (3.2%) 6,461 
Sex 
   
Female 43,761 2,935 (6.3%) 46,696 
Male 57,085 2,846 (4.7%) 59,931 
Missing 191 11 (5.4%) 202 
Age group (years) 
   
15-24 16,628 320 (1.9%) 16,948 
25-34 28,658 1,969 (6.4%) 30,627 
35-44 17,521 2,281 (11.5%) 19,802 
45-54 12,347 872 (6.6%) 13,219 
55-64 9,283 255 (2.7%) 9,538 
65+ 16,576 94 (0.6%) 16,670 
Missing 24 1 (4.0%) 25 
Ethnicity/Country of birth 
   
White, low HIV prevalence 18,470 477 (2.5%) 18,947 
Black African, low HIV prevalence 7,672 249 (3.1%) 7,921 
Indian sub-continent, low HIV 
prevalence 
38,745 179 (0.5%) 38,924 
Other/unknown, low HIV prevalence 8,692 197 (2.2%) 8,889 
White, high HIV prevalence 232 20 (7.9%) 252 
Black African, high HIV prevalence 7,419 3,537 (32.3%) 10,956 
Indian sub-continent, high HIV 
prevalence 
1,325 29 (2.1%) 1,354 
Other/unknown, high HIV prevalence 1,673 254 (13.2%) 1,927 
Country of birth unknown 16,809 850 (4.8%) 17,659 
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  Number of TB cases (whole cohort) 
  HIV-negative HIV-positive (%) Total 
Site of TB disease 
   
Pulmonary, +/- extra-pulmonary* 52,770 3,227 (5.8%) 55,997 
Miliary/meningeal TB 3,747 780 (17.2%) 4,527 
Extra-pulmonary only 44,218 1,761 (3.8%) 45,979 
Missing 302 24 (7.4%) 326 
Homelessness† 
   
No 32,129 1,136 (3.4%) 33,265 
Yes 947 92 (8.9%) 1,039 
Missing 2,693 165 (5.8%) 2,858 
Imprisonment†    
No 31,092 1,102 (3.4%) 32,194 
Yes 958 61 (6.0%) 1,019 
Missing 3,719 230 (5.8%) 3,949 
Drug misuse† 
   
No 31,823 1,125 (3.4%) 32,948 
Yes 980 86 (8.1%) 1,066 
Missing 2,966 182 (5.8%) 3,148 
Alcohol misuse† 
   
No 31,297 1,098 (3.4%) 32,395 
Yes 1,134 55 (4.6%) 1,189 
Missing 3,338 240 (6.7%) 3,578 
IMD decile† 
   
1 7,547 350 (4.4%) 7,897 
2 6,836 287 (4.0%) 7,123 
3 5,531 218 (3.8%) 5,749 
4 4,207 134 (3.1%) 4,341 
5 3,050 112 (3.5%) 3,162 
6 2,294 89 (3.7%) 2,383 
7 1,669 61 (3.5%) 1,730 
8 1,408 48 (3.3%) 1,456 
9 1,228 45 (3.5%) 1,273 
10 994 19 (1.9%) 1,013 
Missing 1,005 30 (2.9%) 1,035 
* Excluding miliary and meningeal tuberculosis. †2010-2014 only. IMD: index of multiple 
deprivation, TB: tuberculosis. 
 
5.3.1.1 Timing of tuberculosis and HIV diagnoses 
Overall, 2,787/5,792 (49%) co-infected people were diagnosed with TB and HIV 
simultaneously, whilst 549 (9%) were diagnosed with TB before and 2,456 (42%) after 
HIV diagnosis. The relationship between TB and HIV diagnosis changed over time 
(Figure 5.3).  The absolute number of TB cases in people with known HIV rose from 
75/224 (33.5%) in 2000 to 210/454 (46.2%) in 2007, then fell to 117/205 (57.1%) by 
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2014, but increased as a proportion of all TB-HIV cases from 2000 to 2014 (Table 5.2), 
whilst the number of cases diagnosed with TB first fell from 22.8% to 4.4%. The 
number of simultaneous diagnoses peaked at 54.9% in 2004, but has since decreased 
to 38.5%. There were corresponding declines in the proportion diagnosed 
simultaneously with TB and HIV from 298/543 (55%) in 2004 to 79/205 (39%) in 2014 
and those first diagnosed with TB (51/224 (23%) in 2000 to 9/205 (4%) in 2014). The 
trend in decreasing proportions of simultaneous diagnoses and increasing proportions 
of TB being diagnosed after HIV was consistent in a sensitivity analysis using a 30 day 
threshold rather than 91 days. 
Figure 5.3: The first diagnosis for TB-HIV co-infected patients diagnosed with TB from 
2000 to 2014. 
 
TB: tuberculosis. Simultaneous diagnoses were defined as TB and HIV diagnosed within 
91 days of each other. 
  




Table 5.2: The relationship between HIV and TB diagnoses in patients diagnosed with HIV 
and TB between 2000 and 2014. 
Case report 
year 
Simultaneous  diagnoses HIV diagnosed first 
TB diagnosed 
first Total 
n % n % n % 
2000 98 43.8 75 33.5 51 22.8 224 
2001 138 49.5 96 34.4 45 16.1 279 
2002 241 54.8 135 30.7 64 14.5 440 
2003 271 53.0 175 34.2 65 12.7 511 
2004 298 54.9 183 33.7 62 11.4 543 
2005 296 53.3 209 37.7 50 9.0 555 
2006 274 52.0 209 39.7 44 8.3 527 
2007 211 46.5 210 46.3 33 7.3 454 
2008 227 48.0 204 43.1 42 8.9 473 
2009 179 45.5 194 49.4 20 5.1 393 
2010 148 40.7 196 53.8 20 5.5 364 
2011 137 43.4 163 51.6 16 5.1 316 
2012 111 40.1 151 54.5 15 5.4 277 
2013 79 34.2 139 60.2 13 5.6 231 
2014 79 38.5 117 57.1 9 4.4 205 
Total 2,787   2,456   549   5,792 
n: number, TB: tuberculosis. Simultaneous diagnosis was defined as TB and HIV 
diagnosed within 91 days of each other. 
 
5.3.1.2 Trends in the demographics of co-infected patients 
During the study period, HIV co-infection was higher in women (2,935/46,696, 
6.3%) than men (2,846/59,931, 4.7%); however the decline was larger in women 
(Figure 5.4). There were also declines in HIV co-infection in TB patients aged 15-44, 
but not in patients aged 45 or older (Figure 5.5). 
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Figure 5.4: The percentage of notified TB cases co-infected with HIV by sex in England, 
Wales and Northern Ireland, 2000 to 2014. 
 
Figure 5.5: The percentage of notified TB cases co-infected with HIV by age in England, 
Wales and Northern Ireland, 2000-2014. 
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The percentage of people with HIV co-infection was highest in TB patients of 
black African ethnicity born in countries with a high HIV prevalence (3,537/10,956, 
32.3%), compared to 477/18,947 (2.5%) in the white UK-born population. Temporal 
changes in the ethnicity of TB patients (Figure 5.6) correlate with overall trends in the 
number and percentage of people with TB and HIV; TB in people of black African 
ethnicity peaked in 2006 and has since been decreasing, whereas the number of Asian 
TB patients was increasing until 2011. 
Figure 5.6: The number (a) and percentage (b) of notified TB cases co-infected with HIV 
by ethnicity in England, Wales and Northern Ireland, 2000 to 2014. 
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5.3.2 Factors associated with HIV co-infection 
5.3.2.1 Univariable results 
In univariable analyses, the odds ratio (OR) for HIV co-infection was higher for 
the years 2001-2010 compared to 2000 (peak OR 2.22 [1.89-2.60]) in 2004) (Table 
5.3). The ORs for 2011-2014 were not significantly different to 2000. Men were less 
likely to be co-infected with HIV than women (OR 0.74 [0.70-0.78]). Compared to TB 
patients aged 25-34 years, HIV co-infection was more likely for patients aged 35-44 
(OR 1.89 [1.78-2.02]) but less likely for patients aged 15-24 (OR 0.28 [0.25-0.32]), 55-
64 (OR 0.40 [0.35-0.46]) or over 65 years (OR 0.08 [0.07-0.10]). 
Compared to TB patients of white ethnicity born in countries with low HIV 
prevalence, the odds of HIV were highest for patients of black African ethnicity born in 
countries with high HIV prevalence (OR 18.46 [16.71-20.39]). The odds of HIV were 
also higher among black African patients born in countries with low HIV prevalence 
(OR 1.26 [1.08-1.47]) and patients born in countries with high HIV prevalence who 
were of white (OR 3.34 [2.10-5.32]) or ‘other’/unknown ethnicity (OR 5.88 [5.01-6.90]); 
but substantially lower among patients from countries with low HIV prevalence who 
were of Indian/Pakistani/Bangladeshi origin (OR 0.18 [0.15-0.21]). 
HIV co-infection was greater among TB patients with miliary or meningeal TB 
compared to patients with pulmonary disease (with or without other extra-pulmonary 
disease) (OR 3.40 [3.13-3.71]) but lower for patients with other extra-pulmonary 
disease only (OR 0.65 [0.61-0.69]). 
  




Table 5.3: Results from univariable and two multivariable logistic regression models of factors associated with HIV co-infection in notified TB cases in 
England, Wales and Northern Ireland, for the periods 2000-2014 and 2010-2014. 
  Univariable results (whole cohort) Multivariable results (whole cohort) 
Multivariable results (2010-
2014) 
  OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
Year 







2001 1.25 (1.04-1.49) 1.22 (1.00-1.48) - 
 
2002 1.85 (1.57-2.18) 1.45 (1.20-1.74) - 
 
2003 2.17 (1.84-2.55) 1.51 (1.26-1.80) - 
 
2004 2.22 (1.89-2.60) 1.56 (1.31-1.87) - 
 
2005 2.04 (1.74-2.39) 1.40 (1.17-1.67) - 
 
2006 1.91 (1.63-2.24) 1.36 (1.14-1.62) - 
 
2007 1.67 (1.42-1.97) 1.22 (1.01-1.46) - 
 
2008 1.70 (1.44-1.99) 1.25 (1.04-1.50) - 
 
2009 1.32 (1.12-1.56) 1.04 (0.86-1.25) - 
 
2010 1.29 (1.09-1.53) 1.06 (0.87-1.28) 1.00 
<0.001 
2011 1.04 (0.87-1.23) 0.83 (0.68-1.01) 0.76 (0.61-0.93) 
2012 0.92 (0.77-1.11) 0.82 (0.67-1.00) 0.81 (0.65-0.99) 
2013 0.85 (0.70-1.02) 0.76 (0.62-0.94) 0.66 (0.53-0.83) 
2014 0.83 (0.69-1.01) 0.72 (0.58-0.89) 0.68 (0.54-0.85) 
Sex 







Male 0.74 (0.70-0.78) 0.84 (0.79-0.90) 0.85 (0.74-0.98) 
Age group (years) 
      






25-34 1.00 1.00 1.00 
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  Univariable results (whole cohort) Multivariable results (whole cohort) 
Multivariable results (2010-
2014) 
  OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
35-44 1.89 (1.78-2.02) 1.97 (1.83-2.13) 2.16 (1.79-2.59) 
45-54 1.03 (0.95-1.12) 1.33 (1.21-1.47) 1.97 (1.60-2.44) 
55-64 0.40 (0.35-0.46) 0.62 (0.54-0.72) 1.35 (1.02-1.78) 
65+ 0.08 (0.07-0.10) 0.16 (0.13-0.19) 0.31 (0.20-0.49) 
Ethnicity/Country of birth 
      






Black African, low HIV prevalence 1.26 (1.08-1.47) 1.07 (0.91-1.26) 1.07 (0.74-1.55) 
Indian sub-continent, low HIV 
prevalence 
0.18 (0.15-0.21) 0.16 (0.14-0.20) 0.20 (0.14-0.28) 
Other/unknown, low HIV prevalence 0.88 (0.74-1.04) 0.73 (0.62-0.87) 0.67 (0.46-0.96) 
White, high HIV prevalence 3.34 (2.10-5.32) 2.43 (1.51-3.91) 3.85 (1.45-10.23) 
Black African, high HIV prevalence 18.46 (16.71-20.39) 13.02 (11.69-14.50) 10.39 (8.13-13.29) 
Indian sub-continent, high HIV 
prevalence 
0.85 (0.58-1.24) 0.69 (0.47-1.01) 0.51 (0.20-1.26) 
Other/unknown, high HIV prevalence 5.88 (5.01-6.90) 4.56 (3.85-5.39) 4.07 (2.79-5.94) 
Country of birth unknown 1.96 (1.75-2.19) 1.62 (1.44-1.82) 1.51 (1.14-2.00) 
Site of TB disease 
      





<0.001 Miliary/meningeal TB 3.40 (3.13-3.71) 3.30 (2.96-3.68) 3.81 (3.02-4.80) 
Extra-pulmonary only 0.65 (0.61-0.69) 0.70 (0.65-0.75) 0.73 (0.63-0.86) 
Homelessness 







Yes 2.75 (2.20-3.43) - 
 
1.22 (0.87-1.72) 
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  Univariable results (whole cohort) Multivariable results (whole cohort) 
Multivariable results (2010-
2014) 
  OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
Imprisonment 


















Yes 2.48 (1.98-3.12) - 
 
2.70 (1.90-3.84) 
       
Alcohol misuse 











      
(for each unit increase) 0.95 (0.93-0.97) <0.001 -   0.99 (0.96-1.02) 0.47 
* Excluding miliary/meningeal tuberculosis. CI: confidence interval, IMD: index of multiple deprivation, OR: odds ratio, TB: tuberculosis. The whole-
cohort model excluded 543 (0.5%) TB cases missing data on sex (n=202), age (n=25) and/or site of TB disease (n=326), and was adjusted for year of TB 
notification, age, sex, ethnicity and HIV prevalence in country of birth and site of TB disease. The 2010-2014 model excluded 7,187 (19%) TB cases 
missing data on sex (n=60), site of TB disease (n=137), homelessness (n=2,693), imprisonment (n=3,719), drug misuse (n=2,966), alcohol misuse 
(n=3,338) and/or IMD decile (n=1,035) and adjusted for all variables in the table. 
  




5.3.2.2 Multivariable results 
Factors associated with HIV co-infection were consistent between the 
univariable and multivariable results (Table 5.3). Year and age were included as 
categorical variables (tests for linearity both P<0.001). 
The odds of HIV co-infection were higher from 2001 to 2008 (peak OR 1.56 
[95% CI 1.31-1.87] in 2004) and lower in 2013 and 2014 (OR 0.72 [0.58-0.89] in 2014) 
than in 2000. The odds of HIV co-infection were lower for men than women (OR 0.84 
[0.79-0.90]). Compared to white patients born in countries with low HIV prevalence, the 
odds of HIV co-infection were higher for people of black African ethnicity who were 
born in countries with high HIV prevalence (OR 13.02 [11.69-14.50]). 
People with miliary/meningeal TB had increased odds of HIV co-infection (OR 
3.30 [2.96-3.68]) versus people with pulmonary TB, whilst people with other extra-
pulmonary disease only were less likely to have HIV (OR 0.70 [0.65-0.75]). 
Sensitivity analyses investigating the impact of excluding weaker matches 
between ETS and HARS showed results consistent with the main models (Table 5.4). 
  




Table 5.4: Sensitivity analyses for two multivariable logistic regression models of factors 
associated with HIV co-infection in notified TB cases in England, Wales and Northern 
Ireland, in 2000-2014 and 2010-2014, which excluded co-infected patients who were 
matched with low probabilistic scores or the weakest deterministic criteria. 
  Whole cohort* 2010-2014≠ 
  OR (95% CI) P value OR (95% CI) P value 
Year 





2001 1.21 (0.98-1.49) - 
 
2002 1.49 (1.23-1.81) - 
 
2003 1.54 (1.27-1.86) - 
 
2004 1.61 (1.33-1.94) - 
 
2005 1.43 (1.19-1.72) - 
 
2006 1.42 (1.18-1.71) - 
 
2007 1.27 (1.05-1.54) - 
 
2008 1.29 (1.07-1.56) - 
 
2009 1.10 (0.90-1.33) - 
 
2010 1.12 (0.92-1.37) 1.00 0.00 
2011 0.88 (0.72-1.08) 0.75 (0.60-0.94) 
 
2012 0.86 (0.69-1.05) 0.80 (0.64-0.99) 
 
2013 0.78 (0.63-0.97) 0.62 (0.49-0.79) 
 
2014 0.76 (0.61-0.96) 0.68 (0.53-0.86) 
 
Sex 




Male 0.82 (0.77-0.88) 0.85 (0.73-0.98) 
 
Age group (years) 
    
15-24 0.27 (0.24-0.31) 
<0.001 
  
25-34 1.00 0.31 (0.22-0.45) <0.001 
35-44 1.99 (1.84-2.14) 1.00 
 
45-54 1.33 (1.20-1.47) 2.23 (1.84-2.71) 
 
55-64 0.62 (0.53-0.72) 2.06 (1.65-2.56) 
 
65+ 0.15 (0.12-0.19) 1.34 (1.00-1.80) 
 




White, UK-born 1.00 
<0.001 
  




Indian sub-continent, low 
HIV prevalence 
0.13 (0.11-0.16) 1.00 <0.001 
Other/unknown, low HIV 
prevalence 
0.64 (0.54-0.78) 1.03 (0.69-1.52) 
 
White, high HIV prevalence 2.43 (1.49-3.94) 0.17 (0.12-0.25) 
 
Black African, high HIV 
prevalence 
12.54 (11.23-14.00) 0.57 (0.39-0.85) 
 
Indian sub-continent, high 
HIV prevalence 
0.70 (0.47-1.04) 4.18 (1.57-11.14) 
 
Other/unknown, high HIV 
prevalence 
4.42 (3.72-5.26) 10.23 (7.92-13.21) 
 
Country of birth unknown 1.55 (1.37-1.75) 0.55 (0.22-1.37) 
 
     
     
     




  Whole cohort* 2010-2014≠ 
  OR (95% CI) P value OR (95% CI) P value 










Miliary/meningeal TB 3.34 (2.99-3.74) 
  







0.72 (0.61-0.85)  
 Yes - 
  
Imprisonment 



























    
(for each unit increase) -   0.98 (0.95-1.02) 0.33 
IMD: index of multiple deprivation, OR: odds ratio, TB: tuberculosis. Sensitivity analyses 
were conducted for both the whole-cohort model and the 2010-2014 model; excluding 
HIV-positive individuals with the lowest 5% of probabilistic matching scores (linking the 
TB and HIV records) and individuals whose records were matched using the three 
weakest deterministic criteria. 
* The whole-cohort sensitivity analysis excluded 506 TB cases co-infected with HIV. 
≠ The 2010-2014 sensitivity analysis excluded 45 TB cases co-infected with HIV. 
 
  




5.3.3 Social risk factors associated with HIV co-infection 
From 2010-2014, 37,162 TB cases were notified, 1,393 (3.8%) were co-infected 
with HIV. Complete data on social risk factors (drug and alcohol misuse, 
homelessness, imprisonment and IMD decile) were available for 30,105 patients 
(81%). The proportion of patients with HIV (Table 5.1) was higher in people with current 
or previous drug misuse (8.1%), homelessness (8.9%), imprisonment (6.0%) or alcohol 
misuse (4.6%) than for patients with no social risk factors (3.2%, Table 5.5).  
Table 5.5 shows the percentage of TB patients with combinations of different 
risk factors, and the proportion with HIV. There was substantial correlation between 
different social risk factors among TB patients.  HIV co-infection was highest among TB 
patients with a history of drug misuse and homelessness (11.5% co-infected). HIV 
prevalence among TB patients with no history of drug misuse, homelessness or 
imprisonment was 3.2%. 
In univariable analyses HIV co-infection was positively associated with 
homelessness (OR 2.75 [2.20-3.43]), imprisonment (OR 1.80 [1.38-2.34]), drug misuse 
(OR 2.48 [1.98-3.12]) and alcohol misuse (OR 1.38 [1.05-1.82]). The associations for 
other explanatory variables were consistent with the whole-cohort model. IMD decile 
was retained as a linear variable (test for linearity P=0.14). In a multivariable model 
adjusted for all variables shown in Table 5.1, the only social risk factor with strong 
statistical evidence for an association with HIV co-infection was drug misuse (OR 2.70 
[1.90-3.84], P<0.001). There was no evidence for statistical interactions between the 
social risk factors in the regression model (P>0.25 for all combinations). 
There was no substantial difference in the year of notification, age, or site of 
disease for patients with completed social risk factor data and patients missing data on 
one or more social risk factors. However, patients with missing social risk factor data 
were more likely to be women, and/or from the Indian subcontinent.  





Table 5.5: The number of notified TB cases with and without a history of drug misuse, homelessness or imprisonment, and the HIV 
prevalence in each of these groups in England, Wales and Northern Ireland, 2010-14. 
    Drug misuse 
Total 
    No Yes 
Total (homeless and not homeless) No Prison 30,711 (3.2%[3.1-3.4]) 506 (8.3%[5.9-10.7]) 31,217 (3.3%[3.1-3.5]) 
n (% with HIV [95% CI]) Prison 480 (4.4%[2.5-6.2]) 365 (6.8%[4.3-9.4]) 845 (5.4%[3.9-7.0]) 
 
Total 31,191 (3.3%[3.1-3.5]) 871 (7.7%[5.9-9.5]) 32,062 (3.4%[3.2-3.6]) 
Homeless No Prison 465 (7.1%[4.8-9.4]) 86 (14.0%[6.6-21.3]) 551 (8.2%[5.9-10.5]) 
n (% with HIV [95% CI]) Prison 99 (3.0%[-0.4-6.4]) 149 (10.1%[5.2-14.9]) 248 (7.3%[4.0-10.5]) 
 
Total 564 (6.4%[4.4-8.4]) 235 (11.5%[7.4-15.6]) 799 (7.9%[6.0-9.8]) 
Not homeless No Prison 30,246 (3.2%[3.0-3.4]) 420 (7.1%[4.7-9.6]) 30,666 (3.2%[3.0-3.4]) 
n (% with HIV [95% CI]) Prison 381 (4.7%[2.6-6.9]) 216 (4.6%[1.8-7.4]) 597 (4.7%[3.0-6.4]) 
  Total 30,627 (3.2%[3.0-3.4]) 636 (6.3%[4.4-8.2]) 31,263 (3.3%[3.1-3.5]) 
CI: confidence interval, n: number, TB: tuberculosis. Excluding 5,899 (16%) cases missing data on homelessness (n=2,693), imprisonment 
(n=3,719) and/or drug misuse (n=2,966). 
  




5.4.1 Summary of findings 
In England, Wales and Northern Ireland, there was a substantial decline in both 
the number and proportion of notified TB cases with HIV since 2005 and 2004 
respectively, particularly in women. Within the decline in the number of co-infected TB 
patients, the proportion who were aware of their HIV infection at the time of their TB 
diagnosis rose during the study period, whilst the proportion who were diagnosed with 
TB before their HIV diagnosis decreased. HIV co-infection was greatest for people of 
black African ethnicity born in countries with a high HIV prevalence. Drug misuse was 
the only social risk factor independently associated with HIV co-infection. 
5.4.2 Strengths and limitations of the study 
This study benefitted from fifteen years of case notifications, representing 
comprehensive coverage of TB cases in England, Wales and Northern Ireland. As with 
the results presented in Chapter 4, the large sample size meant the study had plenty of 
power to detect associations. The narrow confidence intervals and low P values 
(predominantly P<0.001, Table 5.3) for the variables associated with lower risk of HIV 
co-infection indicate that these associations are unlikely to be due to chance. 
There were some limitations. The outcome of this study was HIV co-infection; 
however HIV is a causal factor in the development of TB. The associations reported 
here are therefore not necessarily causal relationships (particularly the associations 
between site of disease and the likelihood of HIV co-infection) but should be interpreted 
as indicators of which TB patients may be more likely to also have HIV. The 
epidemiological implications of the limitations of the matching algorithm used to identify 
co-infected patients were described in section 4.4.2, but additionally there were 695 
patients reported to HARS as having TB as an AIDS-defining illness which were not 
matched to notified TB cases (Chapter 3). As notification of TB cases to PHE is 
mandatory, it is likely that these cases were not matched due to a combination of 
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missing data and common names or other PII, rather than the TB cases not having 
been reported to ETS; although it is possible that extra-pulmonary TB cases managed 
outside of respiratory departments, and TB cases treated in the private sector, are 
under-reported to ETS. Treating these patients as HIV-negative in this analysis may 
have caused underestimation of the prevalence of HIV co-infection and may have 
biased the odds ratios. Sensitivity analyses were conducted, excluding weaker 
matches between TB and HIV records to assess whether associations were different 
for cases whose HIV status was less certain. These provided consistent results, 
suggesting the matching algorithm did not affect the conclusions drawn. 
Most variables had little missing data, however 19% of patients from 2010-2014 
were missing some social risk factor data. These patients were more likely to be 
women or from the Indian sub-continent; both groups have low levels of social risk 
factors.[52] Consequently, any bias in the results is likely to be towards the null, 
underestimating the association between TB and social risk factors. The use of 
routinely collected surveillance data meant that all diagnoses of TB and HIV were 
made according to standard definitions for both infections, thereby minimising 
measurement error and misclassification. Any TB diagnoses later found not to be 
MTBC were de-notified and excluded from the analysis. 
Similarly to Chapter 4, a composite variable was created for ethnicity and 
country of birth due to known interactions between some strata of these variables; 
however, time since migration to the UK (for foreign-born patients) was not adjusted 
for. Recent migration has previously been associated with HIV co-infection in foreign-
born TB cases,[123] although the proportion of TB cases in recent migrants has 
decreased over the last decade since this association was last reported.[52] Instead, 
HIV prevalence in country of birth was adjusted for, as a proxy for exposure to HIV 
which is a causal factor for HIV co-infection. Similarly, it was not possible to adjust for 
other factors influencing exposure to HIV such as having a sexual partner with HIV, or 
time spent in countries where HIV prevalence is much higher. 
5. Trends in factors associated with HIV co-infection among tuberculosis patients 
 
170 
Data on social risk factors (drug and alcohol misuse, homelessness and 
imprisonment) were included in the multivariable model, and the prevalence of HIV co-
infection in TB patients with different combinations of these risk factors was examined. 
Whilst there was substantial overlap between risk factors (a third of cases with social 
risk factors had more than one social risk factor [52]), there was no evidence for 
statistical interactions between these variables in the multivariable model. However, the 
estimated odds ratios may have been confounded by other social risk factors for which 
data was not available; in particular, it was not possible to differentiate between 
injecting drug use (an established risk factor for HIV infection) and other drug misuse, 
and it is possible that there are differential associations between these and other social 
risk factors. Higher deciles of IMD scores were associated with HIV co-infection in 
univariable analyses but not in a multivariable model, and consequently as there was a 
high degree of missing data for this variable due to missing postcode data (from which 
it is derived) it was excluded from the final multivariable model. As IMD score is a 
measure of area-level deprivation, it is not necessarily an accurate measure of 
socioeconomic status for any individual patient, both factors which may influence the 
risk of TB. 
It was only possible to identify co-infected individuals with diagnosed HIV, and 
an estimated 13% of HIV infections were undiagnosed in 2015.[10] However, 94% of 
people diagnosed with TB in 2015 received HIV testing or were already aware of their 
HIV status,[52] and therefore a very low prevalence of undiagnosed HIV would be 
expected in this population. There may have been more undiagnosed HIV among TB 
patients prior to 2008, when BHIVA guidelines were released recommending HIV 
testing for all TB patients;[220] however, it is likely that any of these TB patients with 
undiagnosed HIV would have since presented to care and been diagnosed with HIV. 
As the matching algorithm linked all TB cases from 2000 to 2014 to all PLHIV between 
2000 and 2014, the probability that co-infected patients were not identified is low. As 
this was a retrospective, observational study of TB cases, causality between HIV co-
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infection and TB disease could not be established,[221] but it is likely that HIV infection 
precedes TB disease. 
The analysis of trends in the timings of TB and HIV diagnoses of co-infected 
patients was limited by the need to define a threshold for defining ‘simultaneous’ 
diagnosis. A 91 day threshold for defining simultaneous diagnoses was a pragmatic 
choice to account for possible delays in diagnosis and reporting, and to exclude ART-
induced unmasking immune reconstitution inflammatory syndrome. However, the 
sensitivity analysis using a 30 day threshold for a stricter definition of ‘simultaneous 
diagnosis’ showed a consistent trend, suggesting the results were not biased by the 
choice of threshold. 
5.4.3 Implications of the research 
BHIVA and NICE have recommended HIV testing for all patients diagnosed with 
TB since 2011.[218, 220] Between 2011 and 2015 over 90% of TB patients with 
previously unknown HIV status were tested for HIV.[52] The proportion of TB patients 
diagnosed simultaneously with TB and HIV started declining before the introduction of 
these guidelines, and has since decreased further, however a substantial proportion of 
patients (38.5%) were still diagnosed simultaneously in 2014. The routine testing of 
new TB patients for HIV provides no opportunity to prevent TB disease, and TB in 
patients who were simultaneously diagnosed cases may have been preventable if HIV 
had been diagnosed earlier and ART had been initiated sooner. In 2008, BHIVA 
introduced specific guidelines recommending more HIV testing in populations at high 
risk of infection, and increased the CD4 count threshold at which they recommend 
PLHIV start ART. This is reflected in the rise in median CD4 count representing a 
healthier population of PLHIV,[222] contributing to the observed decline in co-infections 
and the decreasing number and proportion of simultaneous diagnoses. However, more 
community HIV testing in populations at risk for TB is necessary to diagnose HIV 
sooner, to enable previously undiagnosed PLHIV to begin ART and prevent 
progression of LTBI to active disease. The recent change in BHIVA guidelines to 
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recommend ART for all PLHIV regardless of their CD4 count should also further 
decrease TB incidence in PLHIV.  As a substantial proportion of co-infected patients 
are still diagnosed simultaneously, this study demonstrates the continued need for 
universal HIV testing for all patients diagnosed with TB, and highlights the groups that 
should be prioritised for interventions that improve the uptake of HIV testing. 
Changes in the pattern of co-infections mean that a greater proportion of TB-
HIV is now occurring in people with known HIV infection. This may be explained by 
increased HIV testing,[223] resulting in earlier HIV diagnosis. However, as the number 
of people with HIV in the UK increases, sustained success requires better management 
of latent TB infection to prevent the occurrence of TB disease in people diagnosed with 
HIV. The increasing proportion of TB cases in people with diagnosed HIV represents a 
missed opportunity to prevent these TB cases by diagnosing and treating latent and 
incipient TB. This study demonstrates the continued risk of TB in people diagnosed 
with HIV, highlighting the need for more testing and treatment of LTBI in high-risk 
PLHIV. 
Part of the decline in HIV co-infection can be attributed to changing migration 
patterns, resulting in less TB in black African individuals from countries with a high HIV 
prevalence and more among individuals from Asian countries with low HIV 
prevalence.[82] The prevalence of TB in most African countries also declined during 
the study period,[224] as did the number of new HIV infections in Africa between 2010 
and 2015,[225] which may have contributed to the decreasing number of TB and HIV 
infections among migrants. However, whilst the largest decreases in HIV co-infection 
were in black African TB patients, they remain the most at-risk, and the BHIVA 
guidelines recommending LTBI screening in this population of PLHIV remain 
appropriate.  
HIV co-infection was greater among women with TB than men. This reflects the 
gender ratio of heterosexual PLHIV in the UK; where there are more women diagnosed 
with HIV than men, particularly among black Africans.[10] This is partly because of 
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higher diagnostic rates in women [10] due to antenatal HIV testing, and partly due to 
differences in sexual mixing; black African men tend to have more new partners than 
women, leading to a disproportionate number of new HIV infections in women. The 
decline of co-infection in women therefore reflects both the changes in ethnicity of TB 
patients and the healthier cohort of women with HIV. Co-infection declined in TB 
patients aged 15-44, but not in older people, which may be due to the ageing cohort of 
PLHIV and higher rates of late HIV diagnosis in older patients, increasing the risk of 
TB.[10] 
HIV co-infection was higher in TB patients with any social risk factor (drug and 
alcohol misuse, imprisonment and homelessness) than in those without, and overall 
even higher among TB cases with multiple social risk factors. However, after adjusting 
for other social risk factors in the multivariable model, only drug misuse remained 
associated with greater odds of HIV co-infection; probably the result of HIV acquisition 
from injecting drug use. As TB incidence among PLHIV who inject drugs is comparable 
to that among black Africans from countries with high TB burden (Chapter 4), LTBI 
screening and treatment for PLHIV with social risk factors, particularly drug misuse, 
could decrease TB in this population.  
There was a much greater proportion of HIV co-infection among patients with 
miliary and meningeal TB than pulmonary TB, and a lower proportion among patients 
with other extra-pulmonary disease. The results were consistent with other studies 
reporting higher prevalence of HIV co-infection among cases of miliary [226] and 
meningeal [227] TB, and lower HIV prevalence among other forms of extra-pulmonary 
TB. This was consistent over the study period and with previous work [215], probably 
because HIV contributes to a greater risk of severe disseminated TB disease, and 
because other forms of extra-pulmonary TB are common in TB patients from the Indian 
sub-continent [215] where HIV prevalence is low. Recent work in the UK showed 
patients with severe extra-pulmonary TB have worse outcomes than pulmonary TB, 
whilst patients with other extra-pulmonary TB generally have better outcomes, although 
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HIV was not adjusted for.[52] It is unclear whether this is solely because of severe 
disease presentation or whether they could be influenced by higher rates of HIV co-
infection (and corresponding clinical complexity) in these patients. Regardless, as 
diagnosis of extra-pulmonary TB is often difficult, increasing awareness of extra-
pulmonary TB symptoms among PLHIV and populations with high rates of 
undiagnosed HIV might allow earlier diagnosis of extra-pulmonary TB. 
5.4.4 Conclusions 
HIV co-infection in TB patients has substantially decreased over the past 
decade in England, Wales and Northern Ireland, as has the proportion of patients 
diagnosed simultaneously with both infections. However, sub-populations of patients 
with high rates of co-infection remain. Whilst the current policy of testing all patients 
diagnosed with TB for HIV infection is important in ensuring appropriate management 
of TB patients, many of these TB cases would be preventable if HIV could be 
diagnosed before TB develops. Increasing HIV testing and ensuring early treatment of 
HIV infection in black African populations (particularly people born in countries with 
high HIV prevalence) and people with a history of drug misuse could help prevent 
these TB cases. The BHIVA guidelines on LTBI testing for PLHIV from sub-Saharan 
Africa remain relevant, and LTBI screening for PLHIV with a history of drug misuse, 
homelessness or imprisonment should also be considered. 
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6 The role of HIV in tuberculosis transmission 
6.1 Introduction 
6.1.1 HIV and tuberculosis transmission 
HIV infection increases susceptibility to TB disease by increasing the rate of 
progression from LTBI to active disease.[85, 88] However, there is also some evidence 
that patients with HIV co-infection may be less infectious; contact studies have shown 
lower prevalence of TST positivity and lower rates of TST conversion among contacts 
of HIV-positive index patients than HIV-negative index patients,[93-95, 228] particularly 
when the index patients with HIV were immunosuppressed.[96] This may be mediated 
through a shorter duration of infectiousness due to accelerated TB disease progression 
and earlier diagnosis,[88, 89] more rapid commencement of TB treatment,[96] lower 
rates of cavitary[94, 96] or sputum smear-positive[94, 95] TB, or a shorter duration of 
cough[94] among HIV-positive index patients. 
Several studies in low-incidence settings which examined HIV as a risk factor 
for being part of a strain type cluster found no association,[71, 229, 230] including one 
meta-analysis.[231] One study in the USA reported a positive association between HIV 
and being part of a cluster for US-born patients in univariable analyses, but no 
association for foreign-born patients; and their stepwise approach to building a 
multivariable model resulted in HIV status being excluded from the multivariable 
model.[232] Two other studies reported that patients with HIV were less likely to be part 
of a strain type cluster; clusters were defined using 24-locus MIRU-VNTR in 
combination with WGS or spoligotyping.[233, 234] These studies all suffer from one 
major limitation, which is that the risk factors for being part of a strain type cluster could 
either be factors which affect susceptibility to infection or factors which influence 
infectiousness (or both). Consequently, if HIV co-infection lowers onwards transmission 
but increases susceptibility to infection, these effects could cancel each other out and 
no association would be observed. There is also weak evidence that HIV positivity 
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among the first cases of a cluster may be associated with increased numbers of 
secondary cases in clusters, suggesting that TB patients with HIV may be more 
infectious or mix with more susceptible contacts.[72, 235] Similarly, there is some 
evidence that cases arising from recent infection are more likely to be HIV-positive, 
which could be the result of greater susceptibility to infection or more rapid progression 
from LTBI to active TB disease.[236]  
6.1.2 Clustering of tuberculosis cases in the UK 
Molecular strain typing data can help identify cases which may be part of the 
same chain of transmission.[237] Since 2010, all culture-positive MTBC isolates in 
England, Wales and Northern Ireland have been prospectively strain typed using 24-
locus mycobacterial interspersed repetitive units-variable number tandem repeats 
(MIRU-VNTR) strain typing. Between 2010 and 2015, 58.4% of TB cases in England 
were part of a strain type cluster with at least one other case.[52] Being part of a strain 
type cluster was more common for UK-born TB patients (69.9% clustered) than for 
patients born abroad (54.7%). 
There have been a limited number of studies examining risk factors associated 
with clustering in the UK, most of which have not included data on HIV status. The last 
national study of clustering of TB cases in the UK used RFLP data from 1998 and 
reported that pulmonary disease, previous treatment for TB and homelessness were 
positively associated with being part of a strain type cluster, whilst TB patients from 
Asia and the Indian sub-continent were less likely to be clustered.[238] That study did 
not include data on HIV status, but a similar study of TB cases in London reported no 
association between HIV and being part of a strain type cluster.[70] In London, higher 
rates of clustering have been reported among UK-born patients, those with a history of 
drug or alcohol misuse or imprisonment, pulmonary TB (compared to extra-pulmonary 
TB) and those who have had TB previously.[239] Clusters where one of the first two 
cases had a history of imprisonment were more likely to become a large cluster (five or 
more cases) than where neither case had ever been imprisoned.[239] 
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6.1.3 Summary and objectives 
Most risk factors for TB transmission have the same direction of effect on both 
susceptibility to infection and likelihood of onward transmission. In contrast, HIV is 
believed to increase susceptibility to infection and progression to active disease, but its 
impact on onward transmission is unclear. The aims of this chapter were to utilise 
molecular strain typing data, in combination with the national TB and HIV surveillance 
datasets, to examine for the first time whether there are associations between HIV co-
infection and onward transmission of TB, and whether TB is more often due to 
reactivation of LTBI or recent infection in patients with and without HIV. 
6.2 Methods 
6.2.1 Study population 
This was a retrospective study of culture-confirmed patients with MTBC in 
adults (aged ≥15 years) in England, Wales and Northern Ireland, notified to Public 
Health England (PHE)’s Enhanced TB Surveillance System (ETS) between 2010 and 
2014. All patients with disease strain typed with at least 23 loci, using 24-loci MIRU-
VNTR genotyping at PHE’s mycobacteriology reference laboratories, were 
included.[237] Recurrence of TB was identified by record linkage within ETS. Recurrent 
cases of TB were excluded if the strain type of the second notification was the same as 
that of the first (i.e. plausible instances of relapse). 
6.2.2 Outcome: strain type clusters 
The outcome of interest was whether a TB patient was part of a strain type 
cluster. PHE defines a strain type cluster as two or more persons with TB caused by 
indistinguishable 24-loci MIRU-VNTR strain types.[237, 239] At least one case in the 
cluster must be typed at all 24 loci; additional cases can have one unmapped locus 
(which can differ between cases in the cluster). Some loci are prone to typing failures, 
despite repeated attempts, due to very high numbers of tandem repeats; in such 
instances all cases in a cluster are permitted to have an untypeable locus at the same 
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position.[237] TB cases whose strain type differed from all others at 1 or more loci were 
considered to have a unique strain type and therefore not part of a cluster. Where 
cases could belong to multiple clusters (due to untyped loci and thus missing 
information, or mixed infections), the cluster with the earliest sampling date was used, 
unless epidemiological data was available which supported the case belonging to a 
different cluster. 
The earliest date of evidence of TB disease for each patient (including symptom 
onset date, date of presentation to healthcare, earliest specimen date, diagnosis date, 
treatment start date and case notification date) was used to define the order of cases 
within clusters (Figure 6.1). The first case in a cluster was defined as the patient with 
the earliest date and all later cases were considered subsequent cases. Patients who 
were not part of strain type clusters were classed as having zero subsequent cases. I 
examined whether cases were the first case in a cluster (as a surrogate for personal 
infectiousness and likelihood of onwards transmission) and if so, how many 
subsequent cases there were in a cluster. Whether or not a case was a subsequent 
case was also analysed, as a surrogate for recent infection compared to reactivation of 
previous LTBI. 
Cases of TB in children (aged <15 years) were included in the dataset for 
defining strain type clusters and the size of clusters, but excluded from the subsequent 
analysis as record linkage to HIV surveillance to determine HIV status was only 
possible for adults. The adult TB cases which formed clusters with children were 
included in the analysis. Clusters were not limited by geographical area within England, 
Wales and Northern Ireland. 
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Figure 6.1: A diagram of how the order of cases within clusters, the number of 
subsequent cases, and whether a case was the result of reactivation or recent infection 
was determined. 
 
Faces the same colour indicate a common strain type. 
* Dates made up as examples 
 
6.2.3 Exposure variables 
The primary exposure variable was HIV status, which was determined through 
linkage to the national HIV and AIDS Reporting System (HARS),[98, 240] described in 
Chapter 3. 
Potential confounders for the relationship between HIV status and the outcomes 
were identified prospectively in Chapter 4, and a causal framework was built (Figure 
6.2).[199] Exposure variables for both outcomes included year of TB diagnosis, age at 
TB diagnosis, sex, ethnicity, place of birth and time from entry to the UK (if born 
abroad) to TB diagnosis, social risk factors (current or prior imprisonment, 
homelessness, drug misuse, or alcohol misuse hindering self-administration of TB 
treatment) and index of multiple deprivation [IMD] decile. When considering risk factors 
for being the first case in a cluster, the site of TB disease (smear positive/negative 
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pulmonary disease with or without extra-pulmonary disease, or extra-pulmonary 
disease only) was also considered. 
Figure 6.2: Conceptual framework of potential factors associated with HIV co-infection 
and strain type clustering among TB cases. 
 
*Site of TB disease and sputum smear status were only considered causal factors 
onwards transmission of TB, not for comparing reactivation and recent infection. 
IMD: index of multiple deprivation, TB: tuberculosis. 
 
6.2.4 Statistical Analysis 
Data were analysed in Stata version 13.1. Descriptive analyses of the cohort 
were undertaken examining the proportion of cases belonging to a strain type cluster 
and how many of these cases were first cases compared to subsequent cases, 
stratified by HIV status. The number of subsequent cases following the first case of 
pulmonary TB in a cluster, stratified by HIV status of the first case in the cluster, was 
also examined. 
To investigate whether HIV was a risk factor for potential transmission of TB, 
two analyses were conducted. Figure 6.3 shows which TB cases were included in each 
analysis.  









Comparing the number of subsequent 
clustered cases to determine whether 
HIV co-infection influences onwards 
transmission of TB 
Section 6.3.4 
Comparing subsequent clustered TB 
cases to first- and non-clustered TB 
case to determine whether HIV co-
infection is associated with reactivation 
of LTBI or recent infection 
6. The role of HIV in tuberculosis transmission 
 
182 
Firstly, to investigate the impact of HIV on the onward transmission of TB, zero-
inflated Poisson regression [241] was used to examine factors associated with the 
number of subsequent cases after the first pulmonary case of each strain type cluster, 
as it is generally accepted that patients with only extra-pulmonary disease are not 
infectious. Poisson regression was considered, but the Poisson distribution was not a 
good fit for the data as there were a high number of zero counts (non-clustered TB 
patients, who had zero subsequent cases). Zero-inflated Poisson regression assumes 
there are two latent groups within the data; a group which can only have zero as its 
count (in this study, patients who are not infectious) and a group which can have a zero 
or non-zero count, with a Poisson distribution (the number of subsequent cases 
generated by a TB patient who is infectious). Zero-inflated Poisson models give an 
output in two parts; an incidence rate ratio for the number of subsequent cases (given 
that there has been transmission of infection), and an odds ratio for the likelihood of 
having zero subsequent cases by default. The Vuong test was used to determine 
whether a Poisson model or the zero-inflated Poisson model were a better fit for the 
data. 
After calculating the number of subsequent cases for each TB case (zero for 
non-clustered cases, one or more for the first case of each cluster), subsequent cases 
in clusters were excluded from the regression model of factors associated with 
clustering, as it was not possible to determine the exact chain of transmission within 
clusters from MIRU-VNTR strain typing. For each case, the model was offset by the 
time since the earliest date of evidence of TB to the end of the study period (31st 
December 2014). As the model did not explain all the variation in the number of 
subsequent cases seen in the descriptive analyses, a second analysis was conducted 
examining the number of subsequent cases if the first case in a cluster had only extra-
pulmonary disease. 
Secondly, to investigate the impact of HIV on susceptibility to recent TB 
infection compared to reactivation of latent infection, logistic regression was used to 
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examine risk factors for being a subsequent case in a strain type cluster compared to 
being a non-clustered case or the first case of a cluster. All cases were included in this 
analysis. 
For both analyses, univariable results were estimated and multivariable models 
were built, excluding patients missing data on one or more variables. Within-patient 
clustering (in patients with recurrent TB with different strain types) was not adjusted for 
as there were very few cases for which it was relevant. Linearity (of age group, year 
and IMD decile) was assessed using likelihood-ratio tests and variables were treated 
as categorical if P>0.05. To examine the representativeness of the cohort, the 
distributions of variables were compared for cases included and excluded from the 
study. 
6.3 Results 
6.3.1 Descriptive analysis 
There were 37,162 cases of TB in adults aged ≥15 years notified to PHE in 
England, Wales and Northern Ireland between 2010 and 2014. 261/37,162 (0.7%) 
were recurrent cases within this time period. 23,146/37,162 (62.3%) were culture 
confirmed, and 18,913 (81.7%) were strain typed at ≥23 loci. 68 recurrent cases of TB 
had strain typing data available for both the first and subsequent isolates; 49 cases of 
recurrent TB were excluded where the isolates from the recurrent episode had the 
same strain type as the original isolate, however 19 recurrent cases where the strain 
type differed between the first and subsequent isolate(s) were included. Ultimately 
18,864 TB cases were included in the analysis, representing 50.8% of TB cases 
notified in England, Wales and Northern Ireland from 2010-2014. The earliest date of 
evidence of TB was symptom onset date for 76% of cases, the remaining 24% used 
date of presentation to health services, specimen date, diagnosis date or case report 
date. The dates used to define earliest date of evidence of TB did not differ for HIV-
positive and HIV-negative patients. 
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Of the cases included in the analysis, 10,709 (56.8%) were part of 2,284 strain 
type clusters. 2,238 (20.9%) were the first cases in a cluster (in 46 clusters the first 
case was aged <15 years and therefore excluded from the analysis) and 8,471 (79.1%) 
were subsequent cases. The median time between the first case in a cluster and the 
second case was 10 months (IQR 4-19). 
6.3.2 HIV and clustering of tuberculosis cases 
759/18,864 TB cases were co-infected with HIV (4.0%); 410 (54.0%) were 
clustered, of which 99 (24.2%) were the first case in a cluster and 311 (75.9%) were 
subsequent clustered cases. 
Of the 8,471 subsequent cases in clusters, 572 (6.8%) had an HIV-positive first 
case, 7,775 (91.8%) had an HIV-negative first case, and the HIV status of the first case 
was unknown for 124 (1.5%) patients where the first case in the cluster was a child. 
Other demographic, socioeconomic and clinical factors are shown in Table 6.1. 
The HIV status of the first case of a cluster was positively associated with the 
HIV status of subsequent cases (P<0.001). The prevalence of HIV among subsequent 
cases was higher in clusters with an HIV-positive first case (10.7%) than in clusters 
with an HIV-negative first case (3.2%). 6.4% of HIV-negative subsequent cases had an 
HIV-positive first case, compared to 19.9% of HIV-positive subsequent cases. 
1,998/2,284 (87.5%) of clusters consisted of only HIV-negative TB patients, 11 clusters 
(0.5%) consisted of only HIV-positive TB patients, and 275 (12.0%) clusters were 
mixed. 
The mean cluster size in the cohort was 4.8 (median 3, inter-quartile range 2-4, 
range 2-198); 4.7 for clusters where the first patient was HIV-negative, and 7.0 for 
clusters with an HIV-positive first case. 
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Table 6.1: The clustering status of TB cases by risk factor in England, Wales and 







(% of clustered 
cases) 
First cases 
(% of clustered 
cases) 
Total 18,864 10,709 (56.8) 8,471 (79.1) 2,238 (20.9) 
HIV status 
    
Negative 18,105 10,299 (56.9) 8,160 (79.2) 2,139 (20.8) 
Positive 759 410 (54.0) 311 (75.9) 99 (24.1) 
Year of TB notification 
    
2010 3,174 1,795 (56.6) 874 (48.7) 921 (51.3) 
2011 4,296 2,443 (56.9) 1,786 (73.1) 657 (26.9) 
2012 4,327 2,525 (58.4) 2,150 (85.1) 375 (14.9) 
2013 3,696 2,130 (57.6) 1,940 (91.1) 190 (8.9) 
2014 3,371 1,816 (53.9) 1,721 (94.8) 95 (5.2) 
Sex 
    
Female 7,521 4,153 (55.2) 3,272 (78.8) 881 (21.2) 
Male 11,323 6,547 (57.8) 5,196 (79.4) 1,351 (20.6) 
Missing 20 9 (45.0) 3 (33.3) 6 (66.7) 
Age (years) 
    
15-24 3,238 2,059 (63.6) 1,652 (80.2) 407 (19.8) 
25-34 5,632 3,139 (55.7) 2,453 (78.1) 686 (21.9) 
35-44 3,578 2,041 (57.0) 1,601 (78.4) 440 (21.6) 
45-54 2,388 1,423 (59.6) 1,149 (80.7) 274 (19.3) 
55-64 1,488 890 (59.8) 717 (80.6) 173 (19.4) 
≥65 2,540 1,157 (45.6) 899 (77.7) 258 (22.3) 
Ethnicity 
    
White 3,991 2,442 (61.2) 1,959 (80.2) 483 (19.8) 
Black African 3,211 2,031 (63.3) 1,603 (78.9) 428 (21.1) 
Black Other 588 458 (77.9) 391 (85.4) 67 (14.6) 
Indian sub-continent 8,079 4,198 (52.0) 3,300 (78.6) 898 (21.4) 
Mixed/other 2,525 1,330 (52.7) 1,029 (77.4) 301 (22.6) 
Missing 470 250 (53.2) 189 (75.6) 61 (24.4) 
Time since entry to the 
UK     
UK born 4,431 3,000 (67.7) 2,495 (83.2) 505 (16.8) 
Within 2 years 2,535 1,313 (51.8) 979 (74.6) 334 (25.4) 
2-5 years 2,999 1,509 (50.3) 1,154 (76.5) 355 (23.5) 
5-10 years 2,743 1,485 (54.1) 1,149 (77.4) 336 (22.6) 
More than 10 years 4,115 2,329 (56.6) 1,870 (80.3) 459 (19.7) 
Missing 2,041 1,073 (52.6) 824 (76.8) 249 (23.2) 
TB lineage 
    
Beijing 1,041 770 (74.0) 667 (86.6) 103 (13.4) 
Euro-American 7,313 4,300 (58.8) 3,352 (78.0) 948 (22.0) 
Central Asian Strain 5,280 3,285 (62.2) 2,674 (81.4) 611 (18.6) 
East Asian Indian 2,674 1,046 (39.1) 769 (73.5) 277 (26.5) 
Other 2,554 1,306 (51.1) 1,008 (77.2) 298 (22.8) 
Missing 2 
   









(% of clustered 
cases) 
First cases 
(% of clustered 
cases) 
IMD decile 
    
1 3,933 2,360 (60.0) 1,868 (79.2) 492 (20.8) 
2 3,645 2,130 (58.4) 1,678 (78.8) 452 (21.2) 
3 3,008 1,704 (56.6) 1,334 (78.3) 370 (21.7) 
4 2,301 1,314 (57.1) 1,066 (81.1) 248 (18.9) 
5 1,655 906 (54.7) 695 (76.7) 211 (23.3) 
6 1,183 652 (55.1) 516 (79.1) 136 (20.9) 
7 838 453 (54.1) 375 (82.8) 78 (17.2) 
8 728 398 (54.7) 302 (75.9) 96 (24.1) 
9 610 307 (50.3) 241 (78.5) 66 (21.5) 
10 474 243 (51.3) 194 (79.8) 49 (20.2) 
Missing 489 242 (49.5) 202 (83.5) 40 (16.5) 
Drug misuse 
    
No 16,536 9,241 (55.9) 7,291 (78.9) 1,950 (21.1) 
Yes 702 551 (78.5) 473 (85.8) 78 (14.2) 
Missing 1,626 917 (56.4) 707 (77.1) 210 (22.9) 
Alcohol misuse 
    
No 16,260 9,160 (56.3) 7,251 (79.2) 1,909 (20.8) 
Yes 776 528 (68.0) 441 (83.5) 87 (16.5) 
Missing 1,828 1,021 (55.9) 779 (76.3) 242 (23.7) 
Homelessness 
    
No 16,771 9,480 (56.5) 7,500 (79.1) 1,980 (20.9) 
Yes 666 449 (67.4) 372 (82.9) 77 (17.1) 
Missing 1,427 780 (54.7) 599 (76.8) 181 (23.2) 
Imprisonment 
    
No 16,210 9,097 (56.1) 7,200 (79.1) 1,897 (20.9) 
Yes 649 484 (74.6) 410 (84.7) 74 (15.3) 
Missing 2,005 1,128 (56.3) 861 (76.3) 267 (23.7) 
Site of TB disease/Smear 
status†     
Pulmonary, smear positive 4,959 3,137 (63.3) 2,448 (78.0) 689 (22.0) 
Pulmonary, smear 
negative/unknown 
6,952 4,084 (58.7) 3,279 (80.3) 805 (19.7) 
Extra-pulmonary 6,947 3,486 (50.2) 2,742 (78.7) 744 (21.3) 
Missing 6 2 (33.3) 2 (100.0) 0 (0.0) 
IMD: index of multiple deprivation score, TB: tuberculosis. † Patients with both 
pulmonary and extra-pulmonary disease were classed as having pulmonary disease. 
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6.3.3 Risk factors for being the first case in a cluster (a surrogate for 
onwards transmission of tuberculosis) 
The number of subsequent cases for each TB case differed substantially by 
both HIV status, site of disease and smear status (Table 6.2); pulmonary smear-
positive patients had a higher mean number of subsequent cases (1.1) than smear-
negative or extra-pulmonary patients (0.8 and 0.7 respectively). However, extra-
pulmonary TB patients with HIV had a higher mean number of subsequent cases 
compared to HIV-negative extra-pulmonary TB patients (2.5 versus 0.6, Table 6.2). 
Table 6.2: The mean number of subsequent clustered cases, stratified by the HIV status, 
site of disease and smear status of the first TB case. 
Site of disease† and smear status 







Pulmonary smear positive 1.1 (0.02) 0.6 (0.07) 1.1 (0.02) 
Pulmonary smear negative/unknown 0.8 (0.01) 0.9 (0.07) 0.8 (0.01) 
Extra-pulmonary disease 0.6 (0.01) 2.5 (0.14) 0.7 (0.01) 
Total 0.8 (0.01) 1.3 (0.05) 0.8 (0.01) 
SE: standard error of the mean (Poisson distribution), TB: tuberculosis. †Patients with 
both pulmonary and extra-pulmonary disease were classed as having pulmonary 
disease. 
 
Among pulmonary TB cases, there was no association between HIV co-
infection and being the first case of a strain type cluster (compared to not being part of 
a strain type cluster) in univariable or multivariable zero-inflated Poisson regression 
models (multivariable OR 1.10 [0.79-1.53], Table 6.3). However, among pulmonary TB 
cases who were the first case of a strain type cluster, HIV co-infection was associated 
with a decreased number of subsequent clustered cases in the univariable model (IRR 
0.76 [0.68-0.87], Table 6.3). This association remained in a multivariable zero-inflated 
Poisson regression model adjusted for year of TB notification, age, sex, ethnicity and 
country of birth, TB lineage, IMD decile, drug misuse, alcohol misuse, homelessness, 
imprisonment and smear status (IRR 0.76 [0.66-0.87]). 
Extra-pulmonary TB cases with HIV co-infection were less likely to be the first 
case of a cluster (multivariable OR 1.93 [1.12-3.33], Table 6.4). However, where an 
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extra-pulmonary TB case was the first case in a cluster, HIV co-infection was 
associated with an increased number of subsequent cases (multivariable IRR 3.62 
[3.12-4.19]). 
The Vuong test was P<0.001 for both models, indicating that a zero-inflated 
Poisson model was a better fit for the data than the Poisson model. 
  




Table 6.3: Univariable and multivariable zero-inflated Poisson regression of factors associated with the number of subsequent clustered cases for 
























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
Total 11,911 7,221 (60.6) 2,056 (28.5)     
HIV status 
       
Negative 11,366 6,910 (60.8) 1,950 (28.2) 1.00 1.00 1.00 1.00 
Positive 545 311 (57.1) 106 (34.1) 0.76 (0.68-0.87) 0.94 (0.72-1.23) 0.75 (0.65-0.86) 1.10 (0.79-1.53) 
Year of TB 
diagnosis        
2010 2,028 1,205 (59.4) 716 (59.4) 1.00 1.00 1.00 1.00 
2011 2,696 1,638 (60.8) 546 (33.3) 0.63 (0.59-0.66) 1.69 (1.46-1.96) 0.64 (0.60-0.68) 1.52 (1.29-1.80) 
2012 2,650 1,670 (63.0) 379 (22.7) 0.39 (0.35-0.43) 1.87 (1.56-2.24) 0.38 (0.34-0.43) 1.53 (1.25-1.88) 
2013 2,354 1,456 (61.9) 230 (15.8) 0.42 (0.35-0.49) 2.79 (2.20-3.53) 0.40 (0.34-0.48) 2.38 (1.83-3.11) 
2014 2,183 1,252 (57.4) 185 (14.8) 0.64 (0.52-0.79) 4.53 (3.34-6.14) 0.59 (0.47-0.74) 4.04 (2.87-5.69) 
Sex 
       
Female 4,562 2,661 (58.3) 765 (28.7) 1.00 1.00 1.00 1.00 
Male 7,333 4,552 (62.1) 1,285 (28.2) 1.04 (0.99-1.09) 0.86 (0.76-0.96) 1.01 (0.95-1.06) 0.81 (0.70-0.93) 
Missing 16 8 (50.0) 6 (75.0) 
    
Age (years) 
       
15-24 2,254 1,504 (66.7) 405 (26.9) 0.93 (0.87-1.00) 0.78 (0.65-0.92) 0.86 (0.79-0.93) 0.78 (0.63-0.96) 
25-34 3,250 1,947 (59.9) 575 (29.5) 1.00 1.00 1.00 1.00 
35-44 2,089 1,314 (62.9) 395 (30.1) 1.30 (1.22-1.39) 0.89 (0.75-1.05) 1.33 (1.24-1.43) 0.99 (0.81-1.22) 
45-54 1,566 1,000 (63.9) 252 (25.2) 0.90 (0.83-0.99) 0.89 (0.73-1.08) 0.96 (0.87-1.07) 1.08 (0.84-1.38) 
55-64 999 633 (63.4) 167 (26.4) 1.19 (1.09-1.30) 1.10 (0.87-1.39) 1.01 (0.91-1.13) 1.36 (1.01-1.82) 


























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
≥65 1,753 823 (46.9) 262 (31.8) 1.04 (0.96-1.13) 1.61 (1.34-1.94) 1.03 (0.93-1.14) 1.97 (1.53-2.53) 
Ethnicity 
       
White 3,481 2,205 (63.3) 522 (23.7) 1.00 1.00 1.00 1.00 
Black African 1,926 1,270 (65.9) 370 (29.1) 0.96 (0.89-1.02) 0.76 (0.64-0.91) 1.23 (1.12-1.36) 0.91 (0.70-1.19) 
Black Other 406 322 (79.3) 68 (21.1) 0.89 (0.77-1.02) 0.51 (0.35-0.74) 0.86 (0.74-1.01) 0.58 (0.37-0.93) 
Indian sub-
continent 
4,174 2,354 (56.4) 758 (32.2) 0.94 (0.88-0.99) 1.15 (1.00-1.33) 0.93 (0.85-1.01) 1.19 (0.94-1.51) 
Mixed/other 1,621 894 (55.2) 273 (30.5) 0.60 (0.55-0.66) 1.03 (0.85-1.26) 0.68 (0.60-0.77) 1.10 (0.83-1.46) 
Missing 303 176 (58.1) 65 (36.9) 
    
Time since 
entry to the UK        
UK born 3,631 2,526 (69.6) 540 (21.4) 1.00 1.00 1.00 1.00 
Within 2 years 1,536 833 (54.2) 311 (37.3) 0.70 (0.64-0.75) 1.10 (0.91-1.32) 0.65 (0.59-0.71) 1.27 (0.99-1.63) 
2-5 years 1,549 815 (52.6) 267 (32.8) 0.75 (0.69-0.81) 1.24 (1.02-1.50) 0.76 (0.69-0.84) 1.35 (1.05-1.74) 
5-10 years 1,543 897 (58.1) 283 (31.5) 0.82 (0.76-0.89) 1.10 (0.91-1.33) 0.76 (0.69-0.83) 1.25 (0.97-1.60) 
More than 10 
years 
2,423 1,460 (60.3) 423 (29.0) 0.89 (0.83-0.95) 1.23 (1.04-1.46) 0.84 (0.77-0.91) 1.10 (0.87-1.40) 
Missing 1,229 690 (56.1) 232 (33.6) 
    
TB lineage 
       
Beijing 706 525 (74.4) 93 (17.7) 1.00 1.00 1.00 1.00 
Euro-American 5,306 3,233 (60.9) 898 (27.8) 0.51 (0.47-0.56) 1.05 (0.80-1.39) 0.46 (0.41-0.50) 1.11 (0.80-1.54) 
Central Asian 
Strain 
2,955 1,948 (65.9) 547 (28.1) 0.72 (0.66-0.79) 1.05 (0.79-1.40) 0.78 (0.70-0.86) 1.01 (0.72-1.43) 
East Asian 
Indian 
1,271 551 (43.4) 235 (42.6) 0.42 (0.37-0.48) 1.59 (1.16-2.17) 0.52 (0.45-0.59) 1.54 (1.06-2.23) 
Other 1,673 964 (57.6) 283 (29.4) 0.48 (0.43-0.53) 1.17 (0.86-1.59) 0.43 (0.38-0.48) 1.18 (0.82-1.69) 


























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
Missing 2 
      
IMD decile 
       
1 2,581 1,654 (64.1) 440 (26.6) - - - - 
2 2,238 1,383 (61.8) 396 (28.6) - - - - 
3 1,851 1,117 (60.3) 335 (30.0) - - - - 
4 1,425 873 (61.3) 247 (28.3) - - - - 
5 1,039 609 (58.6) 191 (31.4) - - - - 
6 737 437 (59.3) 125 (28.6) - - - - 
7 525 306 (58.3) 80 (26.1) - - - - 
8 486 276 (56.8) 82 (29.7) - - - - 
9 390 224 (57.4) 63 (28.1) - - - - 
10 305 171 (56.1) 54 (31.6) - - - - 
Missing 334 171 (51.2) 43 (25.1) - - - - 
For each decile 
increase 
- - - 0.96 (0.95-0.97) 1.02 (0.99-1.04) 0.96 (0.95-0.97) 1.00 (0.97-1.03) 
Drug misuse 
       
No 10,165 6,061 (59.6) 1,768 (29.2) 1.00 1.00 1.00 1.00 
Yes 639 507 (79.3) 82 (16.2) 1.14 (1.02-1.27) 0.61 (0.45-0.83) 0.88 (0.76-1.01) 0.84 (0.56-1.28) 
Missing 1,107 653 (59.0) 206 (31.5) 
    
Alcohol misuse 
       
No 10,039 6,043 (60.2) 1,747 (28.9) 1.00 1.00 1.00 1.00 
Yes 670 470 (70.1) 87 (18.5) 1.85 (1.71-2.01) 0.97 (0.74-1.26) 1.69 (1.54-1.86) 1.18 (0.84-1.66) 
Missing 1,202 708 (58.9) 222 (31.4) 
    
Homelessness 
       


























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
No 10,398 6,277 (60.4) 1,799 (28.7) 1.00 1.00 1.00 1.00 
Yes 567 393 (69.3) 85 (21.6) 0.90 (0.80-1.02) 0.74 (0.55-0.99) 0.63 (0.54-0.72) 0.88 (0.59-1.30) 
Missing 946 551 (58.2) 172 (31.2) 
    
Imprisonment 
       
No 9,990 5,978 (59.8) 1,725 (28.9) 1.00 1.00 1.00 1.00 
Yes 553 423 (76.5) 82 (19.4) 1.07 (0.96-1.20) 0.86 (0.76-0.96) 1.10 (0.97-1.26) 0.85 (0.57-1.26) 
Missing 1,368 820 (59.9) 249 (30.4) 
    
Smear status 
       
Smear positive 4,959 3,137 (63.3) 901 (28.7) 1.00 1.29 1.00 1.00 
Smear negative 
or unknown 
6,952 4,084 (58.7) 1,155 (28.3) 0.87 (0.83-0.92) 1.94 (1.78-2.12) 0.83 (0.79-0.88) 1.17 (1.02-1.34) 
CI: confidence interval, IMD: index of multiple deprivation score, IRR: incidence rate ratio (Poisson part) for an increased number of subsequent 
clustered cases, OR: odds ratio (zero-inflated part) for the odds of being a non-clustered case, compared to being the first pulmonary case of a cluster, 
TB: tuberculosis. ≠ Adjusted for all variables shown in the table. The multivariable model included 5,694 TB cases after 1,052 were excluded due to 
missing data on one or more of sex (n=14), ethnicity (n=192), time since entry to the UK (n=771) or IMD score (n=206). †Cases missing data were 
considered not to have these social risk factors. 
 




Table 6.4: Univariable and multivariable zero-inflated Poisson regression of factors associated with the number of subsequent clustered cases for extra-


























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
Total 6,953 3,488 (50.2) 744 (21.3) 
    HIV status        
Negative 6,739 3,389 (50.3) 722 (21.3) 1.00 1.00 1.00 1.00 
Positive 214 99 (46.3) 22 (22.2) 4.16 (3.71-4.67) 1.38 (0.86-2.19) 3.62 (3.12-4.19) 1.93 (1.12-3.33) 
Year of TB 
diagnosis 
       2010 1,146 590 (51.5) 293 (49.7) 1.00 1.00 1.00 1.00 
2011 1,600 805 (50.3) 242 (30.1) 0.77 (0.71-0.84) 1.65 (1.34-2.02) 0.72 (0.66-0.80) 1.45 (1.15-1.84) 
2012 1,677 855 (51.0) 122 (14.3) 0.56 (0.48-0.66) 2.84 (2.21-3.64) 0.60 (0.51-0.71) 2.57 (1.93-3.41) 
2013 1,342 674 (50.2) 62 (9.2) 0.39 (0.29-0.51) 2.83 (1.94-4.13) 0.45 (0.34-0.61) 2.82 (1.88-4.22) 
2014 1,188 564 (47.5) 25 (4.4) 0.90 (0.74-1.10) 
6.86 (4.36-
10.80) 1.11 (0.82-1.51) 7.82 (4.67-13.11) 
Sex 
       Female 2,959 1,492 (50.4) 323 (21.6) 1.00 1.00 1.00 1.00 
Male 3,990 1,995 (50.0) 421 (21.1) 1.25 (1.15-1.35) 1.11 (0.94-1.31) 1.22 (1.12-1.34) 0.99 (0.81-1.21) 
Missing 4 1 (25.0)  (0.0) 
    Age (years) 
       15-24 984 555 (56.4) 111 (20.0) 2.26 (2.01-2.54) 1.10 (0.85-1.42) 1.66 (1.46-1.89) 1.07 (0.80-1.45) 
25-34 2,382 1,192 (50.0) 266 (22.3) 1.00 1.00 1.00 1.00 
35-44 1,489 727 (48.8) 156 (21.5) 1.67 (1.49-1.87) 1.27 (1.01-1.60) 1.43 (1.26-1.61) 1.32 (1.00-1.75) 
45-54 822 423 (51.5) 83 (19.6) 1.37 (1.19-1.59) 1.19 (0.89-1.58) 1.39 (1.18-1.63) 1.46 (1.02-2.10) 
55-64 489 257 (52.6) 52 (20.2) 1.73 (1.48-2.02) 1.18 (0.84-1.66) 1.92 (1.60-2.31) 1.45 (0.94-2.24) 
≥65 787 334 (42.4) 76 (22.8) 1.08 (0.92-1.26) 1.34 (1.00-1.81) 0.94 (0.78-1.14) 1.40 (0.92-2.12) 
        
        





























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
Ethnicity 
       White 510 237 (46.5) 49 (20.7) 1.00 1.00 1.00 1.00 
Black African 1,285 761 (59.2) 150 (19.7) 1.76 (1.45-2.14) 0.74 (0.51-1.08) 0.85 (0.65-1.10) 0.49 (0.27-0.89) 
Black Other 182 136 (74.7) 17 (12.5) 3.69 (2.92-4.66) 0.62 (0.32-1.19) 2.84 (2.18-3.70) 0.57 (0.26-1.25) 
Indian sub-
continent 3,905 1,844 (47.2) 414 (22.5) 1.21 (1.00-1.46) 0.96 (0.68-1.35) 0.64 (0.49-0.83) 0.64 (0.36-1.12) 
Mixed/other 904 436 (48.2) 101 (23.2) 0.97 (0.78-1.21) 0.80 (0.54-1.20) 0.58 (0.44-0.78) 0.50 (0.27-0.93) 
Missing 167 74 (44.3) 13 (17.6) 
    Time since entry 
to the UK 
       UK born 800 474 (59.3) 86 (18.1) 1.00 1.00 1.00 1.00 
Within 2 years 999 480 (48.0) 107 (22.3) 1.75 (1.52-2.01) 1.51 (1.09-2.10) 2.06 (1.70-2.50) 2.56 (1.62-4.05) 
2-5 years 1,450 694 (47.9) 156 (22.5) 0.72 (0.61-0.84) 1.16 (0.85-1.59) 0.99 (0.81-1.22) 1.72 (1.10-2.70) 
5-10 years 1,200 588 (49.0) 134 (22.8) 0.87 (0.74-1.01) 1.20 (0.87-1.65) 1.16 (0.94-1.42) 1.83 (1.15-2.89) 
More than 10 years 1,692 869 (51.4) 185 (21.3) 0.95 (0.83-1.09) 1.15 (0.85-1.56) 1.28 (1.04-1.57) 1.42 (0.91-2.23) 
Missing 812 383 (47.2) 76 (19.8) 
    TB lineage 
       Beijing 335 245 (73.1) 34 (13.9) 1.00 1.00 1.00 1.00 
Euro-American 2,007 1,067 (53.2) 236 (22.1) 0.46 (0.39-0.54) 1.21 (0.79-1.87) 0.41 (0.34-0.49) 1.16 (0.70-1.93) 
Central Asian Strain 2,325 1,337 (57.5) 255 (19.1) 0.75 (0.65-0.87) 1.36 (0.89-2.09) 0.76 (0.64-0.90) 1.37 (0.82-2.26) 
East Asian Indian 1,403 495 (35.3) 133 (26.9) 0.48 (0.41-0.58) 2.18 (1.40-3.42) 0.55 (0.45-0.67) 2.07 (1.23-3.48) 
Other 881 342 (38.8) 85 (24.9) 0.66 (0.56-0.79) 2.17 (1.36-3.47) 0.62 (0.51-0.75) 1.92 (1.12-3.30) 
Missing 2 
              
        
        
        





























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
IMD decile 
       1 1,352 706 (52.2) 160 (22.7) - - - - 
2 1,407 747 (53.1) 156 (20.9) - - - - 
3 1,157 587 (50.7) 136 (23.2) - - - - 
4 876 441 (50.3) 72 (16.3) - - - - 
5 616 297 (48.2) 75 (25.3) - - - - 
6 446 215 (48.2) 45 (20.9) - - - - 
7 313 147 (47.0) 26 (17.7) - - - - 
8 242 122 (50.4) 30 (24.6) - - - - 
9 220 83 (37.7) 17 (20.5) - - - - 
10 169 72 (42.6) 12 (16.7) - - - - 
Missing 155 71 (45.8) 15 (21.1) - - - - 
For each decile 
increase - - - 0.93 (0.92-0.95) 1.03 (1.00-1.07) 0.97 (0.95-0.99) 1.03 (0.99-1.08) 
Drug misuse 
       No 6,371 3,180 (49.9) 675 (21.2) 1.00 1.00 1.00 1.00 
Yes 63 44 (69.8) 7 (15.9) 0.41 (0.21-0.82) 0.34 (0.10-1.18) 0.49 (0.27-0.90) 0.31 (0.06-1.66) 
Missing 519 264 (50.9) 62 (23.5) 
    Alcohol misuse 
       No 6,221 3,117 (50.1) 654 (21.0) 1.00 1.00 1.00 1.00 
Yes 106 58 (54.7) 13 (22.4) 1.44 (1.13-1.83) 0.89 (0.47-1.66) 1.79 (1.34-2.38) 1.09 (0.47-2.51) 
Missing 626 313 (50.0) 77 (24.6) 
    Homelessness 
       No 6,373 3,203 (50.3) 679 (21.2) 1.00 1.00 1.00 1.00 
Yes 99 56 (56.6) 7 (12.5) 0.29 (0.12-0.72) 0.71 (0.21-2.33) 0.23 (0.09-0.58) 0.62 (0.10-3.94) 
Missing 481 229 (47.6) 58 (25.3) 
            





























IRR (95% CI) OR (95% CI) IRR (95% CI) OR (95% CI) 
Imprisonment 
       No 6,220 3,119 (50.1) 657 (21.1) 1.00 1.00 1.00 1.00 
Yes 96 61 (63.5) 8 (13.1) 0.06 (0.03-0.13) 1.11 (0.94-1.31) 0.17 (0.04-0.82) 0.36 (0.01-8.94) 
Missing 637 308 (48.4) 79 (25.6)         
CI: confidence interval, IMD: index of multiple deprivation score IRR: incidence rate ratio (Poisson part) for an increased number of subsequent clustered 
cases, OR: odds ratio (zero-inflated part) for the odds of being a non-clustered case, compared to being the first extra-pulmonary case of a cluster, TB: 
tuberculosis. ≠ Adjusted for all variables shown in the table. The multivariable model included 3,576 extra-pulmonary TB cases after 633 were excluded 
due to missing data on one or more of sex (n=3), ethnicity (n=106), time since entry to the UK (n=505), IMD score (n=99) or TB lineage (n=1). †Cases 
missing data were considered not to have these social risk factors. 
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6.3.4 Risk factors for being a subsequent case in a cluster (a surrogate 
for recent infection with tuberculosis) 
HIV co-infection was negatively associated with being a subsequent case in a 
cluster in univariable analysis (OR 0.85 [0.73-0.98], Table 6.5) and multivariable 
analysis (OR 0.82 [0.69-0.98]) adjusted for year of TB diagnosis, age, sex, ethnicity 
and country of birth, TB lineage, IMD decile, drug misuse, alcohol misuse, 
homelessness, and imprisonment. 
6.3.5 Assessment of potential bias and misclassification 
The distribution of variables for cases included in the study population was 
generally similar to those that were excluded for being culture-negative or strain typed 
at <23 loci (Table 6.6). The cases included in the analysis did not substantially differ in 
terms of age, sex, ethnicity, place of birth (UK or abroad), time since entry to the UK, 
year of TB diagnosis or presence of social risk factors, but TB patients with only extra-
pulmonary disease were less likely to be culture-confirmed and typed at ≥23 loci (and 
therefore less likely to be included). 
Of the 18,864 cases included in the analysis, 5,462 (29.0%) were typed at 23 
loci and 1,186 (11.0% of clustered cases) could have belonged to more than one 
cluster. The prevalence of HIV was similar for cases typed with 23 loci (4.1%) and 
cases typed with 24 loci (4.0%). 122 cases (0.7%) had more than one strain type due 
to mixed infection, and 4 cases (0.02%) belonged to more than one cluster. 
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Table 6.5: Univariable and multivariable logistic regression of factors associated with 
being a subsequent TB case in a cluster (a surrogate for recent infection) compared to 




OR (95% CI) 
Multivariable≠ 
OR (95% CI) 
HIV status 
  
Negative 1.00 1.00 
Positive 0.85 (0.73-0.98) 0.82 (0.69-0.98) 
Year of TB notification 
  
2010 1.00 1.00 
2011 1.87 (1.70-2.07) 2.06 (1.84-2.31) 
2012 2.60 (2.36-2.87) 3.06 (2.74-3.43) 
2013 2.91 (2.63-3.22) 3.38 (3.02-3.80) 





Male 1.10 (1.04-1.17) 1.09 (1.02-1.17) 
Age (years) 
  
15-24 1.35 (1.24-1.47) 1.19 (1.08-1.32) 
25-34 1.00 1.00 
35-44 1.05 (0.96-1.14) 0.92 (0.83-1.02) 
45-54 1.20 (1.09-1.32) 0.90 (0.80-1.01) 
55-64 1.21 (1.07-1.35) 0.96 (0.83-1.10) 
≥65 0.71 (0.64-0.78) 0.51 (0.45-0.57) 
Ethnicity 
  
White 1.00 1.00 
Black African 1.03 (0.94-1.13) 1.51 (1.31-1.73) 
Black Other 2.06 (1.72-2.47) 2.25 (1.82-2.78) 
Indian sub-continent 0.72 (0.66-0.77) 0.92 (0.81-1.04) 
Mixed/other 0.71 (0.65-0.79) 0.98 (0.85-1.13) 
Time since entry to the UK 
  
UK born 1.00 1.00 
Within 2 years 0.49 (0.44-0.54) 0.41 (0.36-0.47) 
2-5 years 0.49 (0.44-0.53) 0.39 (0.35-0.44) 
5-10 years 0.56 (0.51-0.62) 0.49 (0.43-0.55) 
More than 10 years 0.65 (0.59-0.70) 0.61 (0.54-0.69) 
TB lineage 
  
Beijing 1.00 1.00 
Euro-American 0.47 (0.41-0.54) 0.38 (0.33-0.45) 
Central Asian Strain 0.58 (0.50-0.66) 0.63 (0.54-0.74) 
East Asian Indian 0.23 (0.19-0.26) 0.23 (0.19-0.28) 
Other 0.37 (0.31-0.42) 0.32 (0.27-0.38) 
IMD decile 
  
For each decile increase 0.97 (0.96-0.98) 0.98 (0.96-0.99) 
Drug misuse 
  
No 1.00 1.00 
Yes 2.62 (2.24-3.08) 1.53 (1.25-1.87) 
   





OR (95% CI) 
Multivariable≠ 
OR (95% CI) 
Alcohol misuse 
  
No 1.00 1.00 
Yes 1.65 (1.43-1.91) 1.21 (1.01-1.45) 
Homelessness 
  
No 1.00 1.00 
Yes 1.58 (1.35-1.84) 1.03 (0.85-1.24) 
Imprisonment 
  
No 1.00 1.00 
Yes 2.16 (1.84-2.54) 1.26 (1.03-1.54) 
CI: confidence interval, IMD: index of multiple deprivation score, OR: odds ratio, TB: 
tuberculosis. ≠ Adjusted for all variables shown in the table. The multivariable model 
included 16,171 TB cases after 2,693 were excluded due to missing data on one or more 
of sex (n=20), ethnicity (n=470), time since entry to the UK (n=2,041), IMD score (n=489) 




6. The role of HIV in tuberculosis transmission 
 
200 
Table 6.6: Distribution of the variables included in the regression models, for cases 
included and excluded from the study population. 
Variable 
Excluded cases 
(not strain typed) 
Included cases 
(strain typed 
  n (column %) n (column %) 
HIV 
  
Negative 17,664 (96.5) 18,105 (96.0) 
Positive 634 (3.5) 759 (4.0) 
Year   
2010 4,358 (23.8) 3,174 (16.8) 
2011 3,789 (20.7) 4,296 (22.8) 
2012 3,581 (19.6) 4,327 (22.9) 
2013 3,480 (19.0) 3,696 (19.6) 
2014 3,090 (16.9) 3,371 (17.9) 
Sex   
Female 8,063 (44.1) 7,521 (39.9) 
Male 10,195 (55.7) 11,323 (60.0) 
Age group   
15-24 2,351 (12.9) 3,238 (17.2) 
25-34 4,958 (27.1) 5,632 (29.9) 
35-44 3,622 (19.8) 3,578 (19.0) 
45-54 2,552 (14.0) 2,388 (12.7) 
55-64 1,964 (10.7) 1,488 (7.9) 
≥65 2,851 (15.6) 2,540 (13.5) 
Ethnicity   
White 3,574 (19.5) 3,991 (21.2) 
Black African 2,739 (15.0) 3,211 (17.0) 
Black Other 472 (2.6) 588 (3.1) 
Indian sub-continent 9,020 (49.3) 8,079 (42.8) 
Mixed/other 2,069 (11.3) 2,525 (13.4) 
Time since entry to the UK   
UK born 4,286 (23.4) 4,431 (23.5) 
<2 years 1,964 (10.7) 2,535 (13.4) 
2-5 years 2,448 (13.4) 2,999 (15.9) 
5-10 years 2,647 (14.5) 2,743 (14.5) 
≥10 years 4,907 (26.8) 4,115 (21.8) 
Drug misuse   
No 16,412 (89.7) 16,536 (87.7) 
Yes 364 (2.0) 702 (3.7) 
IMD decile   
1 3,964 (21.7) 3,933 (20.9) 
2 3,478 (19.0) 3,645 (19.3) 
3 2,741 (15.0) 3,008 (16.0) 
4 2,040 (11.2) 2,301 (12.2) 
5 1,507 (8.2) 1,655 (8.8) 
6 1,200 (6.6) 1,183 (6.3) 
7 892 (4.9) 838 (4.4) 
8 728 (4.0) 728 (3.9) 





(not strain typed) 
Included cases 
(strain typed 
  n (column %) n (column %) 
9 663 (3.6) 610 (3.2) 
10 539 (3.0) 474 (2.5) 
Alcohol misuse   
No 16,135 (88.2) 16,260 (86.2) 
Yes 413 (2.3) 776 (4.1) 
Homelessness   
No 16,494 (90.1) 16,771 (88.9) 
Yes 373 (2.0) 666 (3.5) 
Imprisonment   
No 15,984 (87.4) 16,210 (85.9) 
Yes 370 (2.0) 649 (3.4) 
Site of TB disease   
Pulmonary smear positive 1,280 (7.0) 4,959 (26.3) 
Pulmonary smear negative 6,044 (33.0) 6,952 (36.9) 
Extra-pulmonary disease only 10,843 (59.3) 6,947 (36.8) 
IMD: index of multiple deprivation, n: number, TB: tuberculosis. 
 
6.4 Discussion 
6.4.1 Summary of findings 
The aims of this chapter were to investigate the impact of HIV on the 
infectiousness of TB patients, by examining the association between HIV co-infection 
of TB patients and the number of subsequent clustered cases, and to examine whether 
TB patients with HIV were more often due to recent infection or reactivation of LTBI. 
Pulmonary TB patients with HIV had fewer subsequent clustered cases than HIV-
negative pulmonary TB patients, and there was no association between HIV co-
infection and not being clustered. Extra-pulmonary TB cases with HIV were less likely 
to be the first case of a cluster; but if they were the first case, had a greater number of 
subsequent clustered cases than extra-pulmonary TB patients without HIV. There was 
a negative association between HIV co-infection and being a subsequent case in a 
cluster, compared to being the first case or a non-clustered case. 
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6.4.2 Strengths and limitations of the study 
This study benefitted from a large sample of all culture-positive TB cases strain 
typed at ≥23 loci in England, Wales and Northern Ireland over a five-year period, and 
represents over 50% of all TB cases in the country during this time.  The coverage was 
comparable to national studies of a similar size in the Netherlands,[72, 242] and 
considerably higher than the 31% coverage in a previous study in England which did 
not include data on HIV co-infection.[238] Studies in Norway and Denmark have 
achieved higher rates of coverage nationally (67-69% of all TB cases), however these 
studies had limited or no information on HIV status and much smaller overall sample 
sizes.[243, 244] 
24-loci MIRU-VNTR is a highly discriminative, high-throughput method of 
genotyping MTBC,[245, 246]  and has been widely used in TB cluster investigations. 
Strain typing was done at national reference laboratories according to national 
guidelines, thereby reducing measurement error and misclassification. However, 
analyses using WGS have demonstrated that identical 24-loci MIRU-VNTR profiles do 
not always have sufficiently high resolution to distinguish between closely related, but 
distinct, lineages,[69, 234] particularly in clusters of foreign-born patients.[234] As HIV 
co-infection was negatively associated with both the number of subsequent clustered 
cases (section 6.3.3) and with being recently infected (section 6.3.4), over-estimation of 
clustering among foreign-born TB patients (who are more likely to be co-infected with 
HIV, Chapter 5) may have biased our estimates of the effect of HIV on TB transmission 
towards the null. It is therefore likely that the true magnitude of the association between 
HIV and reactivation of LTBI is even greater than reported here. 
Strain typing cannot be used to confirm transmission between patients with 
identical strain types, only to refute it where strain types are different. Strain typing also 
cannot identify the direction of transmission between two individuals, which can 
sometimes be inferred (although not proven) by using WGS data to examine the 
accumulation of small genomic mutations. Furthermore, shared strain types may not 
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represent recent transmission, particularly in patients born abroad who may have been 
infected with common endemic strain types before entering the UK.[52] It is likely that 
the 54% of TB cases who were clustered in this analysis was an overestimation of the 
proportion of TB attributable to recent transmission.  
Whilst the sample size was large, only approximately 50% of TB cases 
nationally were included in this analysis as strain typing relies on culture of 
mycobacterial samples. Low sampling fractions result in underestimation of the extent 
of clustering,[60, 62] as cases can be misclassified as not-clustered if the case they 
cluster with has not been strain typed. However, it has been shown that a low sampling 
fraction does not bias estimations of risk factors associated with clustering when the 
study is sufficiently powered, because risk factors for being clustered are generally also 
risk factors for increased cluster size.[60, 62] Some of the non-strain typed cases may 
have been the first cases of clusters, meaning some subsequent cases in clusters may 
have been misclassified as the first cases. Some cases may have been misclassified 
as not being clustered due to the time limiting of the sample, however, the effect of this 
is minimal compared to that of low sampling fractions.[62] It is also possible that non-
clustered TB cases, which were assumed to be reactivation of LTBI, could be the result 
of recent infection acquired outside of England, Wales and Northern Ireland. 
Clustered TB cases were classed as being the first case or a subsequent case 
in clusters according to their earliest date of evidence of TB. Consequently, the order of 
patients within clusters may have been misclassified as patients may not present to 
care in the order in which they were infected. In particular, TB patients with HIV may 
reactivate more quickly than those who are HIV-negative, meaning they are more likely 
to develop active TB sooner, whilst people who have been diagnosed with HIV may be 
more engaged with health services and/or diagnosed with TB sooner. If this is the 
case, differential misclassification of TB patients with HIV as the first case in a cluster 
would be expected, when in fact they may just be the first patient in that cluster who 
presented to care. However, HIV-positive cases typically had fewer subsequent cases 
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and were less likely to be subsequent cases in clusters, and so any misclassification to 
this effect would have biased the results towards the null and caused underestimation 
of the impact of HIV. Furthermore, less than 50% of TB patients were aware of their 
HIV infection when diagnosed with TB (Chapter 4) and therefore this would not have 
influenced the time it took them to present to care. Where possible, symptom onset 
date was used to determine the order of patients in clusters, as much onward 
transmission will occur before a TB patient is diagnosed. 
TB cases included in the analysis were more likely to have smear-positive 
pulmonary TB and less likely to have extra-pulmonary TB only compared to cases 
which were excluded as they were not strain typed at ≥23 loci. This is unlikely to have 
biased the association between HIV and whether a case is a subsequent case in a 
cluster (section 6.3.4), as site of disease is not on the causal pathway between HIV 
and infection with or reactivation of TB. However, it may have led to overestimation of 
the odds ratio for the association between HIV and being the first case in a cluster; 
cases with only extra-pulmonary TB were less likely to be the first case in a cluster but 
also less likely to be HIV-positive (Chapter 5), and this over-representation of HIV-
negative extra-pulmonary TB cases in the analyses may have resulted in odds ratios 
closer to the null. 
Cases which were only typed at 23 loci could have been assigned to more than 
one cluster. Misclassifying which cluster a case belonged to could have led to 
misclassification of whether the case was the first or a subsequent case in a cluster. 
However, HIV status was not associated with whether a case was typed at 23 or 24 
loci, and therefore any misclassification is likely to be non-differential, and therefore 
should not have biased the results. Some cases had a mixed infection, and therefore 
could have belonged to more than one cluster; however only four cases with mixed 
infection belonged to more than one cluster and therefore any bias would be very 
minimal. 
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Similarly to Chapters 4 and 5, a composite variable was created for country of 
birth and time since entry to the UK. Due to the smaller sample size available for this 
analysis, this variable was not stratified by the incidence of TB or the prevalence of HIV 
in the patients’ country of birth, which may have confounded the associations between 
HIV and the clustering outcomes. To minimise confounding, factors associated with 
HIV co-infection of TB cases in Chapter 5 were included in the multivariable models, as 
were other factors which were considered a priori to potentially be associated with 
onwards transmission or reactivation of LTBI. However, the results may have been 
confounded by other factors not included in the model. Non-completion of treatment 
and drug resistance may differentially bias the association between HIV co-infection 
and onwards transmission of TB. Missing data meant this study lacked power to 
investigate these associations, which would benefit from further research. The 
relatively small numbers of patients with HIV and/or social risk factors in this analysis 
meant that the study did not have sufficient power to investigate interactions between 
the different social risk factors, HIV, and clustering. This could be a useful area for 
future research. 
As this was a study of routinely collected TB surveillance data, no data was 
available on the HIV status of the contacts of TB cases, which may have confounded 
the association between HIV status and the number of subsequent clustered cases. If 
the contacts of HIV-positive TB patients were more immunosuppressed, then a higher 
number of subsequent clustered cases would be expected; however pulmonary TB 
patients with HIV had fewer subsequent cases than HIV-negative pulmonary TB 
patients. Therefore, the reduction in onwards transmission of TB as a result of HIV co-
infection may have been underestimated in this study. 
Data on HIV status was not available for children (aged <15 years), and 
therefore children could not be included in this analysis. To limit bias, children were 
included when determining whether TB cases were clustered, the size of clusters and 
whether a case was the first or a subsequent case in a cluster; but then excluded from 
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the risk factor analyses. TB in children living with HIV is relatively rare in the UK 
(estimated at 196/100,000 PY from 1996-2014),[172] and therefore the impact of HIV 
on TB transmission from children is likely to be minimal. 
6.4.3 Implications of the research 
Among pulmonary TB cases, HIV co-infection was negatively associated with 
the number of subsequent clustered cases (Table 6.3), particularly for smear-positive 
patients (Table 6.2). This finding is consistent with the results of contact studies across 
high- and low-burden settings, which have found lower risks of LTBI and TB disease 
among the contacts of HIV-positive patients than HIV-negative TB patients, adding 
weight to the suggestion that patients with pulmonary TB and HIV may be less 
infectious. Among extra-pulmonary TB cases, there was a strong association between 
HIV co-infection and not being the first case of a cluster, again suggesting that patients 
with HIV are less infectious, in this case as a result of their extra-pulmonary disease. 
However, where HIV-positive extra-pulmonary TB patients were the first case of a 
cluster, they had a substantially higher number of subsequent clustered cases than 
HIV-negative extra-pulmonary TB patients. As it is generally accepted that patients with 
only extra-pulmonary TB disease are not infectious, it is unlikely that these patients are 
driving transmission within these larger clusters. It is possible that transmission within 
these clusters was driven by patients with undiagnosed TB, or patients whose strain 
type was unknown. Increased cluster size may also be the result of transmission 
chains occurring within clusters. The prevalence of HIV was higher among subsequent 
cases in clusters with an HIV-positive first case than clusters with HIV-negative first 
cases, and so it is likely that the increased size of these clusters is because the 
contacts of the infectious case are more susceptible to infection and progression to 
active disease. Regardless of whether these HIV-positive cases are the ‘true’ first case 
in a cluster or merely the first observed case in a cluster, the first observed patient is 
still a point at which interventions can be considered and targeted for cluster 
investigations. 
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Whilst extra-pulmonary TB cases may not drive transmission, the knowledge 
that extra-pulmonary TB cases with HIV can be the first detected case of a 
substantially larger cluster is important for directing cluster investigations. Furthermore, 
as around 50% of co-infected patients are only diagnosed with HIV at the time of their 
TB diagnosis (Chapter 4), targeting HIV screening to the contacts of TB patients with 
HIV could result in earlier diagnosis of HIV infections, providing the opportunity to 
initiate ART and prevent TB disease from occurring. Targeting LTBI treatment to these 
high-risk contacts could also further decrease the incidence of TB. 
A negative association was found between HIV co-infection and being a 
subsequent case in a cluster, compared to being the first case or a non-clustered case. 
This suggests that TB in patients with HIV is more often the result of reactivation of 
remotely-acquired LTBI than recent infection. These cases of TB may be preventable if 
PLHIV, particularly those born abroad, could be tested and treated for LTBI. This 
finding contrasts with that of a meta-analysis of the association between HIV and 
clustering of TB cases in HIV-endemic populations, which concluded that HIV-
associated TB was more often the result of recent infection than reactivation of 
LTBI.[92] This difference is likely the result of the different settings; the higher 
incidence of TB in the general population in countries where HIV is endemic will lead to 
a greater force of infection which may differentially affect PLHIV, who are more likely to 
be immunosuppressed. In contrast, in the UK (and other low-burden settings) the 
majority of TB cases are in foreign-born patients and transmission is generally 
considered to be minimal.[52] As there is generally less exposure to TB, HIV 
contributes more to reactivation of LTBI than to new TB infections. 
6.4.4 Conclusions 
In conclusion, pulmonary TB patients with HIV had fewer subsequent clustered 
cases than patients without HIV. However, when patients with HIV and extra-
pulmonary TB were the first case of a cluster, they had a higher number of subsequent 
cases. HIV prevalence was higher among the subsequent cases of HIV-positive first 
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cases than the subsequent cases of HIV-negative first cases, suggesting that the 
higher number of subsequent cases for extra-pulmonary TB patients with HIV is 
because their contacts are more susceptible to infection and progression of disease. 
These findings suggest that overall, pulmonary TB patients with HIV are less infectious. 
Furthermore, TB cases with HIV were less likely to be a subsequent case within a 
cluster, which suggests that HIV-associated TB is more often due to reactivation of 
LTBI rather than recent infection. The contacts of HIV-positive TB patients could be a 
useful target population for HIV testing, as the prevalence of HIV was higher among 
contacts of HIV-positive TB cases. More widespread testing for LTBI and preventive 
therapy among people living with HIV could decrease the incidence of TB occurring 
due to reactivation of LTBI. 
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7 Discussion 
7.1 Key findings 
This thesis aimed to improve our understanding of the epidemiology of TB-HIV 
co-infections and the role of HIV in TB transmission in England, Wales and Northern 
Ireland. This was addressed with the following objectives: 
 To conduct a review of the literature for risk factors for TB among people with 
HIV in countries with low TB incidence (Chapter 2). 
 To link the national TB and HIV surveillance datasets held by Public Health 
England to identify co-infected patients (Chapter 3). 
 To describe the epidemiology of TB-HIV co-infections in England, Wales, and 
Northern Ireland, and investigate risk factors for developing TB for people 
diagnosed with HIV (Chapter 4). 
 To examine trends in HIV co-infection among TB cases in England, Wales and 
Northern Ireland, and identify factors associated with HIV co-infection of TB 
cases (Chapter 5). 
 To investigate the influence of HIV on TB transmission by examining 
associations between HIV co-infection of TB cases and the number of 
subsequent clustered cases, and determining whether HIV co-infection is 
associated with reactivation of LTBI or recent infection with TB (Chapter 6). 
These objectives were successfully achieved, with some limitations – as 
described in the relevant chapters. The results and implications from these studies are 
described below. 
The results chapters of this thesis commenced with a review of the literature on 
risk factors for latent and active TB among PLHIV in countries with low TB incidence in 
Chapter 2. This review found that sociodemographic risk factors for LTBI and active TB 
among PLHIV were similar, but that there were differences in clinical risk factors. There 




Hispanic ethnicities than people of white ethnicity, and higher rates among PLHIV born 
outside of low-incidence countries, particularly those born in countries with high TB 
incidence. People who had acquired HIV through injecting drug use or heterosexual 
sex had higher rates of both LTBI and active TB than MSM. There was some evidence 
that social risk factors such as drug misuse, homelessness, and imprisonment were 
associated with TB. Exposure to a contact with TB and having had TB previously were 
both associated with higher risk of LTBI, but the studies of active TB did not report on 
these risk factors. There was strong evidence that low CD4 count, high viral load and 
being ART-naïve increased the risk of active TB for PLHIV; however, there was 
generally no association between these factors and the risk of LTBI. This may be 
because diagnostic tests for LTBI are less sensitive in immunocompromised people; or 
because immunosuppression does not increase the risk of infection, just the risk of 
progression from LTBI to active TB disease. 
In Chapter 3, a new method was developed to link the TB and HIV surveillance 
datasets for England, Wales and Northern Ireland, which was relatively quick, 
repeatable, and had no subjective bias. The linked datasets were then used to analyse 
risk factors associated with TB among PLHIV and risk factors for HIV co-infection 
among TB patients in England, Wales and Northern Ireland in Chapters 4 and 5, 
respectively. 
In England, Wales and Northern Ireland, six percent of PLHIV diagnosed with 
HIV between 2000 and 2014 were found to have had a TB diagnosis, and over half of 
these were not aware of their HIV infection prior to their TB diagnosis (Chapter 4). 
Patients diagnosed simultaneously with TB and HIV were often born in countries with 
high TB incidence and acquired HIV through heterosexual sex, both factors which were 
also associated with development of TB after an HIV diagnosis. Other factors 
associated with developing TB for PLHIV included HIV acquisition by injecting drug 




In chapter 5, trend analyses showed that the number and proportion of persons 
diagnosed with TB who were co-infected with HIV declined from 2005 to 2014; likely a 
result of an increase in the number of TB patients from south-east Asian countries, 
where the prevalence of HIV is low, and a decrease in both the number and proportion 
of TB patients with HIV from sub-Saharan Africa, due to decreases in migration from 
this area and declining rates of HIV co-infection among TB patients in these countries. 
Within the overall decline in the number of TB patients with HIV over the study 
period, there was a shift in the pattern of the timing of TB and HIV diagnoses with an 
increasing proportion of co-infected patients being aware of their HIV infection at the 
time of their TB diagnosis, reflecting improved efforts to diagnose HIV early and a 
reduction in PLHIV who were only diagnosed with HIV as a result of their TB diagnosis. 
The risk of HIV co-infection was higher for women and for persons born in countries 
with high HIV prevalence (particularly people of black African ethnicity). HIV co-
infection was more common among patients with miliary or meningeal TB than 
pulmonary TB, but less common among patients with other forms of extra-pulmonary 
TB only. In a sub-analysis of five years of data (2010-2014) for which data on social 
risk factors was available, drug misuse was the only social risk factor independently 
associated with HIV infection, although co-infection was more common in patients with 
any social risk factor, and there was substantial overlap between risk factors. 
Chapter 6 examined the role of HIV in the transmission of TB at the population-
level in England, Wales and Northern Ireland. Patients with pulmonary TB and HIV had 
fewer subsequent clustered cases than pulmonary TB patients without HIV. However, 
when patients with HIV and extra-pulmonary TB were the first case of a cluster, they 
had a higher number of subsequent clustered cases. As it is unlikely that these patients 
are actually the first in the transmission chain, it is possible that the increased cluster 
size is a result of more extensive TB screening among their contacts in order to find the 
source case. Furthermore, HIV prevalence was higher among the subsequent cases of 




higher number of subsequent clustered cases for some HIV-positive TB cases may 
therefore be because their contacts are more susceptible, rather than because they are 
more infectious. TB cases with HIV were less likely to be a subsequent case in a 
cluster, suggesting they are more likely the result of reactivation of LTBI than recent 
infection. 
7.2 Implications and recommendations 
A number of factors have contributed to the observed decrease in the number 
of patients co-infected with TB and HIV. The demographics of TB patients in the UK 
have changed; a decrease in migration from sub-Saharan Africa has led to fewer TB 
patients from this area,[52, 247] and the decreasing proportion who are co-infected 
with HIV reflects decreasing rates of HIV co-infection among TB patients in sub-
Saharan African countries.[1] There has also been an increase in the number of TB 
patients from south-east Asian countries where the prevalence of HIV is low,[52] which 
also contributed to the decline in the proportion of TB cases with HIV co-infection in the 
UK. The decline can also partly be attributed to the improved health of PLHIV in the 
UK. There have been increases in HIV testing,[223] which led to earlier diagnosis of 
HIV (evidenced by an increase in the average CD4 count at HIV diagnosis) and earlier 
initiation of ART;[222] with the overall result being less immunosuppression among 
PLHIV. 
Within the decline of the number of patients co-infected with TB and HIV from 
2004 to 2014, there was a shift in the pattern of diagnoses with an increasing 
proportion of patients being aware of their HIV infection prior to their TB diagnosis. The 
decline in the number of co-infected patients who were diagnosed with TB more than 
91 days before their HIV diagnosis is a result of widespread HIV testing in TB clinics. 
HIV testing of all new TB patients has been recommended by BHIVA since 2008,[220] 
but has increased in recent years. In 2012, national data on HIV testing was available 
for 64% of TB cases with previously unknown HIV status, of whom 87% were tested for 




unknown HIV status and 93% had received HIV testing.[52, 124] Despite the decline in 
the number of co-infected patients, the substantial proportion of patients who are 
diagnosed with TB and HIV simultaneously demonstrate the continuing importance of 
testing new TB patients for HIV.  Over the duration of the study period, BHIVA 
increased the CD4 threshold at which initiation of ART is recommended, which led to a 
healthier population of PLHIV; it is likely that this contributed to the decrease in the 
number of patients who developed TB after their HIV diagnosis. The recent (2015) 
recommendation that ART be initiated regardless of CD4 count should continue this 
trend and further decrease TB in PLHIV. 
 Recommendation: ART should continue to be offered to PLHIV regardless 
of their CD4 count to reduce the incidence of TB. 
Whilst the number of people with TB and HIV in the UK is relatively small and is 
declining, TB-HIV co-infection remains an important clinical problem for those who are 
affected by it. HIV co-infection complicates diagnosis of TB, due to decreased 
sensitivity of diagnostic tests for LTBI among PLHIV,[103, 104] lower rates of sputum 
smear-positivity among PLHIV with TB,[105] and atypical presentation of TB through 
higher rates of miliary and other extra-pulmonary TB which are difficult to 
diagnose.[110, 248] HIV co-infection also complicates the management of TB patients 
due to drug interactions, IRIS, and higher rates of relapse and acquired drug resistance 
on some TB treatment regimens.[110] TB also substantially increases the risk of death 
for PLHIV; a recent study found an almost five-fold increased hazard of death among 
PLHIV with TB than those without.[98] 
The increasing proportion of patients who are diagnosed with HIV first, and TB 
subsequently, suggests that there are missed opportunities to prevent TB from 
developing in people with diagnosed HIV. This is supported by the data presented in 
Chapter 6 which showed that TB cases with HIV were less likely to be later cases in 
strain type clusters and more likely to be the first case or a non-clustered case, 




acquired LTBI than recent infection. BHIVA and NICE both recommend screening for 
and treating LTBI among PLHIV; the guidelines on eligibility for LTBI testing are based 
on combinations of TB incidence in the person’s country of birth, CD4 count and 
whether the patient has initiated ART.[110, 249] However, a recent survey of 
healthcare providers found that LTBI screening of PLHIV was only offered in 57% of 
geographical areas across the UK; and of those, few complied fully with the BHIVA and 
NICE guidelines (33.5% and 6.5% respectively).[208] Greater promotion of testing for 
and treating LTBI among PLHIV could prevent reactivation of LTBI from occurring and 
reduce the incidence of HIV-associated TB. Further research is required to understand 
whether the barriers to testing and treating LTBI are occurring at the clinic level (i.e., 
are testing and treatment for LTBI being offered) or at the patient level, and how these 
barriers can be overcome to improve the uptake of LTBI testing and treatment. 
 Research question: Is low uptake of LTBI testing and treatment a result of 
it not being offered, not being taken up, or treatment not being completed? 
 Research question: What interventions could be used to improve the 
uptake of LTBI testing and treatment, and are they cost effective for PLHIV? 
Targeting testing and treatment of LTBI to high-risk populations of PLHIV is 
essential to make best use of resources. The risk factor analyses presented in 
Chapters 4 and 5 highlighted that people of black African ethnicity or who were born in 
countries with high levels of TB and HIV have substantially higher rates of co-infection, 
as do PLHIV who were diagnosed late, those with low CD4 counts, and those who 
have not initiated ART. Increasing HIV testing among people born in high-incidence 
countries, people of black African ethnicity, and PWID is essential for earlier diagnosis 
of HIV. The investigation of risk factors for co-infection was limited to persons who 
were diagnosed and reported to the national TB and HIV surveillance systems (HARS 
and ETS). Therefore, as well as the populations that were identified as high-risk for TB-
HIV co-infection, further work could examine whether there are other 




which could be used to develop more targeted screening programs. In particular, the 
literature review showed some evidence that imprisonment and homelessness were 
risk factors for developing TB for PLHIV. In Chapter 5, both of these factors were 
associated with high proportions of HIV co-infection in univariable analyses, although 
not independently. The review of the literature in Chapter 2 found no studies which 
prospectively examined homelessness or imprisonment as risk factors for active TB; 
and the studies which examined associations with LTBI had mixed results and were 
often small and potentially lacking in power. This could be a useful area for further 
research and targeted screening. 
 Research question: What is the incidence of TB among PLHIV who are 
homeless or in prison? 
 Research question: Is screening people with social risk factors for HIV and 
LTBI an effective and cost-effective method of active case-finding? 
 Research question: Are other sociodemographic factors, such as smoking 
status, occupation, income or housing density, associated with higher rates 
of TB-HIV co-infection? 
 The current BHIVA and NICE guidelines for testing and treating LTBI are 
based on TB incidence in country of birth, CD4 count and ethnicity; the results 
presented in this thesis support these recommendations. However, the incidence of TB 
among PLHIV who acquired their HIV infection through injecting drug use was 
comparable to that of black African PLHIV born in countries with high TB incidence, 
and this was reflected in the high proportion of HIV co-infection among TB patients with 
a history of drug misuse. Consequently, testing for and treating PWID for LTBI is likely 
to be of benefit. As drug use was associated with recent infection with MTBC, whereas 
being born abroad was associated with reactivation of LTBI (section 6.3.4), repeated 
testing of PWID for LTBI may be warranted due to the ongoing risk of new infection. 
The optimal frequency at which testing should be offered to maximise efficacy and 




also higher rates of HIV co-infection among TB patients with other social risk factors, 
such as homelessness and imprisonment. Whilst these factors were not independently 
associated with HIV co-infection, the substantial proportion of overlap in these 
populations mean that they could be useful target populations for screening for and 
treating LTBI. The efficacy and cost-effectiveness of LTBI screening among these 
groups, and the frequency at which it should be conducted, should be evaluated. 
 Recommendation: BHIVA guidelines for offering LTBI testing and 
treatment should be extended to include PWID. 
 Research question: At what frequency should PWID be offered LTBI 
testing and treatment to maximise efficacy and cost-effectiveness of the 
screening programme? 
Pulmonary TB cases with HIV co-infection had fewer subsequent clustered 
cases than pulmonary TB cases without HIV, contributing to the body of evidence that 
TB patients with HIV are less infectious. This, in combination with the fact that TB 
patients with HIV are more likely to be the result of reactivation of LTBI than recent 
infection, suggests that HIV is not a substantial contributor to TB transmission in 
England, Wales and Northern Ireland. PHE guidelines on when to conduct cluster 
investigations suggest that a case within a cluster with HIV may be an indicator of 
recent transmission.[237] The results from this study, which used national surveillance 
data over a five year period, suggested that HIV co-infection does not increase 
infectiousness and was more frequently associated with reactivation of LTBI than 
recent infection.  However, as PLHIV have higher rates of progression from LTBI to 
active TB, the absolute risk of TB as a result of recent infection is likely higher for 
PLHIV than for HIV-negative people, and consequently clusters of TB involving PLHIV 
may still merit investigation. 
In contrast with pulmonary TB cases, extra-pulmonary TB cases with HIV had a 
higher number of subsequent cases than HIV-negative extra-pulmonary TB cases. TB 




cluster, but investigating these cases when they first present with symptoms could lead 
to earlier diagnosis of other patients within the cluster, thereby improving treatment 
outcomes and reducing further transmission from other cases within the cluster. 
Furthermore, HIV was more prevalent among the subsequent cases of HIV-positive 
first cases than the subsequent cases of HIV-negative first cases. As a substantial 
number of co-infected patients were unaware of their HIV infection until their TB 
diagnosis, targeting HIV testing towards the contacts of co-infected patients could be a 
useful method for identifying undiagnosed HIV infections in people at risk of developing 
TB. Diagnosing these people with HIV sooner, initiating ART and testing for and 
treating LTBI could further reduce TB incidence. The potential yield and cost-
effectiveness of such a screening program could be investigated. 
 Research question: Is offering HIV testing to the contacts of TB patients 
with HIV a cost-effective method of identifying undiagnosed HIV infections in 
people at high risk of TB? 
7.3 Conclusions 
The linkage of two comprehensive national surveillance datasets for TB and 
HIV allowed epidemiological investigations into TB-HIV co-infection on a national scale. 
There was a substantial decline in TB-HIV co-infection in England, Wales and Northern 
Ireland from 2005 to 2014. The number and proportion of co-infected patients who 
were not aware of their HIV infection at the time of their TB diagnosis has decreased, 
however a substantial proportion of co-infected patients are still diagnosed 
simultaneously with TB and HIV, and this could be further reduced. More screening for 
HIV in populations at risk of both TB and HIV – particularly people of black African 
ethnicity, people born in high-incidence countries, and people who inject drugs, but 
potentially also people with a history of homelessness or imprisonment – would lead to 
earlier diagnosis of HIV and enable TB to be prevented by initiating ART. Among 
people with diagnosed HIV, ART was highly protective against TB, however many of 




TB. Linkage to HIV care and ART initiation have improved over the course of this study 
and continue to improve, which is likely to further decrease TB among PLHIV. TB 
patients with HIV appear to be less infectious than HIV-negative TB patients, and HIV 
co-infection of TB cases was associated with reactivation of LTBI rather than recent 
infection. Consequently, there is an opportunity to prevent these TB cases by 
screening for and treating LTBI. Improving adherence to the BHIVA and NICE 
guidelines on LTBI screening and treatment – and expanding these guidelines to 
include people who inject drugs – could prevent reactivation of LTBI in PLHIV, thereby 
reducing the incidence of TB. 
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9.1 Supporting information for Chapter 2: Detailed search terms 
and search results from the systematic review 
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#
5 
Search (((("american samoa" or andorra or antigua or barbuda or australia or austria or barbados or 
belgium or bermuda or bonaire or “eustatius” or “saba” or "british" or "virgin islands" or canada or "cook 
islands" or cuba or curacao or cyprus or czech* or denmark or finland or france or germany or greece or 
grenada or hungary or iceland or ireland or EIRE or israel or italy or jamaica or jordan or luxembourg or malta 
or monaco or montserrat or netherlands or "new zealand" or NZ or niue or norway or oman or "puerto rico" or 
"saint kitts" or "nevis" or "saint lucia" or "st lucia" or "st vincent" or "saint vincent" or grenadines or "san 
marino" or seychelles or "sint maarten" or "st maarten" or slovakia or slovenia or sweden or switzerland or 
tokelau or turks or caicos or "united arab emirates" or UAE or UK or "united kingdom" or "great britain" or 
"england" or scotland or wales or "united states" or "united states of america" or USA or US or "wallis and 
futuna islands" or "west bank" or gaza)))) AND ((tuberculosis[MeSH Terms]) AND ((hiv[Title]) OR ("human 
immunodeficiency virus"[Title]) OR (anti-retroviral[Title]) OR (antiretroviral[Title]) OR (ART[Title]) OR 




Search ((tuberculosis[MeSH Terms]) OR (mycobacterium tuberculosis[MeSH Terms]) OR 
(tuberculosis[Title]) OR (tb[Title])) AND ((hiv[Title]) OR ("human immunodeficiency virus"[Title]) OR (anti-




Search (("american samoa" or andorra or antigua or barbuda or australia or austria or barbados or 
belgium or bermuda or bonaire or “eustatius” or “saba” or "british" or "virgin islands" or canada or "cook 
islands" or cuba or curacao or cyprus or czech* or denmark or finland or france or germany or greece or 
grenada or hungary or iceland or ireland or EIRE or israel or italy or jamaica or jordan or luxembourg or malta 
or monaco or montserrat or netherlands or "new zealand" or NZ or niue or norway or oman or "puerto rico" or 
"saint kitts" or "nevis" or "saint lucia" or "st lucia" or "st vincent" or "saint vincent" or grenadines or "san 
marino" or seychelles or "sint maarten" or "st maarten" or slovakia or slovenia or sweden or switzerland or 
tokelau or turks or caicos or "united arab emirates" or UAE or UK or "united kingdom" or "great britain" or 
"england" or scotland or wales or "united states" or "united states of america" or USA or US or "wallis and 




Search (tuberculosis[MeSH Terms]) OR (mycobacterium tuberculosis[MeSH Terms]) OR 




Search (hiv[Title]) OR ("human immunodeficiency virus"[Title]) OR (anti-retroviral[Title]) OR 









Age Ethnicity Country of birth or residence Sex Pregnan
cy 
Route of HIV 
infection 
Drug misuse 












Risk of QFT-GIT positivity was 
increased for participants from other 
European countries (compared to 
Austria) and even higher among 
participants from African countries. The 
risk was positively correlated with TB 
incidence in country of birth. 
Men were 
less likely to 
be QFT-GIT 
positive. 
- Route of HIV 












- Birth or residence in a country with TB 
incidence >100/100,000 was 
associated with IGRA-positivity in 
multivariable analysis. 
Men were 
less likely to 
be IGRA-
positive but 





- - - 
Brassard, 2009 - - Patients from Africa or Haiti had higher 
prevalence of TST positivity than 
patients from Canada. 
- - There were 
significant 
differences in TST 
positivity by route of 
HIV infection, but 
they were not 
described. 
- 






- Long-term residence in a country with 
TB incidence >25/100,000 was 
positively associated with positive 
QFT-IT. 





- - Injecting drug 




Cheallaigh, 2013 Age was not 
significantly 
- Being from a country with TB incidence 
>100/100,000 was positively 
Sex was not 
significantly 
- - Injecting drug 

















with QFT-IT or 
T-SPOT.TB 
positivity 














Participants born outside of the 
mainland USA had higher rates of TST 
conversion. Not significant when 
Asians were excluded from the 
analysis. 






- - Recreational 




Elzi, 2007 Age was not 
associated with 
TST positivity. 
- Being from sub-Saharan Africa was 
strongly associated with TST positivity. 
Being from eastern Europe, east Asia 
or the Caribbean was also associated 
with TB positivity. 
Women 
were less 










injecting drug use or 
unknown route, 
compared to MSM. 
- 




- - - 




rates of TST 
conversion 
than white 




- Compared to men 
who have sex with 
men, TST positivity 
was higher for 
people who inject 
drugs or who have a 





individuals. drugs, and even 
higher if both criteria 
apply 
Girardi, 2002 Age was not 
associated with 
TST conversion. 




- - Injecting drug 



















Higher TB incidence in country of birth 
was positively associated with 
increased odds of T-SPOT.TB 
positivity. 





- - - 
Luetkemeyer, 
2007 










TB incidence ≥25/100,000 in country of 
birth was associated with higher 
prevalence of QFT-GIT positivity in 
multivariable analysis. There was no 
association between country of birth 
and TST positivity. 





- - Injecting drug 




McLaughlin, 2003 - - - All 
participants 
were men. 
- - - 
Mofenson, 1995 There was a 
trend towards 
older patients 






















- Higher rates of 











Pullar, 2014 Age was not 
significantly 
associated with 
QFT-GIT or TST 
positivity. 
- Being born in a TB-endemic country 
was positively associated with TST and 
QFT-GIT positivity but the risk 
decreased with time since migration. 




GIT or TST 
positivity. 
- - - 
Schulte, 2002 Age was not 
associated with 
TST positivity. 
- Foreign-born patients were more likely 










- Injecting drug 




Stephan, 2008 Age was not 
associated with 







GIT, TST or 
T-SPOT.TB 
positivity. 
Higher rates of TST positivity among 
participants from countries with high 
TB prevalence. 
Sex was not 
associated 
with QFT-
GIT, TST or 
T-SPOT.TB 
positivity. 
- Route of HIV 
infection was not 
associated with 
QFT-GIT, TST or T-
SPOT.TB positivity. 
Injecting drug 













Lead author, year Alcohol misuse Homelessness Imprisonment Contact with TB 
or other close 




Aichelburg, 2009 - - - - - - - 
Bourgarit, 2015 - Collective living (in a 




- People with a 
contact with TB, 
or people who 
did not know if 
they had a 
contact with TB, 
had higher rates 
of IGRA 
positivity. 
- - - 
Brassard, 2009 - - - - - - - 





- - Exposure to a 
smear-positive 





- - - 










Having a close 


















Those who have 
ever lived in a 
homeless shelter 
had higher rates of 
TST conversion. 
Having ever been 
incarcerated was 
not associated with 
TST conversion. 
- - - - 
Elzi, 2007 - - - - - - - 




Gampper, 1998 - - - - - - - 
Girardi, 2002 - - - - - - - 
Kall, 2012 - - - - - - - 
Luetkemeyer, 2007 - Homelessness in the 
previous year was 
not associated with 
LTBI prevalence. 
- Living or working 
in a homeless 




with higher rates 
of TST positivity 
in multivariable 




with an active TB 
case was not 
associated with 
TST or QFT-GIT 
positivity. 
- - - 
McLaughlin, 2003 - - All participants 




different in the 
dormitory of the 
source patient than 
in other dormitories 
over the same time 
period. 
All participants 






patients on the 
same side of the 
dormitory as the 
source patient 
and patients 
exposed to the 
source patient 
for a longer time 





Mofenson, 1995 - Homelessness and 
living in a shelter 










a close contact 













Pullar, 2014 - - - Contact with a 
TB case was 
associated with 







QFT-GIT or TST 
positivity. 
- - - 





exposed to a TB 
case. No TST 
positivity among 
people who had 
not been 
exposed. 
- - - 
Stephan, 2008 - Being homeless or 
living in a shelter 
was not associated 
with QFT-GIT, TST 
or T-SPOT.TB 
Imprisonment was 
not associated with 
QFT-GIT, TST or T-
SPOT.TB positivity. 
- - Receiving 
public social 







positivity. TST or T-
SPOT.TB 
positivity. 







9.3 Supporting information for Chapter 2: Clinical factors associated with latent tuberculosis infection 
Lead author, year CD4 count Other 
anergy / 
DTH 
Viral load Anti-retroviral 
therapy 
BCG vaccination 
Aichelburg, 2009 QFT-GIT result was not associated with 
median CD4 count but participants with 
CD4 <200 were less likely to be QFT-
GIT-positive. 










Bourgarit, 2015 Participants with higher CD4 count had 
non-significantly higher rates of IGRA 
(QFT-GIT or T-SPOT.TB) positivity. 
- No significant association 
between median viral load and 
IGRA-positivity 
- No significant 
association between 
BCG vaccination and 
IGRA positivity. 
Brassard, 2009 Higher baseline CD4 count was 
associated with higher rates of TST 
positivity. 
- - No significant 
association between 
ART and TST 
positivity. 
- 
Brock, 2006 No significant association between CD4 
count and QFT-GIT positivity. 
- No significant association 




ART and QFT-GIT 
result. 
- 
Cheallaigh, 2013 No significant association between CD4 
count and T-SPOT.TB, but increased 
CD4 count was positively associated 
with QFT-GIT positivity. 
- No significant association 
between viral load and QFT-
GIT or T-SPOT.TB result. 
No significant 
association between 
ART and QFT-GIT or 
T-SPOT.TB positivity. 
- 
Doshi, 2012 Participants whose CD4 count 
increased from baseline had increased 
odds of TST conversion, compared to 
participants whose CD4 count 
decreased. 
- No significant association 
between viral load and TST 
conversion 
- - 
Elzi, 2007 CD4 count was positively associated 
with TST positivity. 
- Lower viral load was 
associated with TST positivity. 
ART was negatively 
associated with TST 
positivity. 
- 
French, 2006 There was a non-significant positive 
correlation between CD4 count and 
- No significant association 
between viral load and TST 






TST positivity. positivity. with time since 
initiation of ART. 
Gampper, 1998 - - - - - 
Girardi, 2002 Increased CD4 count was associated 












No significant association 
between viral load and TST 
conversion. 
All patients were on 
ART. 
- 
Kall, 2012 No significant association between CD4 
count and T-SPOT.TB positivity. 
- - No significant 
association between 
ART and T-SPOT.TB 
positivity. 
- 
Luetkemeyer, 2007 Higher nadir CD4 count was associated 
with higher rates of TST and QFT-GIT 
positivity in univariable analyses, but 
not in adjusted analyses. 
- No significant association 








BCG vaccination and 
TST or QFT-GIT 
positivity. 
McLaughlin, 2003 No significant association between CD4 
count and TST positivity. 
- No significant association 




ART and TST 
positivity. 
- 
Mofenson, 1995 - - - - - 
Pullar, 2014 Nadir CD4 count >350 was associated 
with higher rates of TST and QFT-GIT 
positivity. 
- - Patients on ART had 
lower rates of QFT-
GIT and TST 
positivity, but the 
association was not 
significant. 
- 
Schulte, 2002 - - - - - 




higher median CD4 count than QFT-
GIT-negatives but there was no 
significant association between nadir 
CD4 count and QFT-GIT positivity. CD4 
count was not associated with TST or 
T-SPOT.TB positivity. 
between viral load and QFT-
GIT, TST or T-SPOT.TB 
result. 
association between 
ART and QFT-GIT, 







Lead author, year Previous TB 
disease 














Aichelburg, 2009 Previous active TB 








disease did not 
differ by QFT-GIT 
status. 
- - - - - 
Bourgarit, 2015 Previous active TB 








participants had a 




- - - - 
Brassard, 2009 - - - - - - 
Brock, 2006 Participants with a 
previous TB 
diagnosis had 
higher rates of 
QFT-GIT positivity. 
- - No significant 
association between 
prior AIDS diagnosis 
and positive QFT-GIT. 





number of years 
since HIV diagnosis 
and QFT-GIT 
positivity. 
Cheallaigh, 2013 - - - - - - 
Doshi, 2012 - - - - - - 
Elzi, 2007 - - - - - - 
French, 2006 - - - - - - 
Gampper, 1998 - - - - - - 




was not significantly 
associated with TST 
conversion. 
Kall, 2012 - - - - - - 








between prior TB 
and TST positivity. 
Prior TST positivity 
was associated 
with a positive TST 
result and a 
positive QFT-GIT 
result. 
Higher rates of 
previous 
treatment for LTBI 
among 
participants who 
tested TST or 
QFT-GIT positive 
- - - 
McLaughlin, 2003 - - - - - - 
Mofenson, 1995 - - - - - - 
Pullar, 2014 Higher rates of 
QFT-GIT and TST 
positivity among 
patients with a 
previous TB 
diagnosis. Only 
half of those 
previously treated 
for active TB had a 
positive QFT-GIT. 
- - Prior AIDS diagnosis 
was not significantly 
associated with IGRA 
positivity. 
- Decreasing risk of 
QFT-GIT positivity 
for each year since 
HIV diagnosis in 




TST positivity and 
time since HIV 
diagnosis. 
Schulte, 2002 - - - Prior AIDS diagnosis 
was not significantly 
associated with TST 
positivity. 
- No association 
between HIV being 
undiagnosed at the 
first prenatal visit 
and TST positivity. 
Stephan, 2008 More QFT-GIT or 
T-SPOT.TB 
positive 
participants had a 
- - Higher proportion of 
TST-positive 
participants had a 
prior AIDS diagnosis 
- No association 
between time since 












AIDS: acquired immunodeficiency syndrome. ART: anti-retroviral therapy. BCG: Bacillus Calmette-Guérin. DTH: delayed-type hypersensitivity. IGRA: 




9.4 Supporting information for Chapter 2: Sociodemographic factors associated with active tuberculosis disease 
Lead author, year Age Ethnicity Country of birth or residence Region Sex 
Abgrall, 2010 Age was not 
significantly 
associated with risk 
of TB among both 
migrant and non-
migrant patients. 
- Risk of TB was higher among 
patients originating from sub-
Saharan Africa and other 
migrants than patients born in 
France. 
Among non-migrant patients, risk of 
TB was lower  among residents of 
southern France and other/Reunion 
Island compared to residents of 
Paris area. Among migrant 
patients, there was no significant 
association between region of care 
and risk of TB. 
Grouped with route 
of HIV infection 
Aichelburg, 2009 - - Country of origin not 
significantly associated with 
active TB 
- - 
Antonucci, 1995 Age was not 
significantly 
associated with risk 
of TB in an 
unadjusted 
analysis. 
- - Place of residence 
(North/central/south Italy) was not 
significantly associated with risk of 
TB in unadjusted analysis. 
Sex was not 
significantly 
associated with risk 
of TB in unadjusted 
analysis. 
Brassard, 2009 Mean age of TB 
patients was 
significantly lower 
than entire cohort. 
- Canadian born less likely to 
have TB on univariable analysis 
(no figures shown) 
- Lower proportion of 
males had TB 
compared to entire 
cohort. 
Dooley, 1992 Age was not 
significantly 
associated with risk 
of TB. 
- - - Sex was not 
significantly 
associated with risk 
of TB on crude 
analysis 
Elzi, 2007 Age was not 
significantly 
associated with risk 
of TB. 
- Being from sub-Saharan Africa 
was associated with a higher 
risk of TB. 
- Sex was not 
significantly 
associated with risk 
of TB. 
Girardi, 2000 Age was not 
significantly 
associated with risk 
- Country of birth was not 
significantly associated with risk 
of TB. 
Place of residence 
(North/central/south Italy) was not 
significantly associated with risk of 
Sex was not 
significantly 




of TB. TB. of TB. 
Grant, 2009 Age was not 
significantly 
associated with risk 
of TB. 
Compared to white 
participants, Black 
African and Other 
ethnic groups had 
higher risk of TB. 
- - Grouped with route 
of HIV infection 
Gupta, 2015 Participants 
between 36-55 
years had lower risk 
of TB compared to 
those 16-35 years. 
No significant risk in 
participants 56 
years or more. 
Compared to 
whites, Black 
African, south Asian 
and other 
ethnicities had 
higher risk of TB. 
- - Sex was not 
significantly 
associated with risk 
of TB. 
Hasse, 2014 Participants >40 
years had 
significantly higher 
risk of TB in both 
ART sub-groups (no 
previous ART and 
current ART). 
- Compared to those from 
Europe/North America/Australia, 
participants from other regions 
had higher risk of TB in both 
ART sub-groups. 
- - 
Jones, 2000 Age was not 
significantly 
associated with risk 
of TB. 
Ethnicity was not 
significantly 
associated with risk 
of TB. 
Compared to US-born, foreign-
born participants had a 
significantly higher risk of TB. 
- Women had a lower 
risk of TB disease 
than men. 
Karo, 2014 Age was not 
significantly 
associated with risk 
of TB in both ART 
subgroups (never 
started cART and 
patients on cART) 
- Persons from SSA had higher 
risk of TB compared to those 
from Germany in both ART sub-
groups 
- Sex was not 
significantly 
associated with risk 
of TB in both ART 
sub-groups. 
Manavi, 2016 Age was not 
significantly 
associated with TB 
incidence.  
Ethnicity was not 
significantly 
associated with TB 
incidence.  
Compared to participants from 
low-incidence countries those 
from medium-incidence 





higher risk of TB, and the risk 
was even greater for patients 
from sub-Saharan Africa. 
Maniewski, 2016 Age was not 
significantly 
associated with risk 
of TB on crude 
analysis. 
Among patients 
with TB, 83% were 
Africans, and 14% 
were Caucasian 
while among those 
without TB 45% 
were Africans, and 
48% were 
Caucasian. 
- - Sex was not 
significantly 
associated with TB 
on crude analysis. 
Markowitz, 1997 - Blacks had a higher 




ethnicity was not 
significantly 
associated with risk 
of TB. 
- Compared to residents of the 
Western USA, the risk was not 
significantly higher for patients from 
the Midwest, but was higher for 
patients from the eastern USA. 
Sex was not 
significantly 
associated with risk 
of TB. 
McLaughlin, 2003 - All TB patients were 
black, compared to 
89% of the study 
population. 
- - - 
Miguez-Burbano, 
2003 
- - - - - 
Mohle-Boetani, 2002 - - - - All men 
Mor, 2013 Increasing age was 
significantly 
associated with 
higher risk of TB. 
- Analysis restricted to non-Israel 
born participants. Risk of TB 
higher with increasing interval 
(in years) from arrival in Israel to 
HIV diagnosis. 
- Males had 
significantly higher 
risk of TB. 
Moro, 2000 Age was not 
significantly 
associated with risk 
- - - Sex was not 
significantly 




of MDR-TB. of MDR-TB. 
Pettit, 2011 Age was not 
significantly 
associated with risk 





TB cases. Among 
TB cases, 39% 
were Blacks 
compared to 29% 
among non-TB 
cases. 
Higher proportions of foreign-
born with TB cases. Among TB 
cases, 21% were foreign-born 
compared to 5% among non-TB 
cases. 
- Significantly higher 
proportion of males 
among TB cases. 
Among TB cases, 
91% were males 
while among non-TB 
cases 76% were 
males. 
Pettit, 2016 Age was not 
significantly 
associated with risk 
of TB on crude 
analysis. 
Higher proportions 
of Blacks among 
those with TB 
Higher proportions of foreign-
born among TB cases. Among 
TB cases, 19% were foreign-
born, compared to 5% among 
non-TB cases. 
- Similar proportion of 
males among TB 
cases and non-TB 
cases.  
Rice, 2013 Age was not 
significantly 







Other ethnic groups 
had a significantly 
higher risk of TB. 
No significant risk 
for Black 
Caribbean. 
No association between country 
of birth and risk of TB. 
Participants infected with HIV 
abroad (outside UK) had a 
significantly higher risk of TB. 
- Men had a 
significantly higher 
risk of TB. 
Rubinstien, 1996 - - - - 26/27 patients that 
developed TB were 
males. 
Sackoff, 2001 - - - - - 
Sterling, 2011 Age was not 
significantly 
associated with risk 
of TB. 
Compared to  white 
participants, black 
African Canadians, 
Hispanic and 'other' 
participants had 
higher risk of TB in 
- - Sex was not 
significantly 






analysis. The risk of 
TB was higher for 
black African 
Americans, but the 
significance was 
borderline in a 
multivariable model. 
Sudre, 1996 Age was not 
significantly 
associated with risk 
of TB. 
- Compared to participants from 
Switzerland, those from 
Portugal, eastern Europe, 
Brazil, Africa, other resource-
poor countries had a higher risk 
of TB. TB risk of participants 
from other industrialised 
countries was similar to those 
from Switzerland. There was no 
significant risk among 
participants  with unknown 
country of origin 
- Sex was not 
significantly 
associated with risk 
of TB. 
Taarnhoj, 2011 Participants < 40 
years had a higher 
risk of TB on 
univariable analysis. 
Age was not 
significantly 
associated with risk 
of TB on 
multivariable 
analysis. 
- Compared to participants from 
Denmark, those from Africa or 
Asia had a significantly higher 
risk of TB. No significant risk 
among patients from Europe or 
Other 
- Males had a higher 
risk of TB on 
univariable analysis. 
Sex was not 
significantly 
associated with risk 
of TB on 
multivariable 
analysis. 
Thomas, 2000 - Higher proportions 
of Blacks had TB. 
Among TB cases, 
71%, 24% and 4% 
were Black, 
Hispanic and 
- - Higher proportion of 
females among TB 
cases. Among TB 
cases, 67% were 
females compared to 







cases 57%, 36% 









Hispanic  White 
participants, non-
Hispanic Black, 
Hispanic and Asian 
had a higher TB 
incidence. 
Overall, compared to US-born, 
TB incidence was higher among 
foreign-born. 
- Overall, TB 
incidence was not 
substantially different 
between men and 
women. 
Turkova, 2015 Compared to 
children 5-9 years 
at baseline, children 
< 5 years had a 
lower risk of TB, 
while children 10+ 
years did not have 
any significant risk.  
No significant 
association 
Children born in the UK had a 
significantly lower risk of TB 
than children born abroad. 
No significant association between 
region (London compared to the 











Lead author, year Route of HIV infection Drug misuse Alcohol misuse Imprisonment Level of 
education 
Abgrall, 2010 Among non-migrant patients, 
risk of TB was higher among  
IDU men, heterosexual men, 
other men, IDU women, 
heterosexual women and 
other women than in 
homosexual men. Among 
migrant patients, there was 
no significant association 
between sex/HIV 
transmission group and risk 
of TB. 
- - - - 
Aichelburg, 2009 - - - - - 
Antonucci, 1995 HIV transmission category 
was not significantly 
associated with risk of TB in 
unadjusted analysis 
- - - - 
Brassard, 2009 MSM  less likely to have TB 
on univariable analysis (no 
figures shown) 
- - - - 
Dooley, 1992 - Injecting drug use 
was not significantly 
associated with risk 
of TB. 
- - - 
Elzi, 2007 Route of HIV infection was 
not significantly associated 
with risk of TB. 
- - - - 
Girardi, 2000 Route of HIV infection was 
not significantly associated 
with risk of TB. 
- - - - 
Grant, 2009 Compared to male 
homosexual participants, 
female heterosexual, male 
heterosexual, and female 




other participants had a 
higher risk of TB.  
Gupta, 2015 Compared to MSM, 
heterosexual, IDU and 
maternal-to-child routes of 
infection were significantly 
associated with a higher risk. 
- - - - 
Hasse, 2014 - Injecting drug use 
was associated with 
a higher risk of TB. 
- - - 
Jones, 2000 Compared to male-male sex, 
IDU and heterosexual 
persons had higher risk of 
TB. 
- - - - 
Karo, 2014 Route of HIV infection was 
not significantly associated 
with risk of TB. 
- - - - 
Manavi, 2016 - - - - - 
Maniewski, 2016 - - - - - 
Markowitz, 1997 Compared to homosexual 
men, IDUs had a higher risk 
of TB on univariable 
analysis. On adjusted 
analysis, there was no 
significant association 
between transmission 
category and risk of TB 
- - - No significant 
association 
between level of 
education and risk 
of TB. 
McLaughlin, 2003 - - - All participants were 
prison inmates. 
- 
Miguez-Burbano, 2003 - All patients had a 
history of previous 
or current drug use. 
Long term tobacco 
users had higher 
risk of TB 
- - - 





Mor, 2013 Compared to MSM,  
heterosexual participants 
(from both HIV-epidemic and 
non-epidemic countries) and 
IDUs had a significantly 
higher risk of TB. 
- - - - 
Moro, 2000 - - - - - 
Pettit, 2011 Significantly higher 
proportions of heterosexuals 
among TB cases. Among TB 
cases, 44% had 
heterosexual contact, while 
among non-TB cases 23% 
had heterosexual contact. 
No significant  difference in 
proportions of IDUs and 
MSMs in those with TB and 
those without TB.  
- - - - 
Pettit, 2016 - Injecting drug use 
was significantly 
more common 
(32%) among TB 
cases than PLHIV 
without TB (17%). 
- - - 
Rice, 2013 All participants were 
heterosexual. 
- - - - 
Rubinstien, 1996 - All participants 
were injecting drug 
users. 
- - - 
Sackoff, 2001 - - - - - 
Sterling, 2011 - People who inject 
drugs had a 
significantly higher 
risk of TB. 
- - - 




not significantly associated 
with risk of TB. 
Taarnhoj, 2011 Compared to homosexuals, 
heterosexual and IDU 
participants had a higher risk 
of TB. 
- Alcohol abuse was 
not significantly 
associated with risk 
of TB. 
- - 
Thomas, 2000 HIV-infected children with TB 
were more likely to have 
mothers who acquired HIV 
through injecting drug use 
than heterosexual sex or 
other routes of transmission. 
- - - - 
Trieu, 2010 - - - - - 
Turkova, 2015 - - - - - 






9.5 Supporting information for Chapter 2: Clinical factors associated with active tuberculosis disease 
Lead author, year Year of diagnosis CD4 count Viral load Anti-retroviral therapy Previous TB 
disease 
Abgrall, 2010 Cohort entry at 
later periods was 
associated with 
higher risk of TB in 
both migrant and 
non-migrant sub-
groups. 
CD4 count <500 was associated 
with increasing risk of TB among 
both migrant and non-migrant 
patients.  
VL 10,000+ was 
associated with 
increasing risk of TB 
among both migrant 
and non-migrant 
patients. 
Compared to being ART-naïve, the risk of 
TB was significantly decreased for 
patients on mono/dual therapy. For 
patients on cART, the risk was also 
significantly decreased, and was lower in 
patients who had been on cART >6 
months compared to <6 months. 
- 
Aichelburg, 2009 - Patients with active TB had 
significantly lower median CD4 
count but not lower nadir CD4 count. 
Patients with active 
TB had significantly 
higher HIV-1 RNA 
levels 
Patients with active TB were less likely to 
receive ART 
- 
Antonucci, 1995 - CD4 count < 350 was associated 
with increasing risk of TB on 
multivariable analysis. 
- No significant association between ART 
and active TB. 
History of TB 
was associated 
with higher risk 
of TB on 
multivariable 
analysis. 
Brassard, 2009 - No significant association between 
CD4 count and risk of TB. 
- No significant association between ART 
and active TB, however only 3 patients 
were receiving ART. 
- 
Dooley, 1992 - - - - - 
Elzi, 2007 - Increasing CD4 count was 
significantly  associated with lower 
risk of TB. 
Increasing HIV RNA 
level was significantly  
associated with 
higher risk of TB. 
ART was associated with lower risk of TB - 
Girardi, 2000 - Participants with CD4 count <200 
had higher risk of TB. 
- Participants o 2 or more ART drugs had a 
lower risk of TB. 
- 
Grant, 2009 No significant 
association 
between year of 
cohort entry and 
risk of TB.  
CD4 count <500 was associated 
with increasing risk of TB. 
VL <50 was 
associated with a 
lower risk of TB. 
Being on ART for 2 or more years was 





Gupta, 2015 - Compared to CD4 700 or more, 
having CD4 <500 was significantly 
associated with increasing risk of 
TB. Having unknown CD4 count was 
associated with a higher risk of TB. 
There was no significant difference 
in risk for participants with CD4 500-
699. 
Participants with VL 
50+ or unknown VL 
had a higher risk of 
TB. 
All patients were on ART. - 
Hasse, 2014 - Increase in CD4 count was 
associated with a lower risk of TB in 
both ART sub-groups. 
- - - 
Jones, 2000 - Participants with CD4<100 and 
missing CD4 count had a higher risk 
of TB compared to those with CD4 
250+.  
VL was not 
significantly 
associated with risk 
of TB (but VL 
available only for a 
subset). 
Being on HAART and other ART were 
associated with lower risk of TB. 
- 
Karo, 2014 - CD4 <200 was associated with 
higher risk of TB in both ART sub-
groups. TB risk higher among 
participants that never started ART. 
VL 5 or more was 
significantly 
associated with a 
higher risk of TB in 
both ART subgroups. 
TB risk higher among 
participants  that 
never started ART. 
Multivariable analysis stratified by ART 
status. But crude TB incidence higher 
among participants that never started 
ART. 
- 
Manavi, 2016 - Compared to participants with CD4 
count >500, those with CD4 count 
200 or less had significantly lower 
TB incidence. 
VL 40 or more was 
significantly 
associated with a 
higher TB incidence. 
Duration of ART was not significantly 
associated with TB incidence.  
- 
Maniewski, 2016 - Median CD4 nadir significantly lower 
among persons that developed TB, 
compared to those that did not 
develop TB 
No significant 
association in median 
VL and TB. 
No significant association between ART 
and TB on crude analysis.  
- 
Markowitz, 1997 - Incidence of TB higher among 
participants with CD4 cell count < 
200. 




McLaughlin, 2003 - No significant association between 
CD4 count and risk of TB. 
No significant 
association between 
VL and risk of TB. 
No significant association between ART 
and risk of TB. 
- 
Miguez-Burbano, 2003 - No significant association between 
CD4 count and risk of TB. 
- - - 
Mohle-Boetani, 2002 - No significant association between 
CD4 count and risk of TB. 
- - No significant 
association 
between prior TB 
disease and risk 
of TB. 
Mor, 2013 HIV diagnosis 
after periods of 
ART introduction 
(1997-2010) was 
associated with a 
significantly higher 
risk of TB.  
- - No figures on ART, but risk of TB higher 
during the ART period, compared to pre-
ART period. 
- 
Moro, 2000 - Patients that developed MDR-TB 
had significantly lower median CD4 
%. 
- - - 
Pettit, 2011 - Median baseline CD4 count and 
CD4% were significantly lower 
among TB cases. 
Median baseline VL 
was significantly 
higher among  TB 
cases. 
On multivariable analysis, compared to 
participants not on HAART at baseline, 
the risk of TB reduced after at least 180 
days of HAART. Among those on HAART, 
risk of TB was higher within first 180 days 
of HAART.  
- 
Pettit, 2016 - Median baseline CD4 count 
significantly lower among  TB cases. 
Median baseline VL 
significantly higher 
among TB cases 
HAART (irrespective of duration) was 
associated with significant lower risk of TB 
on multivariable analysis. Accounting for 
duration of HAART, risk of TB was lower 
after being on HAART for > 6 months. 
- 
Rice, 2013 - MV. CD4 count 100+ significantly 
associated with lower risk of TB. 
- TB incidence was higher among 
participants who were not on ART. 
- 
Rubinstien, 1996 - - - - - 
Sackoff, 2001 - - - - - 




significantly associated with an 
increasing risk of TB. 
association between 
VL and risk of TB. 
HAART initiation or HAART type and risk 
of TB. No significant association between 
duration of HAART and risk of TB. 
Sudre, 1996 - Decreasing CD4 count was 
significantly associated with an 
increasing risk of TB. 
- - - 
Taarnhoj, 2011 No significant 
association 
between year of 
HIV diagnosis and 
risk of TB. 
CD4 count 200 or less was 
associated with a higher risk of TB. 
No significant 
association between 
VL and risk of TB. 
Start of HAART (time-updated) was 
significantly associated with a lower risk of 
TB. 
- 
Thomas, 2000 - A significantly higher proportion of 
patients with TB had moderate or 
severe immunosuppression than 
patients without TB. 
- - - 
Trieu, 2010 - - - - - 
Turkova, 2015 No significant 
association 
between period of 
cohort entry (HIV 
diagnosis) and risk 
of TB. 
- Baseline and time-
updated VL were not 
significantly 
associated with risk 
of TB on univariable 
analysis. 
Baseline and time-updated ART were not 












Contact with TB or other 





Time since HIV diagnosis / 
duration of follow-up time 
Abgrall, 2010 - - - Prior AIDS was 
associated with higher 
risk of TB among non-
migrant patients. 
There was no 
significant association 
between prior AIDS 
and risk of TB among 
migrant patients. .  
The risk of TB was highest in 
the first 6 months of follow-up 
and decreased over time in 
both migrant and non-migrant 
patients, although the decline 
for migrants was less steep 
than for non-migrants. 
Aichelburg, 2009 - - - There were not 
enough patients to 
assess the relationship 
between previous 
AIDS-defining illness 
and active TB. 
Patients diagnosed 
with active TB had a 
higher number of 




Antonucci, 1995 TST-positive and 
anergic patients 
had significantly 







- - No significant 
association between 
CDC clinical class and 
risk of TB on 
multivariable analysis. 
- 





active TB compared to 
2/3 not on LTBI 
treatment on 
univariable analysis. 
significantly shorter time 
periods between HIV diagnosis 
and 1st clinic visit compared to 
the entire cohort in univariable 
analyses. 
Dooley, 1992 - - Patients exposed to a TB 
case whilst in the HIV 
hospital unit had 
significantly greater risk of 
developing TB than 
unexposed patients. 
AIDS-status was not 
significantly associated 
with risk of TB. 
- 
Elzi, 2007 Participants with 
positive TST 
results had higher 
incidence of TB 
overall and when 
stratified by 
region of origin. 
None of patients 
treated developed TB 
- - - 
Girardi, 2000 TST-positive 
participants had a 
higher risk of TB. 
- - CDC clinical class was 
not significantly 
associated with risk of 
TB. 
- 
Grant, 2009 - - - - - 
Gupta, 2015 - - - - - 
Hasse, 2014 - - - Co-trimoxazole use 
associated with lower 
risk of TB in both ART 
sub-groups. 
- 
Jones, 2000 - Preventive treatment 
was not significantly 
associated with risk of 
TB. 
- Persons with clinical 
AIDS had higher risk 
of TB. 
- 
Karo, 2014 - - - - TB incidence higher in first 
year of follow-up than in the 
second year. 




Maniewski, 2016 - - - - No significant association 
between follow-up time and 
TB. 







- - - - 
McLaughlin, 2003 - - Persons on same side of 
dorm with TB case had a 
higher risk of TB, and had 
on average been exposed 











infection and risk 




and risk of TB. 
Higher but not 
significant proportion 
of controls had 
preventive therapy. 
Persons spending 20 hours 
or more in the communal 
day room had higher risk of 
TB, whilst those with a TV 
in their cell had lower risk of 
TB. There was no 
association between having 
an inmate with TB in the 
next cell and risk of TB. 
- - 
Mor, 2013 - - - - - 
Moro, 2000 - - - - - 
Pettit, 2011 - - - - - 
Pettit, 2016 - - - - - 
Rice, 2013 - - - - - 





with known LTBI, TB 
incidence was higher 
among participants 









who had not previously 
received isoniazid. 





who were anergic 
or had unknown 
TST status. There 





persons, TB incidence 
reduced with 
increasing duration of 
INH treatment. 
- - - 
Sterling, 2011 - - - - - 
Sudre, 1996 - - - - Compared to patients with less 
than 6 months of follow-up, 
patients with 25-36 moths and 
> 36 months of follow-up had 
higher risk of TB. 
Taarnhoj, 2011 - - - - - 
Thomas, 2000 - - - - - 
Trieu, 2010 - - - - - 




stages none had lower 
risk of TB, while mild 
and advanced stages 
did not have any 







AIDS-status and WHO 
stage and risk of TB. 
AIDS: acquired immunodeficiency syndrome. ART: anti-retroviral therapy. BCG: Bacillus Calmette-Guérin. DTH: delayed-type hypersensitivity. IGRA: 
interferon-gamma release assay. LTBI: latent tuberculosis infection. QFT-GIT: quantiFERON-gold in-tube. TB: tuberculosis. TST: tuberculin skin test. 
 
 
 
 
 
